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In this thesis, I reported a membraneless structure that permeated a major region of the female 
meiotic spindle and formed droplet-like protrusions around the spindle poles. Proteins within this 
previously unknown structure were highly dynamic and could redistribute rapidly throughout the 
entire spindle region. I found that this unusual structure behaves similar to a liquid and forms by 
phase separation and hence, termed it the liquid-like meiotic spindle domain (LISD). Interestingly, 
the LISD was not only present in the spindle of mouse oocytes, but also cow, pig and sheep oocytes 
and is thus widely conserved among mammals. Similar structures were not observed in wildtype 
or centrosome-depleted somatic cells, suggesting that the LISD is likely exclusive to the 
specialized spindle in oocytes. To identify the key proteins driving LISD assembly, I further 
optimized Trim-Away, the technique for acute depletion of endogenous proteins in mammalian 
cells. By combining in vitro and in vivo assays, I identified Aurora A kinase and two LISD proteins, 
transforming acidic coiled-coil-containing protein 3 (TACC3) and clathrin heavy chain 17 
(CHC17), as the proteins essential for LISD assembly. Disruption of the LISD via different means 
released microtubule regulatory factors that reside within this domain into the cytosol and caused 
severe spindle defects. Spindles were half of their original size and failed to segregate 
chromosomes properly. Microtubule growth rates were reduced, and their overall turnover was 
increased. Both kinetochore fibers as well as interpolar microtubules were strongly depleted. A 
TACC3 mutant that loses its ability to phase-separate failed to rescue the substantial loss of 
microtubules in TACC3-depleted oocytes. Together, these data suggest that the LISD is necessary 
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Loss-of-function is a genetic approach that has been extensively used to study protein functions in 
cells, tissues and even whole organisms1. Loss-of-function methods reduce or ablate protein 
function by either interfering with protein synthesis or inducing protein degradation1. At the 
genomic level, protein-coding genes can be disrupted by mutagenesis or genome editing1. Loss-
of-function mutation can be introduced using either chemical mutagens or transposons1. Genome 
editing technologies such as zinc-finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs) and the clustered regularly interspaced short palindromic repeats (CRISPR)-
Cas system are all based on endonucleases that can be engineered to bind to a specific DNA 
sequence and introduce a frameshift or nonsense mutation, or delete part of the coding sequence2. 
At the transcription level, messenger RNA (mRNA) synthesis can be perturbed using transcription 
activator-like effector (TALE) repression or CRISPR interference (CRISPRi)3. In both cases, 
TALE and Cas are fused with a transcriptional repressor instead of a nuclease3. At the post-
transcriptional level, RNA interference (RNAi) can target mRNAs for degradation using sequence-
specific short hairpin RNAs (shRNAs) or small interfering RNAs (siRNAs)3. Once Dicer 
processed the shRNAs into siRNAs, which are then loaded onto Argonaute proteins, the resulting 
RNA-induced silencing complexes bind to and degrade the target mRNAs4. At the translational 
level, morpholinos can be used to block mRNA translation5. These antisense oligomers bind to the 
target mRNAs and sterically block the progression of the translation initiation complex from the 




Although the aforementioned techniques have been proven to be useful for studying many different 
proteins in various model organisms, there are several limitations. One common major limitation 
is that they do not act on already-synthesized proteins inside the cells. Whereas most proteins are 
being constantly degraded and subsequently replaced with newly synthesized proteins, recent 
studies found that some proteins can persist for years in both metabolically inactive and long-lived 
metabolically active cells6,7. Once these proteins are trafficked to certain organelles such as the 
mitochondria and endoplasmic reticulum or incorporated into essential cellular structures such as 
the cohesin and nuclear pore complexes, they turnover slower and thus become resistant to loss-
of-function techniques that target protein synthesis8. Another limitation is that actual protein 
depletion typically takes days after the application of these techniques. This makes them unsuitable 
for studying short-lived biological processes such as membrane trafficking, cell division and early 
embryonic development. Also, interpretation of the results could become complicated as the 
phenotypes can be either a direct consequence or a secondary consequence of earlier defects after 
protein depletion9. Furthermore, the delay in between may allow cells to activate compensatory 
mechanisms, modifying or even masking the expected phenotypes10. 
 
To overcome these limitations, at least partially, several techniques have been developed to 
directly deplete the target proteins. A few ligand- and peptide-based techniques have been 
developed to allow protein degradation without the need of tagging the proteins, however, not all 
proteins can be targeted with these methods11,12. Many protein degradation techniques are based 
on recruiting SKP1-CUL1-F-box (SCF) E3 ubiquitin ligases to the target proteins, such as the 
binding of the F-box protein TIR1 to proteins tagged with an auxin-inducible degron and the 
binding of the GFP nanobody/F-box domain of Slmb fusion to GFP-tagged proteins13,14. Likewise, 
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ELOC-CUL2-SOCS-box (ECS) E3 ubiquitin ligases have been exploited for similar purpose15. 
Other protein degradation techniques are based on modulating protein stability, for instance, by 
fusing the target protein to a destabilizing mutant of FKBP12 or to a HaloTag with hydrophobic 
moiety16,17. In addition to degradation, proteins can be inactivated by knock-sideways, in which 
proteins are rerouted from their principal site of action to the mitochondria upon chemical-induced 
dimerization between the target proteins and the tethering proteins18. Most of these techniques act 
acutely, typically in the range of minutes. Nevertheless, they are not applicable to endogenous 
proteins and hence, unsuitable for applications in nondividing primary cells, which would 
otherwise require the generation of transgenic animals. 
 
1.2 Protein degradation 
Ubiquitin-proteasome system (UPS) and autophagy are two major protein degradation pathways 
in mammalian cells. Whereas the UPS is responsible for the degradation of small, short-lived 
proteins, autophagy is the preferred route for large, heterogeneous cytoplasmic materials which 
cannot fit into the proteasomes19. 
 
Ubiquitin is a small, highly conserved protein, which can be covalently attached to the ε-amino 
group of a lysine residue19. In the UPS pathway, E1 ubiquitin-activating enzyme first activates the C-
terminal glycine of ubiquitin and transfers it to the E2 ubiquitin-conjugating enzyme19. Substrate-specific 
E3 ubiquitin ligase then brings charged E2 and the substrate in close proximity, and facilitate the transfer 
of ubiquitin19. Substrates that are polyubiquitinated with K48-linked chains are recognized by ubiquitin 
receptors, which target the substrates to the proteasomes for degradation19. 
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Depending on how the cytosolic cargoes are directed to the lysosomes, the autophagy pathway can 
be further classified into chaperone-mediated autophagy (CMA), microautophagy and 
macroautophagy19. In CMA, HSC70 recognizes cytosolic proteins that expose a pentapeptide 
signature motif (KFERQ) and in turn binds to LAMP2A on the lysosomes19. The substrates are 
then unfolded and translocated into the lysosomes for degradation, which is assisted by a luminal 
form of HSC7019. In microautophagy, cytosolic content is invaginated by the late endosomal 
membrane, which then pinches off into the lumen in an ESCRT-dependent manner20. In 
macroautophagy, cytosolic material is engulfed by the double-membrane phagophore, which 
elongates and closes to form the autophagosome19. Mature autophagosome is transported along 
microtubules towards microtubule-organizing center, where its outer membrane fuses with 
lysosomes or late endosomes to form autolysosome19. Ultimately, the cargoes are degraded by 
lysosomal hydrolase19. Depending on whether cargo recognition is involved or not, 
microautohpahy and macroautophagy can be selective or non-selective (bulk)19,20. 
 
1.3 TRIM21 
TRIM21 is an Fc receptor that is widely expressed by cells of most histogenic lineages and belongs 
to the tripartite motif containing (TRIM) protein family21,23-25. All TRIM members share an N-
terminal RING E3 ubiquitin ligase domain, one or two B Box domains and a coiled-coil domain21-
26. Approximately half of all known TRIM proteins possess an additional C-terminal PRYSPRY 
domain, which determines ligand specificity and function21-26. The PRYSPRY domain of TRIM21 
binds to residues on the Fc of immunoglobulin (Ig) at the CH2-CH3 domain interface, an epitope 
overlapping with FcRn, protein A and protein G but not FcγR and C1q21,23-26. The coiled-coil 
domain facilitate TRIM21 dimerization in an anti-parallel manner and allows simultaneous 
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binding of both heavy chains, increasing its affinity for Ig through avidity21-26. TRIM21 binds Fc 
independent of pH, and it displays cross-reactivity with IgG from a range of mammalian 
species21,23. Although TRIM21 is the IgG receptor with the highest affinity in human, it also binds 
to IgM and IgA with lower affinity21,23,25,26. 
 
In the presence of intracellular antibody-bound pathogens, TRIM21 first recruits E2 UBE2W, 
which catalyze the automonoubiquitination of TRIM2123-26. E2 heterodimer UBE2N/2V2 is then 
recruited and uses the monoubiquitination to prime anchored K48 and K63 polyubiquitin chain 
extension23-26. The unfoldase/segregase AAA ATPase p97/VCP subsequently interacts with K48-
linked chains, and proteasome-associated deubiquitinase Poh1 liberates K63-linked chains from 
TRIM2123-26. These allow the translocation of the TRIM21/immune complex into the proteolytic 
core of the proteasome23-26. The release of free K63-linked chains activates TAK1-TAB1-TAB2 
and IKKα-IKKβ-NEMO kinase complexes, coupling antibody-dependent intracellular 
neutralization with the activation of transcription factors NF-κB, AP-1 and IRF3/5/723-26. 
 
1.4 Trim-Away 
In 2017, our lab developed a depletion technique for endogenous proteins, which we called ‘Trim-
Away’27. Trim-Away exploits TRIM21 to degrade endogenous proteins targeted by specific 
antibodies delivered into the cells27. A typical Trim-Away experiment involves two steps. (1) 
Expression of TRIM21. Although TRIM21 is broadly expressed in many different cell types, the 
endogenous level may not be sufficient for complete target protein degradation as TRIM21 is co-
degraded during the experiment. Additional TRIM21 can be introduced in the form of transient 
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transfection, stable transfection, mRNA or recombinant protein27. (2) Delivery of antibody. 
Antibody can be delivered into the cells by microinjection or electroporation using the Neon 
Transfection System27. Alternatively, nanobody-Fc fusion can be used, which can even be 
delivered in the form of transfection or mRNA27.  
 
Trim-Away has several unique advantages over the previous protein depletion techniques. First, 
Trim-Away directly degrade endogenous proteins. It does not rely on inherent turnover of the 
target protein and is effective against long-lived proteins. Second, Trim-Away does not require 
prior modification of the target protein. It is therefore applicable to nondividing primary cells and 
also primary immune cells that have active nucleic-acid sensing mechanisms. Third, unlike E3s 
such as VHL used in PROTAC, TRIM21 is not known to have cellular housekeeping function. It 
is less likely that there is competition with endogenous substrates, and normal metabolism is 
affected. Although the TRIM21 pathway could activate immune signaling, thanks to its high 
activation barrier, transcription factors such as NF-κB is only weakly activated in Trim-Away 
experiments27.  
 
Successful applications of Trim-Away include degradation of long-lived cohesin REC8 in mouse 
oocytes, degradation of intracellular signaling molecule NLRP3 in human primary macrophages, 
selective degradation of signaling pathway components and selective degradation of protein 





1.5 Mammalian oocyte development 
At embryonic day 6 post conception (E6.5) in mouse, or the fourth-fifth week in human, the 
extraembryonic ectoderm and visceral endoderm subject a subset of epiblastic cells from the 
primitive embryonic ectoderm to induction by intense BMP4 signaling29,30. This specifies their 
entry into germ lineage29,30. At E8.5 in mouse, or between the fifth and eighth week in human, 
these nascent primordial germ cells (PGCs) expresses pluripotency markers, undergoes epigenetic 
changes resembling that of pluripotent stem cells, and begin their migration into the posterior end 
of the primitive streak, which later becomes the extraembryonic mesoderm29,30. Nascent PGCs 
initially migrate through the allantois and reside temporarily in the yolk sac29,30. They then migrate 
caudally through the hindgut towards the dorsal mesentery and finally colonize the urogenital 
ridges29,30. Throughout the migration, PGCs proliferate rapidly30. 
 
Upon their arrival, nascent PGCs switch off the pluripotency program and switch on sex-specific 
genes30. The urogenital ridges, thickenings of coelomic epithelium superimposed on the anterior 
portion of the mesonephros, develop into the gonadal primordia in a sex-dependent manner and 
become the chief site for PGC development29,30. In XY gonads, transcription factor SRY is 
expressed and binds to TESCO, which upregulates SOX9 and induces differentiation of Sertoli 
cells, driving testicular formation29,30. In XX gonads, where SRY is not expressed, WNT4 and 
RSPO1 maintains β-catenin signaling and drives ovarian formation29,30. Once PGCs complete 




At E10.5 in mouse, or between week 10 and 20 in human, oogonia undergo multiple mitotic 
divisions that do not complete cytokinesis, forming transitory cysts known as germ cell nests29-31. 
These nests are clusters of oogonia interconnected by cytoplasmic bridges and enveloped by 
somatic cells29-31. At E13.5 in mouse, or between week 11 and 13 in human, secretion of retinoic 
acid from adjacent mesonephros triggers the induction of meiosis in an anterior to posterior 
wave29,30. Oogonia enter prophase I through leptotene, zygotene and pachytene, that characterize 
pairing of homologous chromosomes, synapsis and recombination, and arrest at diplotene stage as 
primordial oocytes29-31,33. Shortly after birth in mouse, or between week 16 and 21 in human, some 
cells die through apoptosis, destabilizing and rupturing these nests29-31. Outlying somatic cells then 
invade these nests and surround oocytes of less than 20 µm in diameter, forming primordial 
follicles29-33. Indeed, two-thirds of primordial oocytes undergo apoptosis in a phenomenon known 
as the apoptotic wave29. Only the cells that survive the apoptotic wave constitute the final pool of 
primordial follicles that are available for the entire reproductive lifespan in the female29. 
 
Primordial follicles constitute the ovarian quiescent follicle reserve29,30. Throughout the 
reproductive lifespan, primordial follicles are continuously released from dormancy and recruited 
to the growing pool29,30. The pre-antral phase of folliculogenesis is largely independent on extra-
ovarian hormonal stimuli, but the local production of growth hormones30,32. From primordial 
follicles to primary follicles, oocytes are surrounded by zona pellucida and enlarge to more than 
20 µm in diameter, and squamous (pre-)granulosa cells transform into cuboidal granulosa cells30-
32. From primary follicles to secondary follicles, meiotically incompetent oocytes further increase 
in size, granulosa cells proliferate to from multiple layers, and thecal cells are recruited to the basal 
lamina surrounding the granulosa cells30,33. Once pre-antral follicles reach a species-specific size, 
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granulosa cells secrete glycoproteins and create small fluid-filled cavities, which ultimately 
coalesce into a single cavity known as the antrum30,33. 
 
To progress through the antral and pre-ovulatory phase, follicles become dependent on the cyclical 
pituitary secretion of FSH and LH30,32,33. At the antral stage, meiotically competent oocytes cease 
to grow and suppress the expression of LH receptors in cells surrounding them, regulating the 
phenotypic differentiation of granulosa cells into cumulus granulosa cells and mural granulosa 
cells30,32,33. Other than providing metabolic support, cumulus granulosa cells that are in close 
contact with the oocyte through gap junctions also maintain the oocyte in meiotic arrest30,32,33. By 
contrast, mural granulosa cells line the inner side of the basal lamina and are responsible for 
steroidogenesis30,33. Whereas most antral follicles will undergo atretic degeneration, only a subset 
of follicles known as the dominant follicles reach the pre-ovulatory phase30. Mural granulosa cells 
of these follicles, but not the oocytes, express high level of LH receptors, making them responsive 
to the pre-ovulatory LH surge30. 
 
1.6 Meiosis in mammalian oocytes 
Fully grown oocytes remain arrested in the diplotene stage as dictyate due to the low activity of 
the maturation-promoting factor (MPF), which is a complex of the kinase subunit CDK1 and the 
regulatory subunit cyclin B1 that regulates G2/M-transition30,34-36. The low activity of MPF is 
maintained by three mechanisms: (i) High level of intra-oocyte cAMP promotes the activation of 
PKA that stimulates nuclear WEE1B/WEE2 and cytoplasmic MYT1 kinases, which in turn 
inactivate CDC25B phosphatase required for CDK1 dephosphorylation and its resultant 
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activation29,30,34-36; (ii) CDC14B phosphatase counteracts CDK1 activity and activates nuclear 
APC/C coactivator CDH1, which constantly promotes cyclin B1 degradation by APC/C30,34-36; (iii) 
Cyclin B1 and CDC25B are excluded from the nucleus35,36. The high level of intra-oocyte cAMP 
is attributed by: (i) activation of the Gs by G-protein-coupled receptor on the oolemma and the 
subsequent stimulation of adenylyl cyclase in the oocyte30,34-36; (ii) transfer of cAMP produced in 
cumulus granulosa cells to the oocyte via gap junctions30,35 ; (iii) induction of guanylyl cyclase 
NPR2 in cumulus granulosa cells by the oocyte34. Secretion of NPPC by mural granulosa cells 
activates NPR2 that synthesizes cGMP, which enters the oocyte via gap junctions and inhibit 
oocyte-specific PDE3A that degrades cAMP30,34-36. 
 
Following puberty, cyclic pre-ovulatory LH surge resumes meiosis. Binding of LH to its receptor 
on mural granulosa cells reduces NPPC secretion, and leads to the activation of Gs and 
subsequently adenylyl cyclase34,35. The production of cAMP promotes the activation of PKA, 
leading to the synthesis and release of EGFR ligands34. EGFR signaling decreases the level of 
cGMP and activates MAPK, which promotes the phosphorylation of connexin 43 and reduces gap 
junction permeability, preventing the influx of cGMP29,30,34-36. As a result of increased cAMP 
hydrolysis by PDE3A, reduced level of intra-oocyte cAMP relieves PKA-mediated inactivation of 
CDC25B, resulting in the activation of CDK129,30,34-36. The activation of CDK1 is further 
reinforced by (i) concomitant nuclear translocation of cyclin B1 and CDC25B that causes 
activation of a fraction of MPF, which in turn promotes the export of WEE1B/WEE2 to the 




Unlike the rapid, switch-like activation of CDK1 in mitosis, the slow rise in CDK1 activity, which 
results in a prometaphase I lasting for 6 to 7 hours in mouse oocytes, is accompanied by the 
progressive accumulation of cyclin B136. This is achieved partially by the de novo translation of 
cyclin B1 mRNAs, and partially by the suppression of APC/C activity by CDK1 and MAPK36. 
CDK1 activity peaks at metaphase, when bivalents are properly aligned on the metaphase plate36. 
Once bivalents are correctly attached to kinetochore microtubules from the two spindle poles and 
the spindle assembly checkpoint is satisfied, anaphase onset is initiated36. The loss of SAC-
mediated repression of APC/C and the association of APC/C with its coactivator CDC20 promote 
the degradation of securin and cyclin B1, which in turn promotes the cleavage of cohesin by 
separase and the lowering of CDK1 activity, respectively36. 
 
Following chromosome segregation and polar body extrusion, CDK1 activity is rapidly 
upregulated to promote entry into prometaphase II29,34,36. Oocytes arrest at metaphase II as a result 
of APCCDC20 inhibition by cytostatic factor (CSF), which is an activity of the 
MOS/MEK1/MAPK/p90Rsk and EMI2 pathways29,34,36. Other pathways that act directly upon 
CDK1 also operates36. CSF-mediated stabilization of MPF prevents parthenogenetic activation 
and hence, development of embryos without the contribution of paternal genome29. 
 
1.7 Spindle assembly in mammalian oocytes 
The female meiotic spindle from mammalian oocytes was first observed at ultrastructural level in 
the mouse back in the 1970s37. Although the pathways responsible for microtubule nucleation in 
mammalian oocytes have been identified in the past 50 years, little is known about how 
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microtubules are assembled into the female meiotic spindles, which are of a size larger than a 
somatic cell. 
 
Unlike somatic cells, in which centrosomes dominate the assembly of mitotic spindles, mammalian 
oocytes do not possess centrosomes and assemble acentrosomal spindles38. Centrosomes are 
composed of a pair of centrioles and the pericentriolar material (PCM), which contains factors for 
microtubule nucleation and anchoring39. In mouse oocytes, centrioles are lost after the pachytene 
stage and the PCM persists as acentriolar microtubule organizing centers (aMTOCs)37,40. In 
oocytes from other mammals, centrioles are lost and the PCM is dispersed, degenerating the 
centrosomes completely38. Why mammalian oocytes eliminate their centrioles? One hypothesis is 
that centriole elimination in oocytes balances the number of centrosomes after the introduction of 
sperm centrioles, preventing the formation of multipolar spindle in the first embryonic division38. 
Another hypothesis is that centriole elimination prevents parthenogenetic activation, as 
microinjected centrosomes functions as zygotic centrosomes and induces activation in Xenopus 
eggs38. 
 
In mouse oocytes, aMTOCs form de novo from an interphase-like microtubule network in 
prophase and exist as large clusters around the nucleus at the germinal vesicle (GV) stage40-42. 
Prior resumption of meiosis, CDK1 phosphorylates a wide range of substrates that mediate 
germinal vesicle breakdown (GVBD), chromosome condensation and cytoskeleton 
remodeling35,36. PLK1 decondenses the aMTOCs, which are stretched along the nuclear envelope 
in a BICD2/dynein-dependent manner upon GVBD40,42. After GVBD, aMTOCs are further 
fragmented by KIF1142. Although aMTOCs nucleate few microtubules upon GVBD, they are 
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responsible for initial microtubule nucleation in mouse oocytes and their nucleation capacity 
progressively increases during meiosis I40,41. Meanwhile, as chromosome condenses, the Ran 
guanosine exchange factor RCC1 on chromosomes converts inactive Ran-GDP into active Ran-
GTP43. The Ran-GTP gradient in turn promotes the dissociation of spindle assembly factors from 
their inhibitory binding to importins, contributing to later microtubule nucleation43. Disruption of 
aMTOCs by depleting PCM components or inhibition of Ran-GTP with a dominant-negative 
mutant alone did prevent spindle assembly41,44,45. Nevertheless, no spindle was formed upon Ran-
GTP inhibition in aMTOCs-disrupted oocytes, suggesting that both pathways are essential for 
spindle assembly45. Upon initiation of nucleation, the initial stochastic distribution of aMTOCs 
results in a ball of microtubules, with newly individualized chromosomes having their 
kinetochores orienting inwards41. As the microtubule ball elongates into a barrel-shaped array in a 
KIF11-dependent manner, chromosomes form a loose ring that marks the equator of the forming 
ellipse, termed the prometaphase belt, and HURP mediates the sorting of aMTOCs to the two 
newly formed spindle poles41,46,47. Although aMTOCs cluster and facilitate bipolar spindle 
assembly, they are not absolutely essential for spindle pole formation45,48. Finally, chromosomes 
invade the spindle and form the metaphase plate41.  
 
For human oocytes, in which aMTOCs were not detected, the Ran-GTP pathway is absolutely 
essential for initiation of microtubule nucleation49. However, whether this applies to other non-
murine oocytes and how their spindles are assembled in the absence of aMTOCs remain unknown. 
 
1.8 Phase separation in biology 
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Classic organelles, such as the nucleus, endoplasmic reticulum, Golgi apparatus and mitochondria, 
are compartments best known for their surrounding membrane. Indeed, many cellular 
compartments, such as the nuclear bodies and RNA granules lack a physical barrier separating 
their internal components from the surrounding environment. How these membrane-less 
compartments sequester their components and maintain their structure in the cytosol remained 
elusive for years until the P granules were discovered to be liquid-like. 
 
P granules are perinuclear RNA granules in the germ cells of Caenorhabditis elegans embryos50. 
In 2009, careful inspection revealed that they have the following properties reminiscent of liquids: 
(i) they are spherical; (ii) they can fuse after touching and revert back to a spherical shape; (iii) 
they deform in shear flows; (iv) they rapidly exchange components with the cytosol and undergo 
internal rearrangement50. Since then, other compartments such as the nucleoli and stress granules 
were also found to display liquid-like properties51, 52. Thus, phase separation via liquid-liquid 
demixing is proposed to form these compartments. 
 
Phase separation refers to the change that occur as molecules transit from one configuration (phase) 
to another and the two phases are separated from one another53,54. Phase separation is typically 
referred to liquid demixing in biology53,54. When the interactions between molecules are 
sufficiently stronger than the interactions between the molecule and the solvent, its energetics 
overcome the entropic tendency of the solution to remain homogenously mixed53,54. Consequently, 
the mixture separates into a dilute phase of larger volume and lower concentration and a condensed 
phase of smaller volume and higher concentration53,54. As the chemical potential in both phases is 
equal, this eliminates non-diffusive flux while allows diffusion across the phase boundary53,54. At 
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equilibrium, the concentration difference between the two phases is maintained without constant 
input of energy53,54. In biological systems, phase separation of proteins is driven by multivalency, 
which can be achieved with (i) multiple modular interaction domains and (ii) large intrinsically 
disordered regions that lack a defined tertiary structure but contain low complexity sequence that 
provide short-lived interactions with low affinity and no stereospecificity54. This is in sharp 
contrast to the relatively long-lived interactions with high affinity and stereospecificity that drives 
oligomerization and polymerization, which can arrest the dynamics within54. 
 
There are several functional implications for phase separation in biology. First, phase separation 
can substantially increase the local concentration of reactants, thereby accelerating rate limiting 
steps in reactions53,54. Second, phase separation can selectively concentrate some reactants and 
exclude the others, conferring specificity to reactions54. Third, phase separation can sequester 
components from the cytosol, inhibiting their activity or buffering their concentration in the 
cytosol53,54. Four, all the aforementioned functions can be switched on and off quickly by 
condensation and dissolution of the phase54. 
 
1.9 Phase separation in centrosome and microtubule assembly 
Although tubulin itself does not undergo phase separation but polymerizes through stereospecific 
interactions, phase separation of centrosomal and spindle-related proteins have recently been 





For centrosome assembly, C. elegans PCM scaffold protein SPD-5 was first found to phase-
separate in vitro56. SPD-5 condensates morphologically and dynamically resemble mitotic PCM 
in vivo and can recruit ‘clients’ microtubule polymerase ZYG-9 and microtubule-stabilizing 
protein TPXL-1, concentrating tubulin ~4-fold to nucleate microtubule asters in vitro56. Likewise, 
phase separation of Xenopus PLK4 kinase was found to recruit tubulin and was proposed to recruit 
its substrate STIL and microtubule nucleator γ-tubulin, promoting de novo MTOC formation in 
Xenopus extracts57. 
 
For microtubule assembly, several microtubule-binding proteins have been found to phase-
separate in vitro. One is the Xenopus lamin-B spindle matrix protein BuGZ, whose condensates 
were initially found to bundle microtubules and concentrate tubulin, promoting microtubule 
polymerization near existing microtubules58. Later, phase separation of BuGZ was also found to 
promote the activation of AURA, one of the kinases driving mitotic spindle assembly59. The 
neuronal protein Tau is another one whose condensates can co-condense tubulin and polymerize 
Tau-encapsulated microtubule bundles in vitro60. More recently, phase separation of microtubule-
stabilizing protein TPX2 was similarly found to co-condense tubulin, promoting microtubule 
polymerization from existing microtubules61. Although BuGZ and TPX2 have been implicated in 
mitotic spindle assembly and it is tempting to imply a role of their phase separation, there is no 





Three years ago, when I started my doctoral study with the project ‘Studies of individual 
chromosome behavior in mammalian oocytes’, I wanted to establish a fluorescent reporter for 
kinetochore fibers (k-fibers) to image kinetochore-microtubule interactions in live oocytes. One 
candidate is TACC3, which forms intermicrotubule bridges with CHC17 and chTOG to stabilize 
k-fibers in mitotic cells62. Surprisingly, expression of TACC3-mClover3 labeled not only k-fibers, 
but also a previously unknown structure on the female meiotic spindle in mouse oocytes. 
Interestingly, this structure permeated a major region of the spindle and formed droplet-like 
protrusions around the spindle poles. Therefore, I decided to rather focus on this structure, which 
was later termed the liquid-like meiotic spindle domain (LISD). 
 
As the first goal of my doctoral study, I set out to perform a protein localization screen to identify 
other proteins residing within the LISD. In order to better understand the properties of the LISD, 
the second goal of my doctoral study was to characterize the LISD using different in vivo and in 
vitro assays. The third goal of my doctoral study was to identify the key components that drive 
LISD assembly. To partially achieve this goal, I optimized the Trim-Away technique to improve 
the survival rate, developmental rate and protein depletion efficiency in mammalian oocytes, 
which was the four goal of my doctoral study and led to my first publication (Acute and rapid 
degradation of endogenous proteins by Trim-Away) in Nature Protocols. Having the optimized 
tool, I progressed to the final goal of my doctoral study and investigated the role of the LISD in 
acentrosomal spindle assembly in mammalian oocytes. Ultimately, the successful completion of 
all five goals led to my second publication (A liquid-like spindle domain promotes 
acentrosomal spindle assembly in mammalian oocytes) in Science.
Acute and rapid degradation of endogenous
proteins by Trim-Away
Dean Clift1,4*, Chun So2,4, William A. McEwan1,3, Leo C. James1* and Melina Schuh1,2,4*
Protein depletion is a key approach to understanding the functions of a protein in a biological system. We recently
developed the Trim-Away approach in order to rapidly degrade endogenous proteins without prior modification. Trim-
Away is based on the ubiquitin ligase and Fc receptor TRIM21, which recognizes antibody-bound proteins and targets
them for degradation by the proteasome. In a typical Trim-Away experiment, protein degradation is achieved in three
steps: first, introduction of an antibody against the target protein; second, recruitment of endogenous or exogenous/
overexpressed TRIM21 to the antibody–bound target protein; and third, proteasome-mediated degradation of the target
protein, antibody and TRIM21 complex. Protein degradation by Trim-Away is acute and rapid, with half-lives of
~10–20 min. The major advantages of Trim-Away over other protein degradation methods are that it can be applied to any
endogenous protein without prior modification; that it uses conventional antibodies that are widely available; and that it
can be applied to a wide range of cell types, including nondividing primary human cells, for which other loss-of-function
assays are challenging. In this protocol, we describe the detailed procedures for antibody preparation and delivery in
mouse oocytes and cultured cells via microinjection and electroporation. In addition, we provide recommendations for
antibody selection and validation, and for the generation of TRIM21-overexpressing cell lines for cases in which
endogenous TRIM21 is limited. A typical Trim-Away experiment takes just a few hours.
Introduction
Protein depletion is one of the key tools used in studying protein functions in cells and tissues, and
can be achieved by either interfering with protein synthesis or inducing protein degradation. Protein
synthesis can be blocked at various levels. At the genomic level, protein-coding genes can be disrupted
using genome-editing technologies such as zinc-finger nucleases (ZFNs), transcription activator–like
effector nucleases and the clustered regularly interspaced short palindromic repeats (CRISPR)–Cas
system. All these technologies are based on nucleases that can be targeted to a specific DNA sequence
and introduce a frameshift mutation or a premature stop codon, or delete the coding sequence1. At
the post-transcriptional level, messenger RNAs (mRNAs) can be targeted for degradation using RNA
interference (RNAi). To this end, sequence–specific small interfering RNAs or short hairpin RNAs
are introduced into cells. These are incorporated into RNA–induced silencing complexes, which bind
to and degrade the target mRNA2. At the translational level, morpholino oligomers can be used to
block the translation of mRNAs. These antisense oligonucleotides bind to the target mRNA and block
the progression of the translation initiation complex from the 5′ cap to the start codon3.
Although these techniques have been proven to be highly useful for studying various genes in
different model systems, a common major limitation is that they are not suitable to deplete already-
synthesized proteins. In both metabolically inactive and long–lived metabolically active cells, certain
proteins—particularly those in essential cellular structures—can persist for years after translation4.
These long-lived proteins cannot be depleted by blocking protein synthesis at the gene or mRNA
level. Another limitation of methods that act at the gene or mRNA level is the long delay between the
time of their application and actual protein depletion, which is typically in the range of days. These
methods are therefore not well suited to investigating short–lived biological processes. For example,
many regulatory proteins have multiple functions during different stages of mitosis, which takes only
~1 h in HeLa cells5. If protein degradation is delayed, it is difficult to determine whether the
phenotypes are a direct consequence of protein depletion or a secondary consequence of earlier
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defects6. Delays may also allow cells to activate compensatory mechanisms, which may modify or
even mask the phenotypes7.
To overcome these challenges, several methods have been developed that act directly at the protein
level, targeting the protein itself for degradation. Some of these methods are based on controlling
protein stability, for instance, by fusing the target protein to destabilizing domains that are controlled
by ligands8,9. Others are based on recruiting SKP1–CUL1–F-box (SCF) E3 ubiquitin ligases to the
target protein, such as the binding of an auxin-inducible degron to the F-box protein TIR1 and the
binding of GFP-tagged proteins to a GFP nanobody fused to the F-box domain of Slmb10,11. Proteins
can also be perturbed acutely by knock-sideways approaches, in which proteins are targeted away
from their principal site of action, for instance, by tethering them to mitochondria12. However, all of
these assays require the endogenous protein to be first replaced by a modified variant. Hence, they are
not suitable for studying protein functions in all cell types. For instance, application of these methods
in nondividing primary cells would often require the generation of transgenic animals. This is time
consuming and not feasible for many species. For tag-free degradation, ligand- and peptide-based
techniques have been developed, but the number of proteins that can be targeted with these methods
is very limited13,14.
To achieve acute depletion of any endogenous protein without prior modification, we recently
developed a post-translational protein depletion method, which we called ‘Trim-Away’15. Trim-Away
relies on an E3 ubiquitin ligase called TRIM21 (ref. 16). TRIM21 is involved in the intracellular
immune response; it binds to antibody-bound pathogens and proteopathic agents and targets them
for degradation17–19. The precise mode of action of TRIM21 is not yet fully understood, but it
involves binding of TRIM21 to the Fc-region of an antibody and subsequent autoubiquitination of
TRIM21. In a Trim-Away experiment, the high affinity of TRIM21 to the Fc-region of an antibody is
exploited to target endogenous proteins for degradation. An antibody against the target protein is
introduced, and TRIM21 binds to the antibody–bound target protein and triggers the proteasome-
mediated degradation of the antibody–antigen complex together with TRIM21 (refs. 20,21). Trim-
Away has enabled us to degrade a wide variety of proteins within minutes of application in different
cell types15. For instance, we could acutely deplete Rec8 in unmodified mouse oocytes15, an
experiment that required complex genetics in the past22. We have also been able to deplete the
intracellular signaling molecule NLRP3 in human primary macrophages, which was not possible in
the past with nucleic acid–based depletion techniques15. Here, we (i) describe the design of Trim-
Away experiments; (ii) detail the selection and preparation of reagents for Trim-Away experiments;
(iii) discuss the procedures for use of Trim-Away in mouse oocytes and pre-implantation embryos;
(iv) present the procedures for use of Trim-Away in primary cells and cell lines; and (v) propose
quality controls for Trim-Away experiments. We also highlight and give advice on critical steps in the
Procedure.
Overview of the procedure
For a successful Trim-Away experiment, a specific antibody that targets an intracellular protein of
interest must be delivered into cells that contain TRIM21. If the endogenous levels of TRIM21 are not
sufficient for protein degradation, TRIM21 must also be introduced together with or before antibody
delivery. In this protocol, we outline different methods for introducing antibody and TRIM21 into
cells and give advice on how to preselect specific antibodies for a successful Trim-Away experiment.
A routine Trim-Away experiment involves the following three events (Fig. 1):
1 Ensuring sufficient TRIM21 levels in target cells of interest. TRIM21 is widely expressed in different
cell types23. Depending on the expression level of the target protein, endogenous TRIM21 levels
may be sufficient for Trim-Away15. But as TRIM21 is continuously degraded during a Trim-Away
experiment and typically not expressed at high levels, the endogenous level may be insufficient for
complete target protein degradation. Additional TRIM21 can be introduced in the form of a
transgene (i.e., DNA), mRNA or protein. Using TRIM21-encoding DNA, we have transiently
transfected cell lines or created stable lines with a TRIM21 expression cassette integrated into their
genomes15 (see also Box 1). Stable lines simplify the workflow in a Trim-Away experiment because
only the delivery of the antibody is required for acute protein degradation. In certain cases, cells
with low expression levels of TRIM21 must be preselected by FACS because high expression of
TRIM21 can sometimes lead to the formation of protein aggregates, which are nonfunctional15. We
have also used in vitro–transcribed mRNAs to transiently express TRIM21 in mouse oocytes15.
Using mRNAs accelerates the expression of TRIM21 and allows fine-tuning of the expression level,
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but translation rates may vary for cells at different cell cycle stages. TRIM21 can also be introduced
in the form of a recombinant protein, for instance, by electroporation15. Recombinant TRIM21 (see
also Box 2) eliminates the incubation time that is required for protein expression from DNA or
mRNA before a Trim-Away experiment. However, recombinant TRIM21 can be exhausted if not
replenished.
2 Delivery of antibody. Depending on the experimental setup, the antibody can be delivered by either
microinjection (Step 16) or electroporation (Steps 17–32). We have microinjected antibody into
mouse oocytes and single adherent cells15. Microinjection allows tight control over the amount of
antibody delivered into each cell and is the method of choice when individual cells must be analyzed
rapidly upon triggering protein degradation. For bulk cell populations, we recommend delivering
the antibody by electroporation using the Neon Transfection System15. Unlike protein transfection
reagents, electroporation can be used to simultaneously deliver the antibody into the cytoplasm of
many cells without antibody accumulation in the endosome and/or lysosome. In addition to
conventional antibodies, we have also used a fusion between a nanobody and the Fc-region of
human IgG1 for protein degradation by Trim-Away15. We have introduced this nanobody-Fc
fusion into mouse oocytes as mRNA, but delivery as DNA or protein into other cell types should
work as well15.
3 Target protein degradation. When the antibody has bound to the target protein, TRIM21 targets the
antibody–antigen complex for degradation via the ubiquitin–proteasome pathway20,21. Degradation
typically starts within 5–10 min after application of the antibody15. Complete depletion can be
achieved within ~3 h, depending on the abundance and accessibility of the target protein, as well as
the amount of antibody that was introduced into the cell15.
Applications of the method
Trim-Away uses TRIM21 to degrade endogenous proteins that are bound to an antibody. Our results
suggest that any protein within a cell that is accessible by an antibody can be degraded by Trim-Away.
Because TRIM21 proteins and antibodies are highly conserved among different mammalian species,
Trim-Away works with a wide range of cells and antibodies24. Trim-Away acts very rapidly and does
not require prior modification of the target protein. It also works in various cell types, including
nondividing primary cells. Trim-Away also allows loss-of-function studies in primary immune cells,
which could not be studied efficiently with nucleic acid–based depletion methods in the past.
Some specific examples of what can be studied are (i) the function of a protein within a defined cell
cycle stage without affecting its other potential functions during the other cell cycle stages; (ii) the
roles of proteins for the maintenance of cellular structures, even if these proteins are essential for
the formation of these structures; (iii) the functions of the cytoplasmic pool of certain proteins;
(iv) the functions of certain proteins with a particular post-translational modification; (v) the
functions of specific isoforms of certain proteins; and (vi) structure–function relationships in certain













Fig. 1 | Schematic of the principle of Trim-Away.
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Box 1 | Preparation of TRIM21 stable cell lines ● Timing 2–3 weeks
Although TRIM21 is nearly universally expressed, its expression level varies between cell types. Because TRIM21 is degraded alongside the
antibody and target antigen during Trim-Away, levels of endogenous TRIM21 may be insufficient to elicit complete degradation of the target
antigen, especially in cases in which the target antigen is abundant. This can be remedied by the constitutive expression of TRIM21 stably
integrated into the target cell genome. Here, we describe a protocol for stable cell line generation by transduction with pseudotyped lentiviral
particles. However, alternative approaches for stable cell line generation can also be used.
Reagents
● DMEM (high glucose, GlutaMAX; Gibco, cat. no. 31966)
● FBS (Gibco, cat. no. 10270)
● DPBS (no calcium, no magnesium; Gibco, cat. no. 14190)
● Trypsin-EDTA (0.05% (wt/vol), phenol red; Gibco, cat. no. 25300)
● Opti-MEM I reduced serum medium (Gibco, cat. no. 31985)
● psPAX2 (Addgene, plasmid no. 12260)
● pSMPP-mCherry-hTRIM21 (Addgene, plasmid no. 104972)
● pSMPP-mCherry-mTrim21 (Addgene, plasmid no. 104971)
● pMD2.G (Addgene, plasmid no. 12259)
● FuGENE 6 transfection reagent (Promega, cat. no. E2691)
● Polybrene (Santa Cruz Biotechnology, cat. no. sc-134220)
● Puromycin dihydrochloride (Gibco, cat. no. A1113803)
Equipment
● Corning tissue culture–treated culture dishes (100 mm × 20 mm; Sigma-Aldrich, cat. no. CLS430167)
● 10-ml Syringe (BD Plastipak, cat. no. 302188)
● 33-mm Ezee syringe filters (0.45 μm; PVDF; sterile; Elkay, cat. no. E25-PV45-50S)
● Corning Costar TC-treated multiple-well plates (six wells; clear; polystyrene plate; flat bottom; Sigma-Aldrich, cat. no. CLS3516-50E)
● Corning Costar TC-treated multiple-well plates (24 wells; flat bottom; Sigma-Aldrich, cat. no. CLS3527)
Reagent setup
● DMEM supplemented with 1× GlutaMAX and 10% (vol/vol)FBS. Add 55 ml of FBS to 500 ml of DMEM. Store at 4 °C for up to 1 year from the date
of manufacture until use.
Procedure
! CAUTION Ensure that virus work takes place at an appropriate level of biosafety according to national and institutional regulations.
1 Seed 2.5 × 106 HEK293T cells in a 10-cm dish containing 10 ml of DMEM supplemented with 1× GlutaMAX and 10% (vol/vol) FBS.
2 Incubate the cells for 16–24 h at 37 °C in a 5% CO2 atmosphere.
3 In a sterile 1.5-ml reaction tube, prepare 200 μl of Opti-MEM I, 2 μg of HIV GagPol expression plasmid (e.g., psPAX2), 2 μg of TRIM21 construct
in lentiviral transfer vector (e.g., pSMPP-mCherry-hTRIM21) and 1 μg of VSV-G glycoprotein expression plasmid (e.g., pMD2.G).
4 Mix the plasmids well by gentle vortexing and bring to the bottom of the tube with a brief spin in a microcentrifuge (2,000g, 25°C, 5 s).
5 Add 12 µl of FuGENE 6 transfection reagent to the plasmids and mix immediately by flicking. Bring the liquid to the bottom of the tube with a
brief spin in a microcentrifuge (2,000g, 25°C, 5 s).
6 Incubate the transfection mix for 20 min at room temperature.
7 Add the transfection mix dropwise to the center of the dish of HEK293T cells with gentle swirling.
c CRITICAL STEP Mixing by pipetting or vigorous agitation should be avoided, as it may dislodge HEK293T cells from tissue culture dishes.
8 Incubate the cells for 16–24 h at 37 °C in a 5% CO2 atmosphere.
9 Gently remove the medium and replace with fresh, prewarmed DMEM supplemented with 1× GlutaMAX and 10% (vol/vol) FBS, and then
return the cells to the incubator for a further 48 h.
10 (Optional) Examine the cells under a fluorescence microscope to ensure high levels of mCherry-hTRIM21 expression in virus-producing cells
resulting from transfection and single-cycle re-infection.
11 Harvest the supernatant directly into a 10-ml syringe; then filter at 0.45 µm, separate into 1-ml aliquots and store the virus particles at −80 °C.
j PAUSE POINT Viral particles can be stored indefinitely at −80 °C.
12 Seed adherent target cells at 1 × 105 per well in six-well plates in appropriate medium. Suspension cells can be seeded in 24-well plates in their
normal medium with polybrene at 10 μg/ml and transduced immediately (step 15).
13 Incubate the cells for 16–24 h at 37 °C in a 5% CO2 atmosphere.
14 Replace the medium with fresh medium containing 10 μg/ml polybrene (2× final concentration).
15 Thaw the virus supernatant at room temperature.
16 On the first transduction of a new cell type, or after production of a new batch of virus supernatant, add virus at a range of concentrations to
determine the optimal level for low-multiplicity transduction (<0.1 transducing particles per cell). Prepare a five–fold serial dilution of virus in
medium such that successive wells will receive 1, 5, 25, 125 and 625 μl of virus. Add virus to cells in a volume equal to that of the plating
medium such that the final polybrene concentration is 5 μg/ml. Include a control well that does not receive virus.
17 Incubate the cells for 48 h at 37 °C in a 5% CO2 atmosphere.
18 Analyze for transgene expression by fluorescence microscopy or flow cytometry. Select conditions in which <10% of cells are expressing
mCherry-TRIM21, in order to minimize the number of multiply transduced cells.
19 Add puromycin to the cells at an appropriate concentration for the cell type, typically 0.5–5 µg/ml.
20 After 1 week of selection, all untransduced cells and the untreated control well should be killed. Expand the cell population for freezing and for
use in Trim-Away experiments.
c CRITICAL STEP Regularly ensure that the distribution of mCherry-TRIM21 is diffuse and cytoplasmic by fluorescence microscopy (Fig. 4b,e).
Large crescent-shaped aggregates of mCherry-TRIM21 that are nonfunctional can form if levels of expression are too high or cells become over-
confluent. This seems to be a cell-type-specific phenomenon and occurs in cell types in which expression from viral promoters is particularly
high, for instance, in HEK293 cells. In such a case, consider FACS-sorting low mCherry-positive cells or deriving clonal lines and selecting low-
expressing colonies. Alternatively, consider using a tetracycline-inducible promoter to drive TRIM21 expression.
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Box 2 | Preparation of recombinant TRIM21 protein (3 d)
This box describes the procedure for expression and purification of full-length human TRIM21 protein His-Lipoyl-hTRIM21 (Fig. 2g). His-Lipoyl-
hTRIM21 is expressed from a T7-promoter-driven bacterial expression plasmid HLTV-hTRIM21. HLTV-hTRIM21 is available from Addgene
(Reagents) and is a low copy-number ampicillin-resistant plasmid with an N-terminal His tag that can be optionally cleaved by TEV protease.
Biological materials
● OverExpress C41(DE3) chemically competent cells (Sigma-Aldrich, cat. no. CMC0017)
Reagents
● HLTV-hTRIM21 (Addgene, plasmid no. 104973)
● LB-Agar Miller (Formedium, cat. no. LMM02)
● 2× TY medium (Formedium, cat. no. YDB1L)
● D-(+)-Glucose (Sigma-Aldrich, cat. no. G8270)
● Ampicillin sodium salt (Melford, cat. no. A0104)
● IPTG (Melford, cat. no. MB1008)
● Bugbuster plus benzonase (Merck Millipore, cat. no. 70750-3)
● cOmplete, EDTA-free Protease Inhibitor Cocktail (Sigma-Aldrich, cat. no. 04693132001)
● Trizma base (Sigma-Aldrich, cat. no. T1503)
● Sodium chloride (Sigma-Aldrich, cat. no. S3014)
● Ni-NTA agarose (Qiagen, cat. no. 30210)
● Imidazole (Sigma-Aldrich, cat. no. I5513)
Equipment
● Poly-Prep chromatography column (Bio-Rad, cat. no 7311550)
● ÄKTA pure (GE Healthcare Life Sciences)
● S200 gel filtration column (GE Healthcare Life Sciences, cat. no. 28989336)
Reagent setup
● 100 mg/ml ampicillin. Add 10 g of ampicillin sodium salt to 100 ml of sterile water. Filter at 0.45 µm. Divide into 10-ml aliquots and store at
−20 °C (for up to 1 year) until use.
● LB agar plates supplemented with 100 µg/ml ampicillin. Add 40 g of LB-Agar Miller to 1 L of sterile water. Autoclave at 120 °C for 15 min. Cool down
briefly and add 1 ml of 100 mg/ml ampicillin before pouring plates. Store at 4 °C (for up to 3 months) until use.
● 2× TY medium. Add 31 g of 2× TY medium to 1 L of sterile water. Autoclave at 120 °C for 15 min. Freshly prepare before use.
● 0.1 M IPTG. Add 2.38 g of IPTG to 100 ml of sterile water. Filter at 0.45 µm. Divide into 10-ml aliquots and store at −20 °C (for up to 1 year) until
use.
● 10% (wt/vol) glucose. Add 10 g of glucose to 100 ml of sterile water. Autoclave at 120 °C for 15 min. Freshly prepare before use.
● 1 M Tris (pH 8.0). Add 12.1 g of Trizma base to 90 ml of sterile water. Adjust the pH to 8.0 and bring the final volume to 100 ml with sterile water.
Store at room temperature (for up to 1 year) until use.
● 5 M NaCl. Add 29.2 g of sodium chloride to 90 ml of sterile water. Bring the final volume to 100 ml with sterile water. Store at room temperature
(for up to 1 year) until use.
● PBS (pH 8.0). Add 5 g of PBS tablet to 450 ml of sterile water. Adjust the pH to 8.0 and bring the final volume to 100 ml with sterile water. Store
at room temperature (for up to 1 year) until use.
● 3 M imidazole. Add 102.1 g of imidazole to 450 ml of sterile water. Adjust the pH to 8.0 and bring the final volume to 500 ml with sterile water.
Store at room temperature (for up to 1 year) until use.
● Wash buffer (20 mM Tris (pH 8.0)–200 mM NaCl–10 mM imidazole). Add 1.7 ml of 3 M imidazole, 10 ml of 1 M Tris (pH 8.0) and 20 ml of 5 M
NaCl to 468.3 ml of sterile water. Store at room temperature (for up to 1 year) until use.
● 20 mM Tris (pH 8.0)–200 mM NaCl. Add 10 ml of 1 M Tris (pH 8.0) and 20 ml of 5 M NaCl to 470 ml of sterile water. Store at room temperature
(for up to 1 year) until use.
Equipment setup
● ÄKTA pure. The HiLoad 26/600 Superdex 200 pg column should be set up according to the manufacturer’s instructions.
Procedure
1 Freshly transform C41(DE3) cells with HLTV-hTRIM21, and plate the transformed cells onto a LB-agar plate supplemented with 100 µg/ml
ampicillin overnight at 37 °C.
2 Pick colonies and inoculate overnight cultures in 25 ml of 2× TY supplemented with 2% (wt/vol) glucose and 100 µg/ml ampicillin. Shake at
220 r.p.m. at 37 °C.
3 Inoculate 1 liter of 2× TY medium with 10 ml of overnight culture, and supplement with 0.1% (wt/vol) glucose and 100 µg/ml ampicillin. Shake
at 220 r.p.m. at 37 °C.
4 At OD600 0.8–1.2 (after ~3 h), induce with 0.1 mM IPTG and reduce the temperature to 22 °C.
c CRITICAL STEP Induction at OD values >1.2 or overnight growth at higher temperatures will markedly reduce yields.
5 The next day, harvest the cells in 1-liter centrifuge bottles by centrifuging at 5,000g for 20 min at 4 °C (e.g., using a RC3B rotor). Discard the
medium.
j PAUSE POINT Bacterial pellets can be frozen at −20 °C and stored for up to 1 week, and protein preparation can be continued later.
6 Resuspend the cells in 20 ml of Bugbuster plus 1/2 of a crushed Complete, EDTA-free Protease Inhibitor Cocktail tablet per centrifuge tube.
Add 1 M Tris (pH 8.0) to a final concentration of 20 mM and 5 M NaCl to 200 mM.
7 Keep the cells in 50-ml centrifuge tubes (40 ml per tube) on ice-water. Sonicate for a minimum of 2 min with 10-s pulses followed by 10 s of
rest.
c CRITICAL STEP Sonicated solution should be carefully monitored so that it does not become warm. Successful sonication is indicated by a
noticeable reduction in the viscosity of the solution.
(continued)
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Advantages and limitations of the method
In comparison with other currently available protein depletion techniques, Trim-Away has several
unique advantages. First, Trim-Away acts directly at the protein level. It is therefore effective against
long-lived proteins, and the development of phenotypes does not rely on inherent turnover of the
target protein. Second, Trim-Away does not require modification of the genome. It therefore greatly
facilitates loss-of-function studies in models for which DNA– and RNA–based depletion methods are
often ineffective, including nondividing primary cells. Third, Trim-Away is a protein–based depletion
method and can be used in primary immune cells that have active nucleic acid–sensing machineries.
Fourth, TRIM21 is widely expressed in most tissues. This means that it may often be possible to take
advantage of endogenously produced protein and not rely on ectopic overexpression or introduction
of recombinant protein. Fifth, TRIM21 does not have a cellular housekeeping function, in contrast to
E3s such as von Hippel–Lindau that are typically used in PROTAC applications25. This means there
is no competition for endogenous substrates and less likelihood that normal metabolism will be
impacted. Last, Trim-Away uses off-the-shelf reagents for protein targeting. Antibodies have been
produced for almost all proteins and are widely commercially available.
As with any technique, Trim-Away has limitations. One limitation is that Trim-Away depends on
the intrinsic proteasome activity. Hence, the efficiency of Trim-Away may be compromised in certain
cell types and/or at certain cell cycle stages accordingly. Because Trim-Away is a protein-targeting
method, another limitation is that it is more challenging to evaluate off-targets as compared with
gene- or mRNA-targeting methods. Thus, antibodies used for protein-targeting must be carefully
selected and validated before use, as discussed in the ‘Experimental design’ section (‘Antibody
selection’). In addition, an antigen buried within the native protein or a target stably localized in a
particular cellular compartment such as the nucleus will not be accessible for degradation by the
antibody. But the latter case may be circumvented by the use of a smaller nanobody-Fc fusion15.
Finally, the usefulness of Trim-Away may be limited in certain models such as intact tissues, in which
it is challenging to deliver antibody by microinjection or electroporation. However, as there are
intensive efforts to develop cell delivery reagents, it may become possible in the future to use Trim-
Away even in intact-tissue applications. An important potential limitation in Trim-Away is that
TRIM21 both targets proteins for degradation and can activate innate immune signal transduction
pathways such as NF-κB (ref. 26). This is because TRIM21 synthesizes K63-ubiquitin chains, which
when released by the proteasomal DUB RPN11 act as immune second messengers21. Fortunately,
8 Spin down in a SS34 rotor at 20,000g for 40 min at 4 °C. Carefully decant the supernatant. Proceed to Step 9 during centrifugation.
9 In the meantime, wash 10 ml of Ni-NTA agarose in 50 ml of PBS (pH 8.0). Spin at 2,000g for 3 min at room temperature and discard the
supernatant. Repeat once.
c CRITICAL STEP Centrifugation of Ni-NTA beads at higher speeds for longer time periods will compress the resin and reduce its binding
capacity.
10 Add Ni-NTA agarose to the cleared supernatant from step 8 in centrifuge tubes, supplement with 10 mM imidazole and rotate to allow mixing
at 4 °C for ~1 h.
11 Spin down the resin at 2,000g for 3 min at 4 °C and discard the supernatant.
12 Resuspend the resin in 40 ml of wash buffer, re-spin and discard the supernatant. Repeat this step once.
13 Decant the washed resin into an empty gravity-flow column. Wash the resin in place with two bed volumes of wash buffer.
14 Elute the protein from the resin with wash buffer supplemented with 300 mM imidazole.
15 Analyze the eluted protein by SDS-PAGE to ensure that the purification has been successful. This should be visible as a single band running at
~66 kDa following Coomassie staining (Fig. 2g). If so, proceed to step 16.
16 Apply the eluted protein to an S200 gel filtration column equilibrated with 20 mM Tris (pH 8.0)–200 mM NaCl. Select the size of the S200
column depending on the volume of eluate and total amount of protein to be purified. Follow the manufacturer’s guidelines for column capacity
and flow rate.
c CRITICAL STEP Eluted protein will not remain stable under a high concentration of imidazole for prolonged periods, so it must be immediately
buffer-exchanged, desalted or gel-filtered into 20 mM Tris (pH 8.0)–200 mM NaCl.
c CRITICAL STEP Soluble aggregated materials will elute in the void volume of the column and should be discarded.
17 Analyze the peak fractions by SDS-PAGE to ensure that the correct peak is collected and to determine which fractions should be combined.
c CRITICAL STEP TRIM21 is an elongated molecule with a large Stokes radius; if molecular weight standards are used to guide fraction
collection, then note that TRIM21 will behave as if it is a trimer (i.e., 3× its expected molecular weight (~165 kDa)) in an S200 gel filtration
column.
18 Concentrate the combined fractions of TRIM21 using 50-kDa cutoff centrifugal filter units, prepare aliquots and snap-freeze them in liquid
nitrogen.
c CRITICAL STEP The protein solution should be carefully monitored during centrifugation and regularly mixed to prevent superconcentration
at the cellulose membrane.
j PAUSE POINT The purified protein can be stored at −80 °C as long as no signs of protein degradation can be seen.
Box 2| (continued)
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there is a high activation barrier for TRIM21 signaling, and NF-κB activation is highly sensitive to
changes in antibody affinity, concentration and viral dose27,28. For instance, in our Trim-Away
experiment targeting IκBα for degradation, NF-κB was only weakly activated in control cells in which
mTOR was depleted15. If activation of NF-κB is a concern during Trim-Away, this can be assayed for
either through the use of an NF-κB-luciferase reporter or by qPCR for cytokine transcripts.
Experimental design
Antibody selection
Similar to other antibody-based techniques, the specificity of the antibody is critical for a successful
Trim-Away experiment. A good antibody should degrade all antigens bearing the targeted epitope
(i.e., on-target) but not irrelevant antigens (i.e., off-target). When selecting an antibody for Trim-
Away, several parameters should be considered:
● Antibody species. The TRIM21–antibody interaction is highly conserved and maintained both within
and between murine, canine, primate and human species24. Our preliminary results with anti-GFP
antibodies raised in mouse, rabbit and goat suggest no substantial difference in their Trim-Away
efficiency at the same concentration. We have also successfully used antibodies raised in rat15.
However, antibodies from less common hosts such as guinea pig and sheep should be tested before
actual application. TRIM21 does not bind to chicken antibodies.
● Isotype of antibody. TRIM21 has the highest affinity to IgG, followed by IgM and IgA28. Binding of
TRIM21 to IgD or IgE remains unknown. TRIM21 does not bind to IgY.
● Form of antibody. Commercial antibodies are offered in different forms such as full-length Ig, Fab and
Fab2. Because TRIM21 binds to the Fc-region of antibodies, Fab and Fab2 should be avoided.
Considering the growing supply of nanobodies, we have also successfully used a fusion between a
nanobody and the Fc-region of human IgG1 for Trim-Away experiments15.
● Clonality of antibody. We have had success with both polyclonal and monoclonal antibodies. Because
of lot variations between polyclonal antibodies, we recommend using monoclonal antibodies because
they may yield more reproducible results.
● Antigen of antibody. The epitope should be accessible to the antibody under native conditions.
● Antibodies against post-translationally modified proteins. Our preliminary results suggest that Trim-
Away can also be used to selectively degrade proteins with post-translational modifications, as long as
specific antibodies are available. However, these antibodies must be evaluated particularly carefully
before use. For instance, we observed nonspecific binding of some polyclonal antibodies against
phosphorylated kinetochore proteins to acentriolar microtubule-organizing centers, which are also
enriched in phosphorylated proteins in mouse oocytes (and vice versa).
Antibody validation
Before proceeding to Trim-Away, we generally validate the antibody by performing at least two of the
experiments listed below:
● Co-localization with the fluorescently tagged protein. Most proteins localize correctly when they are
tagged with a fluorescent protein. To evaluate whether an antibody is specific, we compare the
localization of the fluorescent protein with the pattern obtained by immunofluorescence using the
antibody of interest. They should be identical. Exceptions to this are some long-lived proteins such as
Rec8 and CenpA in mouse oocytes22,29. These proteins are loaded correctly only during particular
stages of development, which do not allow further incorporation or displacement by their fluorescent
reporter afterward. In addition, comparison of the staining pattern with published data from other cell
types is a useful way to test for specificity.
● Antibody delivery followed by immunofluorescence. To determine the ability of an antibody to recognize
the target protein in live cells, we deliver the antibody by either microinjection or electroporation, and
fix and stain with a secondary antibody. The delivered antibody should show the same localization
pattern as the immunofluorescence of the target protein using a different antibody. It is also possible to
fluorescently label the antibody in order to observe correct binding to the target protein in live cells30.
However, in some cases, antibody delivery may cause target protein degradation via endogenous
TRIM21 and/or cause target protein mislocalization due to the inhibitory effects of antibody binding.
We therefore recommend traditional immunofluorescence as the preferred method to validate
antibodies.
● Immunoprecipitation followed by western blotting. To determine the ability of an antibody to recognize
the target protein in native conformation in cells, we perform immunoprecipitation on the whole-cell
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lysate in non-denaturing conditions. The specific antibody should enrich a single band corresponding
to the target protein over background band(s) (if any) in western blot. We do not recommend
assessing the antibody by performing western blotting alone, as that provides information on only the
specific binding of the antibody to the denatured epitope.
● Cross-validation with other approaches. To test for specific binding of an antibody, when possible, we
first deplete the target protein with other approaches such as genome-editing or RNAi. This is followed
by immunofluorescence using the antibody of interest. Specific binding of the antibody is confirmed by
a reduction in the signal relative to the control. Such validation may also be provided by some antibody
suppliers.
● Peptide pre-incubation followed by immunofluorescence. To test for nonspecific binding of an antibody,
we pre-incubate the antibody with the immunizing peptide before immunofluorescence (Box 3). The
degree of background binding can be estimated by the level of signal retained after blocking specific
binding of the antibody. We highly recommend this assay for post-translational-modification-specific
antibodies.
Source of TRIM21
TRIM21 is widely expressed in most tissues23. This means that most cell types will contain endo-
genous TRIM21 protein, and this may be sufficient for Trim-Away to work simply by delivering an
Box 3 | Peptide pre-incubation assay ● Timing 2–4 d
This box describes the procedures for pre-incubating a primary antibody with its immunizing peptide before
immunofluorescence. This assay allows the evaluation of nonspecific binding of the antibody under native
conditions.
Reagents
● Paraformaldehyde (4% (wt/vol) in PBS; VWR, cat. no. J61899)
● Immunizing peptide (lyophilized; from solid–phase peptide synthesis by a company such as GenScript; custom
order)
● BSA solution (30% (wt/vol) in DPBS; Sigma-Aldrich, cat. no. A9576)
● PBS tablets (Gibco, cat. no. 18912)
● Triton X-100 solution (10% (vol/vol) in H2O; Sigma-Aldrich, cat. no. 93443)
Reagent setup
PBT. Add 1 g of PBS tablets and 5 ml of 10% (vol/vol) Triton X-100 solution to 95 ml of water. Store at 4 °C until
use (for up to 1 year).
PBT–BSA. Add 1 g of PBS tablets, 5 ml of 10% (vol/vol) Triton X-100 solution and 10 ml of 30% (wt/vol) BSA
solution to 85 ml of water. Store at 4 °C until use (for up to 1 year).
Procedure
1 Add an appropriate volume of solvent to dissolve the lyophilized peptide to a final concentration of 133 μM.
c CRITICAL STEP Recombinant protein has been used with success as well, albeit at a higher cost.
2 Fix the identical samples with 4% (wt/vol) paraformaldehyde in PBS for 15–30 min at 37 °C.
3 Permeabilize the samples in PBT overnight at 4 °C.
4 Block the samples in PBT–BSA overnight at 4 °C.
5 Mix the components in the table below and incubate at 4 °C overnight.
Component Amount per reaction (µl) Final concentration
1 mg/ml (primary) antibody 0.2 10 µg/ml (66.7 nM)
133 µM peptide 0 (for no-peptide control) or 2 (for
pre-incubated peptide sample)
0 or 13.3 µM (200× 66.7 nM)
PBT–BSA To 20
6 Pre-clear the mixes from step 5 by centrifuging at 20,000g for 5 min at 4 °C.
7 Incubate one sample with the precleared mix without peptide from step 4 (i.e., no-peptide control) and the
other sample with the precleared mix with peptide from step 4 (i.e., peptide pre-incubated sample) overnight
at 4 °C.
8 Wash the samples in PBT–BSA for 5 min at room temperature (25 °C) three times.
9 Incubate the samples with secondary antibodies diluted in PBT–BSA for 1 h at room temperature.
10 Wash the samples three times in PBT for 5 min at room temperature.
11 Image the samples in PBS.
12 Assess nonspecific bindings from the signal present in both the no-peptide control and peptide pre-incubated
sample.
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antibody to unmodified cells. Indeed, we have found that RPE-1 cells and primary macrophages
contain sufficient endogenous TRIM21 for Trim-Away of several different target proteins15. Cell
types can be screened for TRIM21 expression levels by RT-PCR or by western blotting using anti-
TRIM21 antibodies (see the ‘Reagents’ section). The relative expression levels of TRIM21 can be
compared with those of low-expressing cells (HEK293T) or high-expressing cells (RPE-1). As an
initial Trim-Away experiment, we suggest delivering the antibody to the cells of interest and
screening for target protein depletion. Depending on the cell type and relative expression levels of
cellular TRIM21 and the target protein, antibody delivery alone may be sufficient for target protein
depletion. If target protein depletion does not occur, or is incomplete, then methods for increasing
cellular TRIM21 levels can be considered from among the following options:
● TRIM21 overexpression. In oocytes and early embryos, we found it necessary to overexpress TRIM21
for successful Trim-Away. In these cell types, microinjection of Trim21 mRNA is the recommended
method. In bulk cell populations, it is important to ensure that all cells in the population overexpress
TRIM21. To achieve this, we recommend generating stable cell lines as described in Box 1.
● Recombinant TRIM21 protein. For some cell types, particularly primary cells, it is not possible to
generate stable cell lines overexpressing TRIM21. In this case, it may be preferable to co-deliver a
recombinant TRIM21 protein together with an antibody. Recombinant TRIM21 protein can be readily
produced from bacteria as described in Box 2. Bacterially produced proteins may contain bacterial
contaminants that could perturb certain cell types, such as immune cells. In these cases, it may be
preferable to purify TRIM21 from insect or mammalian cells.
Trim-Away by microinjection of oocytes and early embryos
In our initial study, we microinjected Trim21 mRNA into arrested germinal vesicle (GV) oocytes, and
incubated the oocytes for expression and recovery for 3 h, followed by microinjection of the anti-
body15. Depending on the biological questions to be addressed, antibodies can be microinjected
immediately before meiotic release or during meiosis. Although sequential injections can be mastered
by scientists with extensive experience in micromanipulation, a significant reduction in oocyte sur-
vival and developmental rates is frequently observed for less experienced operators.
We have therefore developed a simplified protocol that involves single microinjection, which
minimizes harm to the cells. Here, we present protocols for both hydraulic- and pressure-based
microinjection systems. Hydraulic-based systems allow injection of a defined volume but require the
use of mercury-filled needles31. Although it is challenging to consistently inject a defined volume
using pressure-based systems, these systems are more widely available, do not involve mercury and
allow more rapid microinjections. The new protocols offer several benefits. First, single microinjec-
tion improves survival and developmental rates to levels comparable to those of routine live-imaging
experiments. Second, depletion starts immediately after microinjection as Trim21 mRNA is trans-
lated, which can be advantageous for early embryos that cannot be arrested at a particular stage of
development. Last, target proteins that are expressed at high endogenous levels (which can take up to
3–4 h for full depletion) are more completely degraded before meiotic release, and phenotypes during
early meiosis are more consistent between individual oocytes.
In addition, we optimized our protocol for preparing mRNAs encoding Trim21 and reporters for
live-cell imaging with several modifications. First, the use of an anti-reverse cap analog (ARCA) yields
transcripts that are all capped in the correct orientation at the 5′ end and, hence, have a higher
translation efficiency than mRNAs that have been synthesized with a standard cap analog. Second,
the increased ratio of cap analog and GTP relative to other NTPs enables the synthesis of transcripts
of up to 12 kb at high yield. Finally, the incorporation of a column cleanup step removes all free
nucleotides, allowing higher accuracy in determination of mRNA concentration and reproducibility
in expression level.
Trim-Away by electroporation of primary cells and cell lines
A successful Trim-Away experiment in bulk cell populations depends on efficient delivery of antibody
to all the cells in a population. Antibodies are large molecules (~150 kDa) that cannot cross cell
membranes. We initially tested antibody delivery by conventional chemical- and lipid-based trans-
fection reagents in addition to several different commercially available protein and antibody trans-
fection reagents. However, this most often led to antibodies being trapped inside intracellular vesicles
with very little antibody actually reaching the cytosol. We also tested classic electroporation using
conventional cuvettes. However, this caused high levels of cell death, and surviving cells tended to
have morphological changes and exhibit antibodies stuck to the cell surface, trapped inside
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intracellular vesicles, and aggregated inside the cells. We and others have found that a new type of
electroporation device with a capillary electrode15,30,32,33, available commercially as the Neon
Transfection System, can be used to deliver antibodies directly to the cytoplasm of almost 100% of
cells without cell death. Cells are morphologically normal after electroporation with the Neon system
and re-adhere and proliferate at a rate similar to that of non-electroporated cells15. Thus, Trim-Away
experiments can be performed by electroporation of antibodies, and phenotypes can be analyzed as
soon as the target protein is depleted, which is usually within 3 h. In addition, we found that efficient
antibody delivery can also be achieved in primary cells such as normal human lung fibroblasts, mouse
bone-marrow-derived macrophages and human monocyte–derived macrophages15. Here, we include
an optimized antibody electroporation protocol that we found to be suitable for antibody delivery in
all cell types tested so far.
Trim-Away controls
To properly interpret a Trim-Away experiment, certain controls can be included. To control for
antibody delivery, we recommend using isotype control antibodies of the same clonality as the
antibodies used for targeted protein degradation. Control antibodies are often raised against proteins
that are not normally expressed in mammalian cells, such as GFP or yeast proteins, and are readily
available from most antibody suppliers. Additional controls such as delivery of antibody buffer alone
and non-electroporated/microinjected cells can also be included. If a Trim-Away experiment requires
TRIM21 overexpression, we also recommend including non-overexpressing cells as an additional
control. Importantly, we found that both antibody delivery and TRIM21 overexpression did not
perturb cell proliferation or induce major changes in global transcript levels15.
Confirmation of protein depletion by Trim-Away
Confirmation of protein depletion by Trim-Away can be achieved by standard methods used to detect
cellular levels of endogenous proteins. For example, immunofluorescence, flow-cytometry or western
blotting methods are suitable. When using secondary antibody-based detection methods to detect
cellular levels of target proteins after treatment with Trim-Away (and also other nontargeted cellular
proteins), it is important to take into account that secondary antibodies will also detect residual
electroporated/microinjected antibody present in the cell if the secondary antibodies are raised
against the same species of antibody as the delivered antibody. This problem will arise if the antibody
delivered to cells for Trim-Away is also used as a primary antibody for protein detection. When
performing western blotting, this will result in detection of IgG heavy chain and light chain on the
membrane (at ~50 kDa and ~25 kDa, respectively), which may interfere with detection of endo-
genous proteins. When performing immunofluorescence or flow cytometry, this will result in higher
levels of background signal. In all detection methods, this problem can be avoided by using primary
antibodies of a different species than the antibodies delivered to the cells for Trim-Away. If there is no
option but to use the same antibody (or antibodies from the same species) for Trim-Away and for
detection, HRP–conjugated secondary antibodies that bind only to the native non-denatured IgG can
be used for western blotting, and primary antibodies can be directly labeled with fluorophores for
immunofluorescence and flow cytometry.
Confirmation of specificity in a Trim-Away experiment
The specificity of depletion in a Trim-Away experiment is determined by the specificity of the
antibody used. Thus, antibodies should be selected carefully, as described above (see ‘Antibody
selection’). If multiple antibodies raised against different regions of the same target protein are
available, these can be used to confirm the specificity of a Trim-Away phenotype. Rescue experiments
can also be performed by overexpressing exogenous target protein. When performing rescue
experiments, it should be considered that the antibody delivered during Trim-Away will probably also
target the exogenous protein for degradation. In this case, it may be necessary to increase expression
levels of the exogenous protein in order to saturate the cellular antibody and TRIM21 to allow for a
rescue. Similarly, the amount of delivered antibody should be minimized to aid rescue experiments. It
may also be possible to rescue a phenotype by overexpressing exogenous protein from a different
species that is not recognized by the antibody used for Trim-Away. Another way to confirm the
specificity of depletion is to express a fluorescently tagged target protein. Upon acute delivery of the
antibody against the target protein, the fluorescent signal should be reduced as a result of
co-degradation of the fluorescent tag.
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Materials
Biological materials
● Mice (e.g., Charles River, cat. no. FVB/NCrl) ! CAUTION Animal experiments must be carried out
according to institutional and national regulations. All experiments in this procedure involving live
mice were approved by the MRC Cambridge Ethical Review Committee and the UK Home Office
under project license nos. PPL 70/8087 and PPL PCF3F9520.
● Cell lines of interest. We have used 293 (HEK-293; ATCC, cat. no. CRL-1573), NIH/3T3 (ATCC,
cat. no. CRL-1658), hTERT RPE-1 (ATCC, cat. no. CRL-4000), U-2 OS (ATCC, cat. no. HTB-96),
HCT 116 (ATCC, cat. no. CCL-247) and HeLa (ATCC, cat. no. CCL-2) cells, although any mammalian
cell line can be used. Cell lines should be grown in the appropriate growth media and maintained with
standard cell culture methods. ! CAUTION Cell lines should be regularly checked to ensure that they
are authentic and not infected with mycoplasma.
● Primary cells of interest. We have used NHLF (Lonza, cat. no. CC2512), human monocyte–derived
macrophages (from patient blood samples, derived as described in ref. 15) and mouse bone-marrow-
derived macrophages (derived as described in ref. 15), although any mammalian primary cells may be




● NAb Protein A/G Spin Kit (0.2 ml; Thermo Fisher Scientific, cat. no. 89950)
● Water (for embryo transfer; Sigma-Aldrich, cat. no. W1503)
● Phosphate–buffered saline (PBS) tablets (Gibco, cat. no. 18912)
Isolation and culture of mouse oocytes and pre-implantation embryos
● Culture medium such as M2 medium (homemade or Sigma-Aldrich, cat. no. MR-015P)
● NaCl (Sigma-Aldrich, cat. no. S5886)
● KCl (Sigma-Aldrich, cat. no. P5405)
● CaCl2 • 2H2O (Sigma-Aldrich, cat. no. C7902)
● KH2PO4 (Sigma-Aldrich, cat. no. P5655)
● MgSO4 • 7H2O (Sigma-Aldrich, cat. no. 63138)
● NaHCO3 (Sigma-Aldrich, cat. no. S3817)
● HEPES (Gibco, cat. no. 15630)
● Na lactate (Sigma-Aldrich, cat. no. L7900)
● Na pyruvate (Sigma-Aldrich, cat. no. 11360)
● Glucose monohydrate (Sigma-Aldrich, cat. no. 49158)
● Penicillin G (Sigma-Aldrich, cat. no. P3032)
● Streptomycin (Sigma-Aldrich, cat. no. S9137)
● BSA (Sigma-Aldrich, cat. no. A3311)
● Phenol red (Sigma-Aldrich, cat. no. P3532)
● Oil (mineral: Sigma-Aldrich, cat. no. M5310, or paraffin: Merck Millipore, cat. no. 107174)
● Dibutyryl cyclic adenosine monophosphate (Sigma-Aldrich, cat. no. D0627-1G)
Constitutive Trim-Away in mouse oocytes and pre-implantation embryos
● Hydrochloric acid (36.5–38.0% (vol/vol); Sigma-Aldrich, cat. no. H1758)
● Silicon grease (medium vacuum; Bayer; Sigma-Aldrich, cat. no. 85402)
● Sigmacote (Sigma-Aldrich, cat. no. SL2)
● Mercury (Sigma-Aldrich, cat. no. 261017)
● NP-40 Surfact-Amps Detergent Solution (Thermo Fisher Scientific, cat. no. 28324)
● Dimethylpolysiloxane (20 cSt; Sigma-Aldrich, cat. no. DMPS2X, or 50 cSt; Sigma-Aldrich, cat. no.
DMPS5X)
Trim-Away by electroporation in cell lines and primary cells
● DMEM (high-glucose; GlutaMAX supplement; pyruvate; Gibco, cat. no. 31966)
● FBS (Gibco, cat. no. 10270)
● DPBS (no calcium; no magnesium; Gibco, cat. no. 14190)
● Trypsin-EDTA (0.05% (wt/vol), phenol red; Gibco, cat. no. 25300)
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● Mouse anti-TRIM21 (D-12; Santa Cruz Biotechnology, cat. no. sc-25351)
● Rabbit anti-TRIM21 (D1O1D; Cell Signaling Technology, cat. no. 92043S)
Equipment
Antibody preparation
● Amicon Ultra-0.5 centrifugal filter unit with Ultracel-100 membrane (Merck Millipore, cat. no.
UFC100)
● Vivaspin 500 (100,000 MWCO PES; Sartorius, cat. no. VS0141)
Isolation and culture of mouse oocytes and pre-implantation embryos
● TC-treated easy-grip-style cell culture dish (35 mm; Corning, cat. no. 353001)
● Microcapillary tube (100 µl; Sigma-Aldrich, cat. no. P1174)
● Aspirator tube assemblies for calibrated microcapillary pipettes (Sigma-Aldrich, cat. no. A5177)
● Stereomicroscope (Zeiss, cat. no. SteREO Discovery.V8)
● Galaxy 48R (Eppendorf, cat. no. CO482)
Constitutive Trim-Away in mouse oocytes and pre-implantation embryos
● Inverted microscope (Zeiss, cat. no. Axio Vert.A1)
● Crossline micrometer (Zeiss, cat. no. 474066-9901-000)
● Vibration-free table (Gutmann, cat. no. 14.860)
● Stage micrometer for transmitted light (Zeiss, cat. no. 474026-0000-000)
● Coarse manipulator (Narishige, cat. no. MN-4)
● Three-axis joystick oil hydraulic micromanipulator (Narishige, cat. no. MO-202U)
● Zeiss 2 adapter (for Eppendorf micromanipulation systems; Eppendorf, cat. no. 5192312002)
● TransferMan 4r (Eppendorf, cat. no. 5193000012)
● 22 × 22 mm no. 0 glass coverslips (Sigma-Aldrich, cat. no. C9802)
● Diamond pencil (CellPath, cat. no. MEA-0301-00A)
● Microinjection chamber (design adapted from ref. 31)
● Capillary that fits into the groove of the microinjection chamber (e.g., Drummond Scientific, cat. no.
1-00-0300)
● Microcaps (Drummond Scientific, cat. no. 1-000-0500)
● Flaming/Brown micropipette puller (Sutter Instrument, cat. no. P-97)
● Calibrated syringe (10 µl; Hamilton, cat. no. 80300)
● CellTram Oil (Eppendorf, cat. no. 5176000076)
● Microloader (Eppendorf, cat. no. 5242956003)
● Femtotip II (Eppendorf, cat. no. 5242957000)
● FemtoJet 4i (Eppendorf, cat. no. 5252000013)
● Holding capillary (VacuTip: Eppendorf, cat. no. 5175 108.000, or VacuTip FCH: Eppendorf, cat. no.
5175 240.006)
● CellTram Air (Eppendorf, cat. no. 5176000068)
● TC-treated easy-grip-style cell culture dish (60 mm; Corning, cat. no. 353004)
Trim-Away by electroporation in cell lines and primary cells
● Corning tissue culture–treated culture dishes (100 mm × 20 mm; Sigma-Aldrich, cat. no. CLS430167)
● Tube (15 ml; polypropylene; screw cap; Greiner Bio-One, cat. no. 188285)
● Eppendorf Safe-Lock tubes (1.5 ml; Eppendorf, cat. no. 0030120086)
● Neon Transfection System starter pack (Invitrogen, cat. no. MPK5000S)
Reagent setup
Trim21 and reporter mRNA
mRNAs encoding Trim21 and reporters for live-cell imaging such as meGFP-MAP4 and
H2B-mCherry are prepared by in vitro transcription as described in Box 4 and can be stored at
−80 °C as long as no signs of mRNA degradation can be seen.
TRIM21-overexpressing stable cell lines
TRIM21-overexpressing cell lines are prepared as described in Box 1 and can be cultivated at
37 °C/5% CO2 as long as no signs of senescence can be seen.
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Box 4 | Trim21 and reporter mRNA preparation ● Timing 8 h
This box describes the procedures for preparing mRNAs encoding Trim21 and reporters for live-cell imaging. The
resulting mRNAs are suitable for microinjection into mouse oocytes or early embryos for expression.
Reagents
● pGEMHE-mCherry-mTrim21 (Addgene, plasmid no. 105522)
● pGEMHE-mEGFP-mTrim21ΔRING-Box (Addgene, plasmid no. 105520)
● pGEMHE-mCherry-mTrim21ΔRING-Box (Addgene, plasmid no. 105523)
● pGEMHE-mEGFP-mTrim21ΔPRYSPRY (Addgene, plasmid no. 105521)
● pGEMHE-mCherry-mTrim21ΔPRYSPRY (Addgene, plasmid no. 105524)
● Nuclease-free water (not DEPC-treated; Invitrogen, cat. no. AM9930)
● CutSmart buffer (NEB, cat. no. B7204S)
● AscI (NEB, cat. no. R0558S or R0558 L)
● Glycogen (RNA grade; Thermo Fisher Scientific, cat. no. R0551)
● Phenol–chloroform–isoamyl alcohol (IAA) mixture (25:24:1; Sigma-Aldrich, cat. no. 77617)
● Sodium acetate buffer solution (3 M; pH 7.0; Sigma-Aldrich, cat. no. S2404)
● Ethanol (Sigma-Aldrich, cat. no. 51976)
● Liquid nitrogen (Sigma-Aldrich, cat. no. 00474-1L)
● HiScribe T7 ARCA mRNA Kit (with tailing; NEB, cat. no. E2060S)
● TURBO DNase (2 U/µl; Invitrogen, cat. no. AM2238)
● NucleoSpin RNA Clean-up XS (Macherey-Nagel, cat. no. 740903)
● Phenol–chloroform–IAA mixture (125:24:1; Sigma-Aldrich, cat. no. 77619)
● Ethylenediaminetetraacetic acid solution (0.5 M; pH 8.0; Sigma-Aldrich, cat. no. 03690)
● Sodium acetate buffer solution (3 M; pH 5.2; Sigma-Aldrich, cat. no. S7899)
● Sodium dodecyl sulfate (SDS) solution (10% (wt/vol) in H2O; Sigma-Aldrich, cat. no. 71736)
Equipment
● Snaplock microcentrifuge tube (1.5 ml; RNase/DNase-free; nonpyrogenic; Corning, cat. no. MCT-150-C)
● Centrifuge, model no. 5424R (refrigerated; Eppendorf, cat. no. 5404000413)
● NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, cat. no. ND-2000)
Reagent setup
● 0.25 M sodium acetate–5 mM EDTA–0.5% (wt/vol) SDS. Add 0.1 ml of 0.5 M EDTA solution, 0.5 ml of
10% (wt/vol) SDS solution and 0.833 ml of 3 M sodium acetate buffer solution (pH 5.2) to 8.567 ml of
nuclease-free water. Divide into 1-ml aliquots and store at −20 °C (for up to 1 year) until use.
● 70% (vol/vol) ethanol. Add 35 ml of ethanol to 15 ml of nuclease-free water. Store at −20 °C (for up to 1 year)
until use.
Equipment setup
● NanoDrop 2000 spectrophotometer. Set up the NanoDrop 2000 spectrophotometer according to the
manufacturer’s instructions.
Procedure
1 Linearization and purification of DNA template (steps 1–12). Mix the components listed below in a 1.5-ml
nuclease-free tube and incubate at 37 °C for 1 h.
Component Amount per reaction (µl) Final concentration
Nuclease-free water 20
0.5 µg/µl Trim21 or reporter construct (in pGEMHE) 20 0.2 µg/µl
10× CutSmart buffer 5 1×
10 U/µl AscI 5 1 U/µl
c CRITICAL STEP We generally use pGEMHE as the vector because it contains a T7 promoter, multiple
cloning sites flanked by 5ʹ- and 3ʹ-untranslated regions (UTRs) of the Xenopus β-globin gene, a short stretch
of (~35-bp) poly(A) sequence and linearization sites. Constructs in other vectors such as pCS2 can also be
used, but the translation efficiency may be lower because of the lack of 5ʹ and 3ʹ UTRs, and poly(A) tailing may
be required.
2 Add 0.5 µl of glycogen, 150 µl of nuclease-free water and 200 µl of phenol–chloroform–IAA (pH 8.0) to
terminate the linearization reaction.
c CRITICAL STEP Addition of glycogen as a co-precipitant is optional, but the yield of precipitated DNA is
higher.
c CRITICAL STEP Phenol–chloroform–IAA is saturated and stored with an equilibration buffer. Do not take in
the upper aqueous layer to avoid dilution.
3 Invert end-to-end to mix well and centrifuge at 20,000g for 5 min at room temperature.
4 Transfer ~180 µl of the upper phase to a new 1.5-ml nuclease-free tube, add 20 µl of 3 M sodium acetate
(pH 7.0) and 400 µl of ice-cold 100% (vol/vol) ethanol.
c CRITICAL STEP Do not use isopropanol, as more salts will be precipitated.
5 Invert end-to-end to mix well and snap-freeze in liquid nitrogen.
(continued)
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6 Centrifuge at 20,000g for 30 min at 4 °C.
c CRITICAL STEP Start centrifugation before the mixture thaws.
7 Discard the supernatant and add 1 ml of ice-cold 70% (vol/vol) ethanol in nuclease-free water.
8 Invert end-to-end to mix well and centrifuge at 20,000g for 1 min at 4 °C.
c CRITICAL STEP Do not vortex, in order to avoid fragmentation of the pellet.
9 Discard ~900 µl of the supernatant and centrifuge at 20,000g for 30 s at 4 °C.
c CRITICAL STEP This step is necessary for avoiding ethanol carryover.
10 Discard the rest of the supernatant and air-dry for 3 min at room temperature.
c CRITICAL STEP After drying, the center of the pellet should remain white, with the edge being transparent.
Over-drying, as indicated by a completely transparent pellet, should be avoided.
11 Add 6 µl of nuclease-free water and pipette up and down to fully dissolve the pellet.
12 Use 1 µl to measure the DNA concentration with a NanoDrop spectrophotometer. We typically recover
~7–8 µg of linearized DNA.
j PAUSE POINT Linearized DNA can be stored at −20 °C for up to 1 week until use.
13 In vitro transcription of capped mRNA (step 13). Mix the components listed below in a 1.5-ml nuclease-free tube
and incubate at 40 °C for 4 h.
Component Amount per reaction (µl) Final concentration
Nuclease-free water 19 or 21.5
~1.2 µg/µl linearized DNA 2.5 (for mRNA of <6 kb) or 5 (for mRNA of ≥6 kb) 0.05 or 0.1 µg/µl
2× ARCA/NTP mix 30 1×
T7 RNA polymerase mix 6
c CRITICAL STEP We use the HiScribe T7 ARCA mRNA Kit (with tailing) for successful transcription of full-
length mRNAs of up to 12 kb at high yield. Other in vitro transcription kits can also be used, but the ratio of
ARCA:GTP:CTP:ATP:UTP should be adjusted from 0.8:0.2:1:1:1 to 4:1:1:1:1.
c CRITICAL STEP For constructs with other promoters such as T3 or SP6, the corresponding RNA polymerase
should be used.
14 Removal of DNA template (step 14). Add 3 µl of 2 U/µl TURBO DNase and incubate at 37 °C for 15 min.
c CRITICAL STEP Other DNase I can be used as well.
15 (Optional) Poly(A) tailing of mRNA (steps 15 and 16). Mix the components listed below and incubate at 37 °C for
3 min.
Component Amount per reaction (µl) Final concentration
Nuclease-free water 192
Mix from step 13 63
10× Poly(A) polymerase reaction buffer 30 1×
c CRITICAL STEP We generally omit steps 15 and 16 when we synthesize mRNAs from pGEMHE-based
plasmids, and instead add 237 µl of nuclease-free water and directly proceed to step 17. However, poly(A)
tailing can be advantageous for assays with a longer time frame (i.e., >24 h) or for mRNAs transcribed from
constructs without a short stretch of poly(A) tail.
16 Add 15 µl of poly(A) polymerase and incubate at 37 °C for 30 min.
17 Removal of free nucleotides (step 17). Purify the mRNA using NucleoSpin RNA Clean-up XS and elute with
160 µl of nuclease-free water.
c CRITICAL STEP This step can be omitted, but then the final RNA concentration cannot be directly
determined with a NanoDrop spectrophotometer because of free-nucleotide contamination.
18 Purification of mRNA (steps 18–23). Add 0.5 µl of glycogen, 40 µl of 0.25 M sodium acetate–5 mM EDTA–0.5%
(wt/vol) SDS and 200 µl of phenol–chloroform–IAA (pH 4.0).
c CRITICAL STEP Addition of glycogen as a co-precipitant is optional, but the yield of precipitated mRNA is
higher.
c CRITICAL STEP Phenol–chloroform–IAA is saturated and stored with an equilibration buffer. Do not take in
the upper aqueous layer to avoid dilution.
19 Invert end-to-end to mix well and centrifuge at 20,000g for 5 min at room temperature.
20 Transfer ~180 µl of the upper phase to a new 1.5-ml nuclease-free tube and add 360 µl of ice-cold
100% (vol/vol) ethanol.
c CRITICAL STEP Do not use 100% isopropanol, as more salts will be precipitated.
21 Repeat steps 5–10.
22 Add 11 µl of nuclease-free water and pipette up and down to fully dissolve the pellet.
23 Use 1 µl to measure the RNA concentration with a NanoDrop spectrophotometer.
c CRITICAL STEP RNA concentration can also be determined with other techniques such as agarose gel
electrophoresis and comparison with RNA markers of known concentration or fluorescence–based Qubit RNA
assays.
c CRITICAL STEP We typically obtain mRNA at ~1–3 µg/µl.
j PAUSE POINT mRNA should be divided into 0.6-µl single-use aliquots and can be stored at −80 °C as long
as no signs of mRNA degradation can be seen.
Box 4| (continued)
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Recombinant TRIM21 protein
TRIM21 protein is prepared by purification from bacteria as described in Box 2 and can be stored at
−80 °C as long as no signs of protein degradation can be seen.
PBS for antibody preparation
Dissolve 5 g of PBS tablets in 500 ml of embryo-tested or nuclease-free water. Store at room
temperature as long as no signs of contamination can be seen.
Homemade culture medium for isolating mouse oocytes and pre-implantation embryos
We routinely use modified M2 medium as described in ref. 34 for culture of mouse oocytes and pre-
implantation embryos. The modified M2 medium contains 5.53 g/liter NaCl, 0.36 g/liter KCl,
0.25 g/liter CaCl2 • 2H2O, 0.16 g/liter KH2PO4, 0.29 g/liter MgSO4 • 7H2O, 0.35 g/liter NaHCO3, 4.97
g/liter HEPES, 2.6 g/liter Na lactate, 0.04 g/liter Na pyruvate, 1.1 g/liter glucose monohydrate, 4 g/liter
BSA, 0.06 g/liter penicillin G, 0.05 g/liter streptomycin and 0.002 g/liter phenol red. We reduce the
concentration of phenol red from 0.01 g/liter to 0.002 g/liter, as phenol red is toxic for mouse oocytes
and early embryos. Store at 4 °C for up to 2 weeks. c CRITICAL We obtain higher developmental rates
with homemade M2 medium than with commercial M2 medium. c CRITICAL Drugs such as 250 μM
dibutyryl cyclic adenosine monophosphate should be added to the culture medium to maintain meiotic
arrest for GV oocytes.
DMEM supplemented with 1× GlutaMAX and 10% (vol/vol) FBS
Add 55 ml of FBS to 500 ml of DMEM. Store at 4 °C for up to 1 year from the date of manufacture
until use.
Equipment setup
Mouth pipette for isolation and culture of mouse oocytes and pre-implantation embryos
Pull microcapillary tubes above a gas burner. Break the tip by striking a pair of pipettes against each
other to obtain a smooth opening of ~80–100 μm. Attach a pipette to the aspirator tube assembly.
More details on mouth pipettes can be found in ref. 35.
Microinjection setup
Install the inverted microscope on a vibration-free table. For the use of hydraulics-based systems,
mount the coarse manipulator and the three-axis joystick oil hydraulic micromanipulator on one side
of the arm. For the use of pressure-based systems, install the Adapter Zeiss 2 and mount a Trans-
ferMan 4r on both sides of the arm.
Coverslips
Boil 0.5 liter of deionized water in a microwave oven, add a few drops of dishwashing detergent and
add 22 × 22 mm no. 0 glass coverslips one by one. Incubate for 20 min at room temperature and
discard the detergent solution. Rinse with deionized water three times, boil and rinse with deionized
water three times again. Transfer the coverslips one by one to 0.5 liter of 5 M hydrochloric acid and
incubate overnight at room temperature. Rinse five times with deionized water and three times with
double-distilled water. Transfer the coverslips one by one to 70% (vol/vol) ethanol for storage. Blot-
dry excess ethanol solution and air-dry before use. c CRITICAL Using unwashed coverslips for
microinjection may compromise the survival rate of oocytes and early embryos during microinjection.
Microinjection chamber
Cut a washed coverslip along the edges into six equal rectangular pieces (shelves) and a center square
piece with a diamond pencil. Attach a piece of double-sided tape of approximately the same
dimensions as a shelf (as a spacer of ~100 μm) close to the center of another washed coverslip at
~5 mm from one edge. Attach a shelf to the double-sided tape to form an ~0.5-mm loading space at
the side closest to the edge. Apply a thin layer of silicon grease along the U-shaped cut on both sides
of the microinjection chamber. Attach the coverslip, with the loading space facing away from the
U-shaped cut, to the side of the microinjection chamber with a groove for placing the capillary.
Attach another washed coverslip to the other side of the microinjection chamber. Gently press on the
coverslips to spread the silicon grease. Fill the U-shaped reservoir with culture medium, and keep the
microinjection chamber in a humidified container at 37 °C before use. After loading and before
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microinjection, apply a thin layer of silicon grease along the groove and insert the capillary with
mRNA and/or antibody.
Microinjection needle
Siliconize the microcaps by dipping one end into a beaker containing ~0.5 cm of Sigmacote. A column
of Sigmacote will form as a result of capillary action. Invert the microcaps end to end several times so
that the entire length is fully covered with Sigmacote. Blot-dry excess Sigmacote at one end and air-dry
for at least 2 weeks. Pull siliconized microcaps in a Flaming/Brown micropipette puller to obtain pairs
of pipettes with an opening of ~0.5–1 μm after breaking the tip. Back-load ~1 µl of mercury as close to
the tip as possible with a 10-µl calibrated syringe. c CRITICAL Siliconizing the microcaps largely
facilitates the flow of mercury within the microinjection needle. c CRITICAL Insufficient drying of
Sigmacote increases the chance of breaking the mercury column during microinjection.
CellTram oil
Set up the CellTram Oil according to the manufacturer’s instructions. Fill it with mineral oil.
FemtoJet 4i
Set up the FemtoJet 4i according to the manufacturer’s instructions.
CellTram Air
Set up the CellTram Air according to the manufacturer’s instructions.
Neon Transfection System for electroporation in primary cells and cell lines
The Neon Transfection System should be set up according to the manufacturer’s instructions.
Procedure
Antibody preparation for Trim-Away ● Timing 1–2 h
c CRITICAL This section describes how to prepare the antibody of interest for Trim-Away.
Ultrafiltration is necessary for removing contaminants that are cytotoxic (e.g., sodium azide) or interfere
with microinjection (e.g., glycerol).
1 If the antibody is from an unpurified source such as serum, ascites fluid or cell culture
supernatant, or contains BSA or gelatin, pre-purify the antibody using the 0.2-ml NAb protein
A/G Spin Kit.
c CRITICAL STEP This step is necessary for removing contaminating proteins, which lead to an
overestimation of the IgG concentration. Gelatin is not compatible with the Amicon Ultra-0.5
100-K devices used in Step 3.
2 Mix the components listed below in a 1.5-ml nuclease-free tube on ice.
Component Amount per reaction (µl) Final concentration
PBS (in embryo-tested or nuclease-free water) 400–450
1 mg/ml antibody 50–100 0.1–0.2 µg/µl
c CRITICAL STEP For co-injection of Trim21 mRNA and antibody using FemtoJet, PBS should be
prepared in nuclease-free water instead to reduce the chance of RNase contamination.
3 Insert an Amicon Ultra-0.5 100-K device into a provided collection tube.
4 Apply 500 µl of diluted antibody from Step 2 to the device.
5 Align the cap strap of the collection tube and the membrane of the device toward the center of
the rotor.
6 Centrifuge at 14,000g for 10 min at 4 °C.
c CRITICAL STEP Higher centrifugal force may damage the membrane and cause sample loss.
7 Discard the flow-through.
8 Add 480 µl of PBS to the Amicon Ultra-0.5 100-K device and carefully mix well.
c CRITICAL STEP Mixing is necessary to avoid a high local concentration during ultrafiltration,
which can cause protein aggregation and loss. Avoid touching the membrane with the pipette tip, as
this may damage the membrane and cause sample loss.
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9 Repeat Steps 5–7 twice.
? TROUBLESHOOTING
10 Insert the inverted Amicon Ultra-0.5 100-K device into another provided collection tube.
11 Align the open cap toward the center of the rotor.
12 Centrifuge at 1,000g for 2 min at 4 °C.
13 Use 2 µl to measure the IgG concentration with a NanoDrop spectrophotometer.
c CRITICAL STEP 1.0 OD280 is equivalent to 0.714 mg/ml IgG.
c CRITICAL STEP We typically retrieve ~20 µl of purified antibody at ~1.25–2.5 mg/ml from 50 µg
of input.
? TROUBLESHOOTING
14 Snap-freeze in liquid nitrogen.
c CRITICAL STEP The purified antibody should be divided into 1- to 2-µl single-use aliquots to
minimize freeze–thaw cycles in the absence of cryoprotectant.
j PAUSE POINT The antibody can be stored at −80 °C as long as no loss of activity can be seen.
Isolation and culture of mouse oocytes and pre-implantation embryos ● Timing >1 h
15 Isolate and culture mouse GV, meiosis II (MII) oocytes or early embryos in oil as previously
described in refs. 36–41.
Trim-Away by microinjection of mouse oocytes and pre-implantation embryos ● Timing
4–5 h
16 To perform constitutive depletion (Fig. 3a) using hydraulic systems, follow option A. To perform
constitutive depletion using pressure-based systems, follow option B. To perform acute depletion
(Fig. 3b), follow option C.
(A) Constitutive depletion using hydraulic-based systems such as CellTram Oil ● Timing 4–5 h
(i) Mix the components listed below in a 1.5-ml nuclease-free tube on ice.
Component Amount per reaction (µl) Final concentration
2 µg/µl Trim21 mRNA 0.5 400 ng/µl
Reporter mRNA(s) Variable Usually 30–300 ng/µl each
Nuclease-free water To 2.5
j PAUSE POINT The mRNA mix can be stored at −20 °C or −80 °C (for up to 1 year)
until use. We usually freeze–thaw the mRNA mix up to four times without noticeable RNA
degradation.




2 mg/ml antibody/antibodies from Step 14 1.25 1 mg/ml each
0.5% (vol/vol) NP-40 (in embryo-tested water) 0.25–0.5 0.05–0.1% (vol/vol)
PBS (in embryo-tested water) To 2.5
c CRITICAL STEP Antibody at a final concentration of 1 mg/ml is a good starting point for
complete depletion of most target proteins. However, we suggest titrating individual
antibodies to the minimal effective concentration, as some can have secondary inhibitory
effects.
c CRITICAL STEP For antibody at a final concentration of <0.1 mg/ml, storage in a low-
protein-binding tube or preparation of fresh antibody mix is recommended.
c CRITICAL STEP NP-40 largely facilitates the flow of the viscous antibody mix within the
microinjection needle and reduces the chance of clogging.
j PAUSE POINT For short-term storage (up to 1 week), the antibody mix can be stored at
4 °C in a 1.5-ml tube with the opening sealed with Parafilm. However, changes in ionic
strength due to repeated evaporation and condensation at the cap can denature the
antibody/antibodies. For long-term storage (up to at least 1 month), the antibody mix can
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be stored at −20 °C or −80 °C until use. We usually freeze–thaw the antibody mix up to
four times without noticeable loss of activity.
(iii) Centrifuge the mRNA mix and antibody mix at 20,000g for 5 min at 4 °C before capillary
loading.
c CRITICAL STEP This step is necessary for reducing the amount of precipitated material
loaded into the capillary.
(iv) Load 0.5 µl of dimethylpolysiloxane into a capillary.
c CRITICAL STEP Avoid introducing air bubbles from Step 16A(iv) to Step 16A(viii).
c CRITICAL STEP Follow the order of loading (Fig. 3c) from Step 16A(iv) to Step 16A(viii).
? TROUBLESHOOTING
(v) Load 0.5 µl of precleared antibody mix.
c CRITICAL STEP As little as 0.25 µl can be used.
? TROUBLESHOOTING
(vi) Load 0.5 µl of dimethylpolysiloxane.
? TROUBLESHOOTING
(vii) Load 0.5 µl of precleared mRNA mix.
c CRITICAL STEP As little as 0.25 µl can be used.
? TROUBLESHOOTING
(viii) Load 0.5 µl of dimethylpolysiloxane.
c CRITICAL STEP The loaded capillary should be kept on ice until use.
? TROUBLESHOOTING
(ix) Transfer oocytes or early embryos to the loading space of the microinjection chamber using
a mouth pipette under the stereomicroscope.
(x) Mount a microinjection needle onto the capillary holder attached to the CellTram Oil.
(xi) Attach the capillary holder to the micromanipulator.
(xii) Carefully tap the tip of the microinjection needle against the wall of the capillary to obtain
an opening of ~0.5–1 μm and slowly push the mercury column to the front.
c CRITICAL STEP An opening of >1 μm will increase the risk of lysis after microinjection,
but an opening of <0.5 μm will increase the chance of clogging.
(xiii) Determine the injection volume by loading different amounts of polydimethylsiloxane into
the microinjection needle and carefully expelling it into the mRNA mix. A
polydimethylsiloxane droplet will form. The corresponding volume can be calculated
using the formula 4/3 × π × (d/2)3, in which d is the diameter of the droplet.
(xiv) Load ~1 pl of polydimethylsiloxane into the microinjection needle.
(xv) Load 3.5 pl of mRNA mix.
(xvi) Load ~1 pl of polydimethylsiloxane.
(xvii) Load 3.5 pl of antibody mix.
(xviii) Load ~1 pl of polydimethylsiloxane.
c CRITICAL STEP The mRNA mix and antibody mix should not be mixed within the
microinjection needle in order to avoid RNA degradation before microinjection.
c CRITICAL STEP The antibody mix can be injected at a volume of up to 8.5 pl without
harming the oocytes, which may be necessary for antibody/antibodies that cannot be
concentrated to the desired concentration.
(xix) Adjust the level of the microinjection needle until the plasma membrane of the oocyte or
early embryo is in focus.
(xx) Carefully press the tip of the microinjection needle against the oocyte or early embryo until
it penetrates the plasma membrane.
(xxi) Expel the column of polydimethylsiloxane–mRNA mix–polydimethylsiloxane–antibody
mix into the cytoplasm.
(xxii) Quickly withdraw the microinjection needle to release the oocyte or early embryo.
(xxiii) Repeat Steps 16A(xiv)–(xxii).
c CRITICAL STEP A successful microinjection is indicated by cytoplasmic movement and
the presence of two dimethylpolysiloxane droplets.
c CRITICAL STEP A video and an illustration describing hydraulic-based microinjection
step by step can be found at https://health.uconn.edu/cell-biology/wp-content/uploads/
sites/115/2017/07/follicleinjection.mp4?_=2 and in ref. 41, respectively.
(xxiv) Transfer microinjected oocytes or early embryos from the microinjection chamber to a
50-µl drop of culture medium covered with oil in a 35-mm dish.
PROTOCOL NATURE PROTOCOLS
2166 NATURE PROTOCOLS | VOL 13 |OCTOBER 2018 | 2149–2175 |www.nature.com/nprot
(xxv) Incubate at 37 °C for 3 h before performing an assay such as live imaging or
immunofluorescence.
c CRITICAL STEP Full depletion of some target proteins can take up to 4 h.
(B) Constitutive depletion using pressure-based systems such as the FemtoJet 4i● Timing 4–5 h




2 µg/µl Trim21 mRNA 0.25 200 ng/µl
Reporter mRNA(s) Variable Usually 15–150 ng/µl each
2 mg/ml antibody/antibodies from Step 14 0.625 0.5 mg/ml each
0.5% (vol/vol) NP-40 (in nuclease-free water) 0.25–0.5 0.05–0.1% (vol/vol)
PBS (in nuclease-free water) To 2.5
c CRITICAL STEP Antibody at a final concentration of 0.5 mg/ml is a good starting point for
complete depletion of most target proteins. However, we suggest titrating individual antibodies
to the minimal effective concentration, as some can have secondary inhibitory effects.
c CRITICAL STEP For antibody at a final concentration of <0.1 mg/ml, storage in a low-
protein-binding tube or preparation of fresh mRNA and antibody mix is recommended.
c CRITICAL STEP NP-40 largely facilitates the flow of viscous mRNA and antibody mix
within the Femtotip II and reduces the chance of clogging.
j PAUSE POINT The mRNA and antibody mix can be stored at −20 °C or −80 °C for up
to 1 year until use. We usually freeze–thaw the mRNA and antibody mix up to four times
without noticeable denaturation and/or RNA degradation.
(ii) Centrifuge the mRNA and antibody mix at 20,000g for 5 min at 4 °C before loading.
c CRITICAL STEP This step is necessary for reducing the amount of precipitated materials
loaded into the capillary.
(iii) Load 0.5 µl of mRNA and antibody mix into the tip of a Femtotip II using a Microloader.
c CRITICAL STEP Avoid introducing air bubbles.
(iv) Mount a Femtotip II onto the capillary holder of the FemtoJet 4i.
(v) Mount a holding capillary onto the capillary holder of the CellTram Air.
c CRITICAL STEP We have also successfully used the FemtoJet 4i with a microinjection
chamber instead of a holding capillary.
(vi) Attach the capillary holders to the TransferMan 4r.
(vii) Transfer oocytes or early embryos to a drop of culture medium covered with oil on the lid
of a 60-mm dish.
(viii) Determine the appropriate settings for the microinjection program to inject a volume of
~7 pl by first microinjecting different amounts of a fluorescent dye into oocytes or early
embryos and measuring the intracellular fluorescence intensity and the fluorescence
intensity of a series of dye solutions of known concentration. The injection volume can
then be calculated using the formula Fdye injected × Vdye injected = Fcell × Vcell, in which
Fdye injected and Vdye injected are the fluorescence intensity and volume of the dye
solution microinjected, respectively, and Fcell and Vcell are the fluorescence intensity and
volume of the oocyte or early embryo microinjected, respectively. More details can be
found in refs. 42 and 43.
c CRITICAL STEP This step depends on the experience of the scientist and may be
optional.
c CRITICAL STEP The mRNA and antibody mix can be injected at a volume of up to 12 pl
without harming the oocytes, which may be necessary for antibody/antibodies that cannot
be concentrated to the desired concentration.
(ix) Adjust the level of the holding capillary until the oocyte or early embryo is in focus.
? TROUBLESHOOTING
(x) Secure an oocyte or early embryo in place by applying a negative pressure at the holding
capillary.
(xi) Adjust the level of the Femtotip II until the plasma membrane of the oocyte or early
embryo is in focus.
? TROUBLESHOOTING
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(xii) Push the tip of the Femtotip II against the oocyte or early embryo until it penetrates the
plasma membrane.
(xiii) Press the ‘Inject’ button on the FemtoJet 4i to expel ~7 pl of mRNA and antibody mix into
the cytoplasm.
(xiv) Quickly withdraw the microinjection needle.
(xv) Release the oocyte or early embryo by applying a positive pressure at the holding capillary.
(xvi) Repeat Step 16B(ix–xv).
c CRITICAL STEP A successful microinjection is indicated by a cytoplasmic movement.
c CRITICAL STEP A video describing pressure-based microinjection step by step can be
found in ref. 44.
? TROUBLESHOOTING
(xvii) Transfer microinjected oocytes or early embryos from the stage to a 50-µl drop of culture
medium covered with oil in a 35-mm dish.
(xviii) Incubate at 37 °C for 3 h before performing an assay such as live imaging or
immunofluorescence.
c CRITICAL STEP Full depletion of some target proteins can take up to 4 h.
? TROUBLESHOOTING
(C) Acute depletion ● Timing >4 h
(i) Prepare the mRNA mix as in Step 16A(i).
(ii) Microinject 3.5 pl using a hydraulic-based system as in Step 16A(iii–xix) or a pressure-
based system as in Step 16B(ii–ix).
? TROUBLESHOOTING
(iii) Transfer microinjected oocytes or early embryos to a drop of culture medium covered with
oil.
(iv) Incubate at 37 °C until the desired developmental stage.
(v) Prepare the antibody mix as in Step 16A(ii).
(vi) Repeat Step 16C(ii).
? TROUBLESHOOTING
(vii) Immediately proceed to an assay such as live imaging or immunofluorescence
? TROUBLESHOOTING
Trim-Away by electroporation in primary cells and cell lines ● Timing <1 h
17 Trypsinize the cells using standard cell culture procedures and transfer them to a 15-ml tube.
18 Pellet the cells at 300g for 5 min at room temperature and discard the supernatant.
19 Resuspend the cell pellet in 10 ml of PBS and count the cells.
c CRITICAL STEP The cells should be thoroughly resuspended in PBS to avoid cell clumping,
which can provide inaccurate results in cell counting.
20 Transfer n × (8 × 105) cells to a new 15-ml tube (where n = number of electroporation reactions).
c CRITICAL STEP We routinely use 8 × 105 cells per electroporation reaction with a 10-µl Neon tip.
However, it is possible to use any number of cells between 1 × 105 and 1.5 × 106, depending on the
type and size of cells, without any detrimental effects on antibody delivery or cell survival.
21 Pellet the cells at 300g for 5 min at room temperature and discard all but ~1 ml of supernatant.
22 Using residual supernatant, transfer the cells to a new 1.5-ml tube.
23 Pellet the cells at 300g for 5 min at room temperature. In the meantime, proceed with Step 24.
24 During Step 23, insert a Neon Tube into the Neon Pipette Station and fill the Neon Tube with 3 ml
of Neon Buffer E.
25 Carefully remove the supernatant.
c CRITICAL STEP The supernatant should be removed carefully, using a Gilson pipette, to avoid
disturbing the cell pellet and subsequent cell loss.
26 Resuspend the cell pellet in n × 10 µl of Neon Buffer R (where n = number of electroporation
reactions).
c CRITICAL STEP Once the cells are resuspended in Neon Buffer R, it is important to proceed with
electroporation immediately. Prolonged incubation (>30 min) in Neon Buffer R can reduce cell
viability.
27 Add 10.5 µl (~8 × 105) of cells per electroporation reaction to 1.5-ml tubes.
c CRITICAL STEP It is important to avoid introducing air bubbles, which can cause arcing during
electroporation.
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28 Add 2 µl of antibody from Step 14 to the cells and mix gently.
c CRITICAL STEP Antibody at a concentration of 1 mg/ml is a good starting point for complete
depletion of most target proteins. However, we suggest titrating individual antibodies to the
minimal effective concentration, as some can have secondary inhibitory effects.
c CRITICAL STEP It is important to avoid introducing air bubbles, which can cause arcing during
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Fig. 2 | Trim-Away in cell lines. a,d, NIH3T3, NIH3T3-mCherry-mTRIM21, HEK293T and HEK293T-mCherry-hTRIM21 cell lines were analyzed by flow
cytometry. At least 2,000 cells were counted for each condition. Percentages correspond to mCherry-positive cells falling within the gate drawn. b,e,
NIH3T3-mCherry-mTRIM21 and HEK293T-mCherry-hTRIM21 cells were imaged by confocal microscopy, detecting mCherry fluorescence. Scale bars,
50 µm. c, NIH3T3 and NIH3T3-mCherry-mTRIM21 cell lines were electroporated with control IgG or anti-pericentrin antibodies and analyzed 16 h later
by immunoblotting. f, HEK293T and HEK293T-mCherry-hTRIM21 cell lines were electroporated with PBS or anti-IKKα antibody and analyzed 3 h later
by immunoblotting. g, Coomassie-stained gel shows His-Lipoyl-hTRIM21 protein. Asterisks indicate bacterial contaminants (*) and degradation
products (**). h, The indicated cell lines were electroporated with PBS, anti-ERK1 antibody, His-Lipoyl-TRIM21 or anti-ERK1 + His-Lipoyl-TRIM21 and
analyzed 3 h later by immunoblotting. a.u., arbitrary units; Pcnt, pericentrin. a–f and h adapted from ref. 15 (https://doi.org/10.1016/j.cell.2017.10.033;
original material licensed under a Creative Commons Attribution License 4.0).
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12.5 µl per electroporation reaction should be used, as this helps prevent any air bubbles being
taken up into the 10-µl Neon Tip in Step 28.
29 Take up the cell/antibody mix into the 10-µl Neon Tip.
c CRITICAL STEP It is essential to avoid taking up air bubbles into the 10-µl Neon Tip, as these can
cause arcing during electroporation. Using a single smooth pipetting action combined with
gentle swirling is recommended. Avoid pipetting up and down. For detailed instructions on how to
insert the 10-µl Neon Tip into the Neon Pipette, refer to the Neon Transfection System manual
(https://tools.thermofisher.com/content/sfs/manuals/neon_device_man.pdf).
? TROUBLESHOOTING
30 Insert the Neon Pipette with the sample in the tip into the Neon Tube containing 3 ml of Neon
Buffer E assembled in the Neon Pipette Station. Push down vertically until a click is heard.
31 Electroporate using the following parameters: 1,400 V, two pulses, 20 ms per pulse.
c CRITICAL STEP If there is a visible spark, discard the sample and return to Step 28.
32 Transfer the sample to a 1.5-ml tube containing 1 ml of prewarmed cell growth medium without
antibiotics. Electroporated cells can now be plated as determined by the scientist. An incubation
time of ~3 h is usually sufficient for target protein degradation.
? TROUBLESHOOTING
Troubleshooting
Troubleshooting advice can be found in Table 1.
Table 1 | Troubleshooting table
Step Problem Possible reason Solution
Antibody preparation
9 The antibody cannot be concen-
trated further than to ~20 µl
The membrane is clogged with
precipitated materials
Pre-clear the antibody at 20,000g for 5 min at 4 °C and
use the supernatant for Step 2
Rotate the device 180° to make use of the other
membrane
Use a Vivaspin ultrafiltration device instead, as it can
concentrate antibody down to 5 µl
13 Antibody is lost after
ultrafiltration
The membrane is damaged Check the centrifugal force and avoid touching the
membrane with the pipette tip
The antibody is binding to the
regenerated cellulose membrane
Use a Vivaspin ultrafiltration device instead, as it uses
polyethersulfone rather than a regenerated cellulose
membrane
Antibody concentration is much
higher than expected
The antibody solution contains
stabilizing proteins such as BSA
Pre-purify the antibody using a 0.2-ml Nab Protein
A/G Spin Kit
Trim-Away by microinjection of mouse oocytes and pre-implantation embryos
16A(iv–viii) mRNA mix mixes with the
antibody mix within the capillary
The mRNA mix was loaded before the
antibody mix






Femtotip II becomes clogged
every few injections
Precipitated materials were loaded into
the capillary
Pre-clear for longer and/or break the tip more
Precipitated materials were loaded into
the Femtotip II
Pre-clear for longer, break the tip more and/or use the
‘Clean’ function
The antibody concentration is too high Use 0.1% (vol/vol) NP-40 and/or inject a larger
volume of diluted antibody mix
Oocytes and early embryos do
not survive the microinjection
The GV is damaged Inject close to the GV but do not penetrate the
membrane of the GV
The opening of the microinjection
needle is too wide
Adjust the program of the needle puller to obtain a
thinner microinjection needle
Break the tip of the microinjection needle just enough
for the mercury to flow to the tip
The injection volume is too large Do not inject more than 12 pl (~6%) for mouse oocytes
The intracellular NP-40 concentration is
too high
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Table 1 (continued)




Target protein is not degraded The antibody does not recognize the
antigen
Use another antibody
TRIM21 does not recognize the
antibody
Confirm that the antibody contains an exposed Fc
region or use another antibody
The microinjection was not successful Confirm that the microinjection needle or Femtotip II
penetrates the plasma membrane and there is
cytoplasmic movement due to liquid outflow
Oocytes and early embryos were
treated with a proteasome inhibitor
such as MG132
Do not use a proteasome inhibitor during incubation or
apply it after incubation
Depletion is not efficient or
complete
The endogenous level of the target
protein is too high
Incubate longer to allow degradation before the start of
the assay, use a higher concentration of antibody and/
or inject more antibody mix
The expression level of Trim21 mRNA is
too low
Incubate longer to allow expression before the start of
the assay, use a higher concentration of Trim21 mRNA
and/or poly(A)-tail Trim21 mRNA
The Trim21 mRNA is degraded Make sure that all materials are handled in an RNase-
free manner
Oocytes and early embryos do
not develop normally
Microinjected oocytes and early
embryos were left outside the incubator
for too long
Inject fewer oocytes and early embryos at a time and
replace the medium in the microinjection chamber after
each round of microinjection
The injection volume was too large Do not inject more than 12 pl (~6% of the oocyte
volume) for mouse oocytes
The intracellular NP-40 concentration is
too high
Use 0.05% (vol/vol) NP-40 and/or inject less antibody
mix
The mRNA mix and/or antibody mix is/
are contaminated by embryo-toxic
substance(s)
Test the nuclease-free water and/or repeat the mRNA
and/or antibody preparation
The antibody has secondary inhibitory
effects
Reduce the injection volume or antibody concentration
and/or use another antibody
Reporter mRNA(s) is/are
overexpressed
Reduce the injection volume and/or mRNA
concentration
29 Air bubbles are present in the
10-µl Neon Tip
Air bubbles are present in the sample,
inaccurate pipetting or insufficient
sample volume
Gently tap the sample tube to remove air bubbles
before taking up sample into the10-µl Neon Tip, ensure
that the electroporation reaction sample has a volume
of 12.5 µl or take up the sample into the 10-µl Neon Tip
more slowly
32 Target protein is not degraded The antibody does not recognize the
antigen
Use another antibody
The antibody does not recognize the
native protein inside the cells
Use an antibody that has been tested to work by
immunofluorescence
The electroporated antibody cannot
gain access to the target protein
Allow a longer incubation time; incubation of cells for at
least one cell division cycle allows degradation of
retained nuclear target proteins
TRIM21 does not recognize the
antibody
Use whole IgG molecules from mammalian hosts
Electroporation of the antibody was not
successful
Check the antibody concentration before
electroporation; check for arcing (sparks) during
electroporation (likely caused by air bubbles in the
Neon Tip)
Cells were treated with proteasome
inhibitor such as MG132
Do not use proteasome inhibitor during Trim-Away
Depletion is not efficient or
complete
The endogenous level of the target
protein is too high
Incubate longer to allow degradation before the start of
the assay; use a higher concentration of the antibody
TRIM21 levels are too low Use TRIM21-overexpressing stable cell lines; co-
electroporate recombinant TRIM21 protein together
with the antibody
Cells have low survival rates Arcing (sparks) occurs during
electroporation
Ensure that there are no air bubbles in the 10-µl Neon
Tip
Cells were incubated for too long in
Neon Buffer R
Proceed to antibody electroporation within 10 min of
resuspending cells in Neon Buffer R
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Timing
Steps 1–14, antibody preparation: 1–2 h
Step 15, isolation and culture of mouse oocytes and pre-implantation embryos: >1 h
Step 16, Trim-Away by microinjection of mouse oocytes and pre-implantation embryos: 4–5 h
Steps 17–32, Trim-Away by electroporation in primary cells and cell lines: <1 h
Box 3, peptide pre-incubation assay: 2–4 d
Box 4, Trim21 and reporter mRNA preparation: 8 h
Box 1, preparation of TRIM21 stable cell lines: 2–3 weeks
Box 2, preparation of recombinant TRIM21 protein: 3 d
Anticipated results
Generation of TRIM21 stable cell lines as described in Box 1 should result in all cells overexpressing
TRIM21 diffusely in the cytoplasm (Fig. 2a,b,d,e). Representative results for Trim-Away assays in cell
lines overexpressing TRIM21 are shown in Fig. 2c,f. The expression and purification protocol
described in Box 2 should provide TRIM21 protein yields of at least 1 mg/ml (Fig. 2g). Fig. 2h shows
Trim-Away of ERK1 in five different unmodified human cell lines by either electroporating anti-
ERK1 antibody alone or together with recombinant TRIM21 protein.
Representative results for a Trim-Away assay in mouse oocytes are shown in Fig. 4. In the
example shown, it can be seen that depletion of motor protein kinesin-5 (Eg5) by Trim-Away
resulted in a monopolar spindle during meiosis I (MI) (Fig. 4a). This is consistent with
inhibition of the motor activity of Eg5 with monastrol45. Subsequent expression of Eg5-meGFP
c
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Fig. 3 | Schematic of Trim-Away experiments in mouse oocytes. a, For constitutive depletion, mouse oocytes
are co-injected with Trim21 mRNA and antibody, and the target protein is degraded as Trim21 mRNA is expressed
for 3–4 h before release. b, For acute depletion, mouse oocytes are first injected with Trim21 mRNA, and Trim21
mRNA is expressed for 3–4 h before release. At the desired time point, the antibody is acutely injected into
the oocytes. c, For a hydraulic–based microinjection system, the capillary is loaded with the first oil, antibody
mix, the second oil, and the mRNA mix, followed by the third oil. The liquids are taken up into the microinjection
needle in the reverse order. d, For rescue, mRNA encoding the degraded target protein is acutely injected
into the oocytes.
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from mRNA reverted the phenotype (Figs. 3d and 4b), confirming the specificity of Eg5 depletion by
Trim-Away.
Reporting Summary
Further information on experimental design is available in the Nature Research Reporting Summary
linked to this article.
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A liquid-like spindle domain
promotes acentrosomal spindle
assembly in mammalian oocytes
Chun So1*, K. Bianka Seres1,2,3*, Anna M. Steyer4,5, Eike Mönnich1, Dean Clift2,
Anastasija Pejkovska1, Wiebke Möbius4,5, Melina Schuh1,2†
Mammalian oocytes segregate chromosomes with a microtubule spindle that lacks
centrosomes, but the mechanisms by which acentrosomal spindles are organized
and function are largely unclear. In this study, we identify a conserved subcellular
structure in mammalian oocytes that forms by phase separation. This structure, which
we term the liquid-like meiotic spindle domain (LISD), permeates the spindle poles
and forms dynamic protrusions that extend well beyond the spindle. The LISD
selectively concentrates multiple microtubule regulatory factors and allows them to
diffuse rapidly within the spindle volume. Disruption of the LISD via different means
disperses these factors and leads to severe spindle assembly defects. Our data
suggest a model whereby the LISD promotes meiotic spindle assembly by serving
as a reservoir that sequesters and mobilizes microtubule regulatory factors in proximity
to spindle microtubules.
O
nce everymenstrual cycle, an oocyte prog-
resses through the first meiotic division
to mature into a fertilizable egg. To this
end, the oocyte eliminates half of its chro-
mosomes in a small cell, called a polar
body. The remaining chromosomes become
aligned in the second metaphase spindle, and
the egg is released into the fallopian tube, where
it can be fertilized. Upon fertilization, the egg
completes the second meiotic division, during
which it eliminates half of the remaining sister
chromatids into the second polar body. Subse-
quently, the male and female pronuclei form
and progress toward each other, and the mitotic
divisions of the embryo begin.
However, mammalian embryos frequently de-
velop abnormally, resulting in miscarriages and
genetic disorders such as Down syndrome. The
major cause for aberrant embryonic develop-
ment is aneuploidy in the egg, which results
from chromosome segregation errors during
oocyte meiosis. Unlike somatic cells and male
germ cells, oocytes segregate chromosomes with
a specialized microtubule spindle that lacks cen-
trosomes (1). Canonical centrosomes consist of a
pair of centrioles surrounded by pericentriolar
material and are the main microtubule organiz-
ing centers in centrosomal spindles. These or-
ganelles serve as the major sites of microtubule
nucleation and form the two poles of mitotic
spindles. Oocytes have developed mechanisms
to nucleate microtubules independently of cen-
trosomes. For instance, in Drosophila oocytes,
the augmin complex and subito (kinesin-6) me-
diate microtubule nucleation from the spindle
poles and spindle equator, respectively, by recruit-
ing the g-tubulin complex (2–4). The g-tubulin
complex resides at the minus ends of micro-
tubules and serves as a template for microtubule
nucleation (5). Chromosomes can also serve as
sites of microtubule nucleation, as studied most
comprehensively in Xenopus egg extracts: They
locally activate the small guanosine triphospha-
tase Ran, which releases spindle assembly factors
from inhibitory binding to importins to promote
local microtubule assembly (6).
How acentrosomal spindles are organized in
mammalian oocytes is still incompletely un-
derstood. Despite the absence of centrosomes,
mammalian oocytes express many centrosomal
proteins (7). Some of these proteins have been
mapped to the acentriolar microtubule organiz-
ing centers (aMTOCs) (table S1), which func-
tionally replace centrosomes in mouse oocytes
(8, 9). However, a comprehensive map of cen-
trosomal protein localization in oocytes is lack-
ing. Such a map would not only shed light on
the roles of centrosomal proteins during oocyte
meiosis but may also reveal previously unknown
functions and subdomains of centrosomes in
other cell types.
Results
Identification of the LISD: A liquid-like
meiotic spindle domain
We analyzed the localization of 70 centrosomal
and spindle-related proteins in mouse meta-
phase I oocytes (Fig. 1A; fig. S1, A and B; and
table S1). We identified several previously un-
known aMTOC components, including CEP120,
CP110, DISC1, KIF2B, MCRS1, and TOP2A. Of
the 17 centriolar proteins that we examined,
only CNTROB, CNAP1, and CP110 localized to
aMTOCs, consistent with the absence of centrioles
in oocytes (1). Proteins that constitute the pericen-
triolar material of centrosomes mostly localized
to aMTOCs. Several centrosome-associated regu-
latory kinases and their substrates also localized
to aMTOCs, and many of the mapped proteins
showed enrichment to the overall spindle region.
Unexpectedly, we observed a previously un-
described domain that contains 19 proteins, in-
cluding centrosomal proteins (AKAP450, CEP170,
and KIZ), centriolar satellite proteins (CEP72,
PCM1, and LRRC36), minus-end binding pro-
teins (CAMSAP3 and KANSL3), dynein-related
proteins (HOOK3, NDE1, NDEL1, and SPDL1)
and proteins that control microtubule nuclea-
tion and stability (CHC17, chTOG,GTSE1,HAUS6,
MCAK,MYO10, and TACC3) (fig. S1, A and B, and
table S1). This domain permeated a large region
of the spindle and formed prominent spherical
protrusions that extended well beyond the spin-
dle poles during late meiosis I as well as in the
metaphase II spindle (Fig. 1, A to C) and was
conserved in oocytes from other mammalian
species (Fig. 1C and fig. S2).
Many of the proteins observed within this
domain have been studied extensively inmitosis,
yet similar structures have not been reported in
somatic cells. To investigate whether the domain
is a specific feature of acentrosomal spindles in
mammalian oocytes, we depleted centrosomes
in somatic cells by centrinone treatment (10)
(fig. S3, A and B). Notably, mitotic spindles in
centrosome-depleted mouse embryonic fibro-
blasts did not possess a related domain (fig. S3,
B to D). This result suggests that the domain is
not a general feature of acentrosomal spindles
but is likely exclusive to femalemeiotic spindles.
Aswe outline in detail below, this domain forms
by phase separation and behaves similar to a
liquid. We will therefore refer to it as the liquid-
like meiotic spindle domain (LISD).
AURA, TACC3, and CHC17 are essential
for LISD assembly
To investigate LISD assembly, we first examined
the role of the regulatory kinases aurora A
(AURA), polo-like kinase 1 (PLK1), and polo-like
kinase 4 (PLK4), which control spindle assem-
bly in multiple systems, including oocytes (11).
Whereas pharmacological inhibition of PLK1
and PLK4 did not affect LISD assembly, in-
hibition of AURA led to disruption of the LISD
(fig. S4, A to E). Of the LISD-associated proteins
that we identified, only TACC3 and GTSE1 are
known mitotic substrates of AURA (12–15).
Specific depletion of endogenous TACC3 by
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Trim-Away fully disassembled the domain (fig.
S5, A to D), leading to complete dispersion of
multiple LISD-associated proteins, including
CAMSAP3 (minus-end stability) (16), chTOG
(microtubule nucleation and stability) (17, 18),
and GTSE1 (microtubule stability) (19, 20) (fig. S6).
Some LISD-associated proteins, such as CHC17
(microtubule stability) (21), HAUS6 (microtubule
nucleation) (22, 23), and KANSL3 (minus-end
stability) (24), were no longer detected as prom-
inent protrusions and were strongly depleted
from the spindle but still showed some residual
association with microtubules upon depletion
of TACC3 (fig. S6). By contrast, depletion of GTSE1
had only a minor effect on LISD assembly (fig. S7,
A and B). LISD assembly was also disrupted upon
depletion of CHC17 (fig. S8, A and B), which binds
to microtubules together with TACC3 (25, 26).
TACC3 truncations (26) that are unable to in-
teract with CHC17 (fig. S8C) or bindmicrotubules
(fig. S8D) were not incorporated into the LISD,
consistent with the codependence of LISD assem-
bly on TACC3 and CHC17. Thus, AURA, TACC3,
and CHC17 are essential for LISD assembly.
The LISD is a liquid-like assembly
To further analyze LISD assembly, we performed
live imaging and immunofluorescence on mouse
oocytes at different maturation stages. We used
TACC3 as the reporter, as it is a core component
of the LISD. The LISD accumulated within the
center of the microtubule mass after nuclear
envelope breakdown (NEBD), permeated the
entire microtubule ball as the spindle grew and
the aMTOCs fragmented, and translocated toward
the two spindle poles together with the aMTOCs
during spindle bipolarization (Fig. 2, A and B).
As the bipolar spindle increased in size from
early to late metaphase I, the LISD grew and
extended beyond the spindle poles (Fig. 2, A and
B). The LISD was not only enriched in the pole
region but also formed projections toward the
midzone in the metaphase I spindle (Fig. 1B and
movie S1). Protein-retention expansion micros-
copy and short-term treatment with the EG5
inhibitor monastrol further demonstrated that
the LISD was present throughout the spindle
body (Fig. 2C and fig. S9), with enrichments on
kinetochore fibers (K-fibers) confirmed by cold-
stable assays and immunoelectron microscopy
(Fig. 2C and fig. S10, A to D). Also, the LISD
components CHC17 and PCM1 showed similar
localization patterns as TACC3 throughout
oocyte maturation (fig. S11, A to C).
High-resolution time-lapsemicroscopy of fluo-
rescently labeled TACC3 further revealed that the
spindle pole–associated protrusions of the LISD
were dynamic and fused with each other, gen-
erating larger protrusions (Fig. 3A). Given that
the protrusions of the LISD existed in a region
that is largely devoid of microtubules, we ex-
plored whether the LISD can be maintained
independently of microtubules. Indeed, mouse
oocytes acutely treated with the microtubule-
depolymerizing drug nocodazole transiently
maintained the LISD, even after the bulk of
the microtubules had disappeared (Fig. 3B and
movie S2). The LISD eventually disappeared and
then reassembled into new AURA-dependent
spherical condensates after a fewminutes (Fig. 3B,
fig. S12, and movie S2). Endogenous TACC3 and
PCM1 also formed these spherical condensates in
oocytes fixed after nocodazole addition (Fig. 3C),
demonstrating that they were not an artifact of
ectopically expressed, fluorescently labeled TACC3.
Notably, even in the absence of microtubules,
the spherical condensates fused with each other
and formed larger foci (Fig. 3D and movie S3).
This droplet-like behavior was reminiscent of
properties of phase-separated structures reported
in recent studies (27). We hence investigated
whether the LISD might form by phase separa-
tion. Phase separation is characterized by the
absence of membrane surrounding the phase-
separated structure. To test for the absence of
membrane, we established aworkflow for focused
ion beam–scanning electron microscopy (FIB-
SEM) of mouse oocytes and imaged the meiotic
spindle pole at isotropic resolution in three di-
mensions (fig. S13A). This analysis confirmed
that the LISD was not enclosed by membranes
(fig. S13, B and C).
Phase-separated structures are further char-
acterized by their ability to rearrange internally.
To test for rearrangement, we performed fluo-
rescence recovery after photobleaching (FRAP)
on half of a TACC3-labeled spherical condensate
in nocodazole-treated oocytes. The TACC3 sig-
nal recovered most prominently directly adja-
cent to the bleached region, indicating diffusion
of fluorescent TACC3 from within the non-
bleached region into the bleached region. While
the signal recovered in the bleached region, the
nonbleached region became dimmer over time,
consistent with internal rearrangement within
the spherical condensate (Fig. 3E). Consistent
with these results, photoactivated bars of TACC3
and PCM1 in intact spindles rapidly spread out
bidirectionally within the LISD. By contrast, the
photoactivated bar of themicrotubule-associated
protein TPX2, which is not a LISD component,
moved slowly and unidirectionally toward the
spindle pole (Fig. 3F). In addition to droplet-like
behavior and internal rearrangement, proteins
in the LISD and spherical condensates recovered
after bleaching (fig. S14, A and B). Notably, pro-
teins in the LISD recovered with similar, rapid
kinetics (fig. S14B). By contrast, core aMTOC
proteins such as CDK5RAP2, CEP192, and PCNT
showed no prominent turnover on aMTOCs in
metaphase I spindles (fig. S14C).
Depending on protein dynamics and revers-
ibility, phase-separated structures can be further
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Fig. 1. Identification of a previously unknown spindle domain in mammalian oocytes.
(A) Schematic representation of the mouse metaphase I spindle (scheme; LISD in green, aMTOCs in
magenta, kinetochores in blue, Golgi in purple, and spindle microtubules in gray). (B) Immuno-
fluorescence images of a mouse metaphase I spindle. Green, LISD (TACC3); magenta, aMTOCs
(pericentrin); gray, microtubules (a-tubulin). (C) Immunofluorescence images of metaphase I and II
spindles in mouse, bovine, ovine, and porcine oocytes. Green, LISD (TACC3); magenta, microtubules
(a-tubulin). Scale bars, 5 mm.











classified into liquid-like (dynamic and revers-
ible), gel-like (arrested and reversible), and solid-
like (arrested and irreversible) categories (28). As
proteins in the LISD were highly dynamic (fig.
S14B) and the LISD reversibly disassembled and
reassembled uponnocodazole addition andwash-
out (Fig. 2B and fig. S15A), we hypothesized that
the LISD is liquid-like. To test this hypothesis fur-
ther, we discriminated liquid-like from solid-like
condensates in oocytes by treating them with
1,6-hexanediol, whichdissolves liquid-like conden-
sates by disruptingweakhydrophobic interactions
(29). The spherical condensates in nocodazole-
treated oocytes dispersed within minutes of
1,6-hexanediol addition (Fig. 3G). 1,6-hexanediol
treatment also strongly depleted the LISD on
intact spindles, though not completely (fig. S15,
B and C). Finally, thioflavin T, which stains the
amyloid-like interactions that are characteristic
of solid-like condensates, did not stain the LISD
(fig. S15D). Together, these data strongly suggest
that the LISD is a liquid-like condensate.
TACC3 phase-separates via its
N terminus
We discovered that the spherical condensates in
nocodazole-treated oocytes were dependent on
TACC3 but onlymildly affected by CHC17 deple-
tion (fig. S16, A and B). We thus tested whether
TACC3 can phase-separate on its own in vitro.
In the presence of themacromolecular crowding
agent polyethylene glycol (PEG), recombinant
TACC3 self-assembled into micrometer-sized
spherical droplets over a range of pH values, ionic
strengths, PEG concentrations, and protein con-
centrations (fig. S17, A to C). TACC3 droplets
were able to wet glass surfaces, fuse into larger
droplets, and exclude fluorescently labeled 70-kDa
dextran (Fig. 4, A to C), consistentwith character-
istics of phase separation (27). In further support
of liquid-liquid phase separation, TACC3 drop-
lets rapidly recovered after bleaching (Fig. 4D
and fig. S17D).
In silico predictions suggested that both hu-
man and mouse TACC3 are bipartite, with a
disordered N terminus and a structured, coiled-
coil–containing C terminus (Fig. 4E). Both dis-
ordered and coiled-coil domains have been
implicated in driving phase separation (30). To
address which region of TACC3 mediates phase
separation, we purified TACC3 fragments that
contained only the coiled-coil TACC domain
[amino acids (aa) 594 to 838] or the rest of
the protein TACC3(DTACC) (aa 1 to 593). TACC3
(DTACC) retained the ability to form droplets,
similar to full-length TACC3 (Fig. 4F). By contrast,
the TACC domain self-organized into network-
like structures (Fig. 4F). These results reveal
that the previously uncharacterized disordered
N terminus of TACC3 is necessary and sufficient
for phase separation in vitro.
Although the N terminus of TACC3 is required
for its phase separation in vitro, it is dispensable
for TACC3 localization in Xenopus mitotic ex-
tracts (15) and in mitotic cells (26). To deter-
minewhether the TACC3N terminus is essential
for LISD assembly, we expressed TACC3(DNT)
(aa 522 to 838) in TACC3-depleted oocytes.
TACC3(DNT) lacks the disordered N terminus
but still contains the regions required to bind both
CHC17 andmicrotubules. Although TACC3(DNT)
localized properly to the spindle and associated
with K-fibers, as confirmed by cold treatment, it
failed to restore LISD assembly (Fig. 4, G andH).
Instead, consistent with the behavior of the puri-
fiedTACCdomain in vitro (Fig. 4F), TACC3(DNT)
and CHC17 assembled network-like structures
at the spindle poles in vivo (Fig. 4G). These data
indicate that the N terminus of TACC3 is essen-
tial for phase separation in vivo. Notably though,
the N terminus of TACC3 is not sufficient for
TACC3 recruitment to the LISD in vivo, as
TACC3(DTACC) was not incorporated into the
LISD (fig. S8D). Microtubule binding via the
TACC domain is apparently required for LISD
formation and may help to stabilize the con-
densates in vivo, as also suggested by the higher
resistance of TACC3 condensates to 1,6-hexanediol
treatment on intact spindles than in nocodazole-
treated oocytes (Fig. 3G and fig. S15, B and C).
The LISD promotes acentrosomal
spindle formation by sequestering
microtubule regulatory factors
Phase separation can selectively enrich factors to
promote reactions or storage (27). Recent studies
proposed that the phase-separated Xenopus
microtubule-binding protein BuGZ, regulatory
kinase PLK4, and the Caenorhabditis elegans
centrosomal protein SPD-5 promote microtubule
nucleation in centrosomal spindles by locally
enriching tubulin dimers by a factor of 4 to
10 (31–33). By contrast, LISD protrusions and
spherical condensates did not significantly con-
centrate tubulin dimers (fig. S18, A to E). However,
microtubule dynamics were altered in TACC3-
depleted oocytes: Microtubule growth rates were
significantly decreased, and their overall turnover
was significantly increased (fig. S19, A to D). We
thus hypothesized that the LISD locally seques-
ters microtubule regulatory factors to promote
spindle assembly. To investigate this hypothesis, we
examined acentrosomal spindle assembly upon
ablation of the LISD by three different means:
inhibition of AURA, depletion of TACC3, and
depletion of CHC17, all of which are essential for
LISD assembly (see above). Under all condi-
tions, the total microtubule intensity and spin-
dle volumewere severely reduced, to about half
of the values in control oocytes (Fig. 5, A to C;
figs. S20, A to E, and S21, A to I; and movies S4
and S5). Moreover, aMTOCs were no longer
scattered around the spindle poles but coa-
lesced into two single foci (figs. S22, A to K, and
S23, A to I). Similarly, AURA inhibition and
TACC3 depletion in bovine oocytes caused a
severe reduction in microtubules as well as spin-
dle assembly defects (Fig. 5, D to F, and fig. S24),
in line with the abnormal spindles observed in a
previous RNA interference (RNAi) study (34).
In mitotic cells, depletion of TACC3 causes a
minor loss of spindle microtubules (17, 23) but
results in misaligned chromosomes and meta-
phase arrest (25, 35–38). To uncover LISD-specific
functions, we took advantage of TACC3(DNT),
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Fig. 2. Dynamics of LISD assembly during meiosis I in mouse oocytes. (A) Immunofluorescence
images of mouse oocytes fixed at different times after nuclear envelope breakdown (NEBD).
Gray, microtubules (a-tubulin); green, LISD (TACC3); magenta, aMTOCs (pericentrin). Insets are
magnifications of regions outlined by dashed boxes. (B) Still images from time-lapse movies
of meiotic maturation of mouse oocytes. Green, LISD (TACC3-mClover3); magenta, aMTOCs
(CEP192-mScarlet). Time is given as hours:minutes after NEBD. (C) Single sections of expansion
microscopy of a mouse early metaphase I spindle. Gray, LISD (TACC3). Yellow arrowheads highlight
spherical protrusions at the spindle poles; white arrowheads highlight the K-fibers. Chr.,
chromosome. Scale bars, 5 mm.











which can neither phase-separate in vitro nor
restore LISD assembly in vivo (Fig. 4G). We
do not exclude the possibility that there are
additional, phase separation–independent func-
tions associated with the N terminus of TACC3.
However, TACC3(DNT) has been shown to rescue
the phenotypes induced by TACC3 depletion in
Xenopusmitotic extracts and inmitotic cells, and
the N terminus of TACC3 has hence been sug-
gested to be dispensable for TACC3 function in
these systems (15, 26). Notably, expression of
TACC3(DNT) in TACC3-depleted mouse oocytes
did not rescue the reduction in total micro-
tubule intensity, and the spindle volume was
still significantly reduced compared with that
in wild-type oocytes, albeit not as strongly as in
TACC3-depleted oocytes, as microtubules in
the spindle appeared less densely packed and
more spread out (Fig. 6, A to C, and movie S6).
Moreover, spindle bipolarization was severely
delayed in TACC3(DNT)-TACC3–depleted oocytes
relative to wild-type oocytes, and spindles prog-
ressed through a prolonged phase of spindle
instability and fragmentation before becoming
bipolar (Fig. 6A and fig. S25, A and B). Also the
association between aMTOCs and spindles in
TACC3(DNT)-TACC3–depleted oocytes was ab-
normal (fig. S25C). By contrast, TACC3(DNT)
rescued progression into anaphase and mark-
edly reduced lagging chromosomes in TACC3-
depleted oocytes, demonstrating that the construct
is functional (fig. S25, D to G). Together, these data
establish that the LISD is required for efficient
microtubule assembly and to form stable acentro-
somal spindles.
K-fibers and interpolar microtubules are
depleted upon LISD disruption by
TACC3 depletion
To further investigate the role of the LISD in
spindle assembly, we examined K-fibers and in-
terpolar microtubules. To assess K-fibers, we
briefly placed oocytes on ice, which depolymer-
izes dynamic microtubules within the spindle
while preserving the more stable, kinetochore-
bound microtubules. K-fibers were significantly
diminished in TACC3-depleted oocytes (Fig. 7, A
to C). To assess interpolar microtubules, we
treated oocytes with calcium, which preserves
both K-fibers and stable interpolar microtubules
in mouse oocytes (39). Stable interpolar micro-
tubules were strongly depleted in TACC3-depleted
oocytes (Fig. 7D and movies S7 and S8). Quantifi-
cation revealed a more severe microtubule loss
than in the cold-stable assay (Fig. 7, E and F).
We also labeled spindles with the microtubule
cross-linker PRC1, which associates with interpolar
microtubules (40). Consistent with the calcium-
stable assay, PRC1-marked microtubules were
drastically reduced in TACC3-depleted oocytes
(Fig. 7, G and H, and movies S9 and S10). In ad-
dition, oocytes in anaphase displayed a signifi-
cant reduction in the total intensity and volume
of the central spindle (fig. S26, A to C), which
consists of interpolar microtubules and is largely
devoid of K-fibers (41). Thus, both K-fibers and
interpolar microtubules are depleted upon LISD
disruption by TACC3 depletion.
Discussion
Our data uncover a previously unknown prin-
ciple of acentrosomal spindle assembly inmam-
malian oocytes: Meiotic spindle assembly is
facilitated by a prominent liquid-like domain
that contains multiple microtubule regulatory
factors and enriches them in a dynamic manner
in proximity to spindlemicrotubules. The domain
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Fig. 3. The LISD forms by phase separation. (A) Stills from time-lapse movies of mouse late
metaphase I oocytes. Gray, LISD (TACC3-mClover3). Yellow lines mark the position of xz planes on
the corresponding xy planes. Arrowheads highlight fusing LISD protrusions. (B) Still images from
time-lapse movies of acutely nocodazole-treated mouse metaphase I oocytes. Green, LISD (TACC3-
mClover3); magenta, microtubules (EB3-3×mCherry). Time is given as minutes after 10 mM
nocodazole addition. (C) Immunofluorescence images of spherical condensates in acutely 10 mM
nocodazole–treated mouse metaphase I oocytes. Gray, microtubules (a-tubulin); green, spherical
condensates (TACC3 or PCM1); magenta, aMTOCs (pericentrin). (D) Still images from time-lapse
movies of acutely 10 mM nocodazole–treated mouse metaphase I oocytes. Gray, spherical condensates
(TACC3-mClover3). Arrowheads highlight fusing spherical condensates. (E) Partial bleaching of
TACC3-mClover3 in a spherical condensate in acutely 10 mM nocodazole–treated mouse metaphase
I oocytes. The bleached area is outlined by the dashed box. Scale bar, 1 mm. (F) Photoactivation
(PA) of different proteins on mouse metaphase I spindles. Spindle poles are outlined with white dashed
lines; photoactivated bars are marked with yellow dashed lines. Time is given as minutes after
photoactivation with a 405-nm laser. (G) Still images from time-lapse movies of acutely 1,6-hexanediol-
treated mouse metaphase I oocytes pretreated with 10 mM nocodazole. Time is given as minutes
after 3.5% 1,6-hexanediol addition. Scale bars, 5 mm unless otherwise specified.











permeates the spindle poles and forms dynamic
protrusions extending outward well beyond the
spindle region in mouse, bovine, ovine, and por-
cine oocytes. Ablating the domain results in
microtubule loss and defective spindle assembly.
Enriching microtubule regulatory factors in
local proximity to the spindlemay be particularly
important for spindle assembly in large cells
such as oocytes, where they would otherwise
be dispersed throughout the large cytoplasmic
volume. Liquid-liquid phase separation may be
an ideal principle for this purpose: It sequesters
factors within proximity to microtubules but still
allows them to diffuse dynamically throughout
the spindle region. This could also help to control
the local concentration of certain spindle-related
factors and prevent them from accumulating
within specific spindle regions such as the spin-
dle poles or kinetochores but may instead pro-
mote their even distribution throughout the
entire spindle volume.
Does the LISD play a role in spindle assembly
beyondmammalian oocytes? Structures that re-
semble the LISD have not yet been reported in
other cell types (42), although many LISD pro-
teins have been extensively studied in mitotic
cells. Given the absence of LISD-related struc-
tures in centrosome-depleted mitotic cells, it
appears likely that the LISD is an oocyte-specific
structure. Notably though, when TACC3 is highly
overexpressed in somatic cells, it forms large
structures that can associate with the mitotic
spindle (43).Whether phase separation also plays
a role in the formation of these structures is unclear.
In centrosomal spindles, phase separation has
been proposed to enrich tubulin dimers to facil-
itate microtubule nucleation (31–33). However,
the LISD does not concentrate tubulin dimers
but enriches different microtubule regulatory
factors in acentrosomal spindles. One could
speculate that an enrichment of tubulin dimers
is less important in large oocytes, as tubulin is
not limiting in large cytoplasmic volumes (44, 45).
Indeed, recent studies implymicrotubule dynam-
ics as a key factor in determining spindle size
when tubulin is not limiting (46). Mammalian
oocytesmay use phase separation ofmicrotubule
regulatory factors as a mechanism to modulate
microtubule dynamics and to thereby promote
the assembly of large meiotic spindles. The LISD
differs from other phase-separated structures in
terms of morphology, composition, and mecha-
nism of action, underscoring that phase separa-
tion is a widely used principle that can promote
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Fig. 4. The N terminus of TACC3 is
necessary for phase separation in vitro
and in vivo. (A) Bright-field and fluores-
cence images of GST-TACC3 droplets
in vitro. Inset is the magnification of the
region marked by the dashed line box.
(B) Still images from time-lapse movies
of fusing GST-TACC3 droplets in vitro.
Scale bar, 1 mm. Arrowheads highlight
fusing GST-TACC3 droplets. (C) Fluores-
cence images of GST-TACC3 droplets
in the presence of 70-kDa dextran in vitro.
Green, GST-TACC3; magenta, 70-kDa
dextran. Insets are magnifications
of regions marked by dashed line boxes.
Scale bar, 2.5 mm. (D) FRAP of GST-TACC3
droplets in vitro. Gray, GST-TACC3.
The number of analyzed droplets is
specified in italics. M.F., mobile fraction.
Scale bar, 1 mm. (E) Domain organization
of human and mouse TACC3 showing
the disordered region [purple; analysis
with DisEMBL (100)] and the coiled-coil
domain [yellow; analysis with MARCOIL
(101)]. (F) Fluorescence images of
GST, GST-TACC3, GST-TACC3(DTACC),
and GST-TACC in vitro. (G and
H) Immunofluorescence images of
the metaphase I spindle in control,
TACC3-depleted, and TACC3(DNT)-TACC3–
depleted mouse oocytes with and without
cold treatment. IgG, immunoglobulin G.
Insets are magnifications of regions
marked by dashed line boxes. All in vitro
assays were performed in pH 6.4 buffer
with 150 mM KCl and 12% PEG. Scale
bars, 5 mm unless otherwise specified.











spindle assembly via distinct mechanisms in diff-
erent species and cell types.
Materials and methods
Preparation and culture of mouse
oocytes and follicles
All mice were maintained in a specific pathogen-
free environment according to animal ethics
guidelines of the Animal Facility of the Max
Planck Institute for Biophysical Chemistry and
U.K. Home Office regulations.
Oocytes were isolated from ovaries of 8- to
12-week-old FVB/N or CD1 female mice. For
some experiments that required large numbers
of germinal vesicle (GV) oocytes, the mice were
primed with 7.5 IU of pregnant mare serum
gonadotropin 48 hours before isolation. Fully
grown oocytes of ~75 mm in diameter with a
centeredGVweremaintained at prophase arrest
in homemade phenol red-free M2 medium sup-
plemented with 250 mM dibutyryl cyclic AMP
(dbcAMP) (Sigma-Aldrich) under paraffin oil
(ACROS Organics) at 37°C.
Follicleswere isolated from 12-day-old (C57BL×
CBA) F1 female mice as previously described (47)
with some minor modifications. Briefly, com-
pact follicles of ~100 mm in diameter with a
centered oocyte were cultured in MEM-alpha
with GlutaMax (Gibco) supplemented with 5%
fetal bovine serum (FBS) (Gibco), 0.01 mg/ml
ovine follicle stimulating hormone (National
Hormone and Peptide Program), 1× insulin/
transferrin/sodium selenite (Sigma-Aldrich),
and 0.1× penicillin G/streptomycin (Gibco) on
collagen-coated inserts (Corning) at 37°C/5%CO2.
Medium surrounding the insert was replaced
every 3 days. After 8 days of culture, in vitro
grown oocytes were denuded and matured in
modified M2 medium with 10% FBS instead
of 4 mg/ml bovine serum albumin (BSA).
Preparation and culture of bovine, ovine,
and porcine oocytes
All ovaries were obtained from local slaughter-
houses. Bovine ovaries were transported to the
laboratorywithin 2 hours of retrieval in a thermo-
flask. Ovine and porcine ovaries were transported
to the laboratory within 1 hour of retrieval in a
portable 37°C incubator in M2 medium sup-
plemented with 1 mM dbcAMP. Oocytes were
recovered by aspiration of antral follicles with
an 18-gauge needle affixed to a 1-ml syringe. For
bovine oocytes, 140 ml of 5000 IU/ml heparin
(Merck Millipore) was added to every 20 ml of
aspirates. Cumulus-oocyte complexes (COCs)were
allowed to sediment and then washed extensively
with HEPES-buffered medium 199 (for bovine
oocytes) or M2 medium (for ovine and porcine
oocytes) supplementedwith 1mMdbcAMP. Only
fully grown oocytes with a homogeneous cyto-
plasm and several layers of compact cumulus
cells were selected for experiments. Bovine and
ovine/porcine oocytes were maintained in pro-
phase arrest in dbcAMP-containing medium at
39° and 37°C, respectively. Surrounding cumulus
cells of bovine and ovine/porcine oocytes were
removed by vortexing and with 30 nM hyaluron-
idase (Sigma-Aldrich), respectively. Ovine and
porcine oocytes were released into dbcAMP-free
M2 medium to resume meiosis.
Cell culture
NIH3T3 cells (ATCC) were cultured in high-
glucose DMEM supplemented with GlutaMAX,
pyruvate, and 10% calf serum (Gibco). To deplete
centrosomes, cells were treated with 300 nM
centrinone (Tocris Bioscience) for 12 days. To
obtainmitotic spindles, cells were synchronized
with 10 mMRO-3306 (Tocris Bioscience) for 1 day
and then released into RO-3306-free medium for
45 min.
Immunofluorescence
To obtain mouse and ovine/porcine metaphase I
spindles, oocytes were incubated at 37°C for
around 7 and 12 hours, respectively, upon release
into dbcAMP-free medium. To obtain bovine
metaphase I spindles, oocytes were incubated
at 39°C/5% CO2 for ~12 hours upon release into
dbcAMP-free medium. To obtain mouse, bovine,
ovine and porcinemetaphase II spindles, oocytes
were incubated for ~16 hours upon release into
dbcAMP-free medium. None of the oocytes used
for immunofluorescence analyses was subjected
to live imaging before fixation.
Oocytes and cells were fixed in 100mMHEPES
(pH 7.0, titratedwithKOH), 50mMEGTA (pH7.0,
titratedwithKOH), 10mMMgSO4, 2%methanol-
free formaldehyde, and 0.5% triton X-100 at 37°C
for 15 to 60 min. Fixed oocytes and cells were
extracted in phosphate-buffered saline (PBS)
with 0.5% triton X-100 (PBT) overnight at 4°C
and blocked in PBT with 5% BSA (PBT-BSA)
overnight at 4°C. All antibody incubations were
performed in PBT-BSA at 10 mg/ml overnight at
4°C (for primary antibodies) or at 20 mg/ml for
1 hour at room temperature (for secondary anti-
bodies). Primary antibodies used were human
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Fig. 5. Microtubule loss and defective spindle assembly in TACC3-depleted oocytes. (A) Stills
from time-lapse movies of control and TACC3-depleted mouse oocytes. Green, microtubules
(mClover3-MAP4-MTBD); magenta, aMTOCs (CEP192-mScarlet); blue, chromosomes (H2B-miRFP).
Time is given as hours:minutes after NEBD. (B and C) Quantification of total fluorescence
intensity of microtubules and spindle volume in control and Tacc3-depleted mouse oocytes.
(D) Immunofluorescence images of the metaphase I spindle in control and TACC3-depleted bovine
oocytes. Gray, LISD (TACC3); green, microtubules (a-tubulin); magenta, chromosomes (Hoechst).
(E and F) Quantification of total fluorescence intensity of microtubules and spindle volume in control
and TACC3-depleted bovine metaphase I (MI) oocytes. The number of analyzed oocytes is specified
in italics. Error bars (shaded areas) represent SD. Scale bars, 5 mm.











anti-centromere antibody (ACA) (FZ90C-CS1058;
EuropaBioproducts), rabbit anti-AKAP450 (NBP1-
89167;NovusBiological), rabbit anti-ASPM(NB100-
2278;NovusBiological), rat anti-a-tubulin (MCA78G;
Bio-Rad),mouse anti-AURA (NBP2-50041;Novus
Biological), rabbit anti-pT288-AURA (NB100-2371;
Novus Biological), rabbit anti-CAMSAP3 (48),
rabbit anti-CDK5RAP2 (ABE236; Merck Milli-
pore), mouse anti-pan centrin (04-1624; Merck
Millipore), rabbit anti-CEP63 (06-1292; Merck
Millipore), rabbit anti-CEP120 (PA5-55985;Thermo
Fisher Scientific), rabbit anti-CEP135 (ab75005;
Abcam), rabbit anti-CEP152 (ab183911; Abcam),
rabbit anti-CEP164 (HPA037606; Sigma-Aldrich),
rabbit anti-CEP170 (27325-1-AP;Proteintech), rabbit
anti-CEP192 (18832-1-AP; Proteintech), mouse anti-
CHC17 (610500; BDBiosciences), rabbit anti-CHC17
(ab21679; Abcam), rabbit anti-chTOG (PA5-59150
and PA5-58763; Thermo Fisher Scientific), rabbit
anti-CNAP1 (14498-1-AP; Proteintech), rabbit anti-
CP110 (12780-1-AP; Proteintech), rabbit anti-DHC
(12345-1-AP; Proteintech), rabbit anti-DISC1
(NB110-40773; Novus Biological), goat anti-GFP
(600-101-215;Rockland Immunochemicals),mouse
anti-GM130 (610822; BD Biosciences), mouse anti-
GMAP210 (611712; BD Biosciences), rabbit anti-
GTSE1 (20), rabbit anti-GTSE1 (A302-425A; Bethyl
Laboratories), mouse anti-g-tubulin (11-465-C025;
Exbio), rabbit anti-HAUS6 (49), rabbit anti-
HOOK3 (NBP2-44279; Novus Biological), rabbit
anti-KANSL3 (HPA035018; Sigma-Aldrich), rabbit
anti-KIF2A (NB500-180;NovusBiologicals), rabbit
anti-KIZ (21177-1-AP; Proteintech),mouse anti-LIS1
(H00005048-M03; Abnova), rabbit anti-MCRS1
(HPA039057; Sigma-Aldrich), sheep anti-MCAK
(50), rabbit anti-MKLP2 (51), goat anti-MYO10
(sc-23137; Santa Cruz Biotechnology), rabbit anti-
NDE1 (10233-1-AP;Proteintech), rabbit anti-NDEL1
(H00081565-D01P; Abnova), mouse anti-NEDD1
(H00121441-M05; Abnova), rabbit anit-ninein
(ABN1720; Merck Millipore), mouse anti-NUMA
(610561; BD Biosciences), rabbit anti-pS395-
NUMA (3429; Cell Signaling Technology), rabbit
anti-NUMA (14951; Cell Signaling Technology),
rabbit anti-ODF2 (12058-1-AP; Proteintech),mouse
anti-P50 (611002; BD Biosciences), mouse anti-
P150 (612708; BD Biosciences), rabbit anti-PCM1
(52), rabbit anti-PCM1 (HPA023374;Sigma-Aldrich),
mouse anti-pericentrin (611814; BD Biosciences),
rabbit anti-pericentrin (ab4448; Abcam), mouse
anti-PLK1 (ab17056; Abcam), mouse anti-pT210-
PLK1 (558400; BD Biosciences), goat anti-PLK4
(NB100-894;NovusBiological), rabbit anti-SSX2IP
(HPA027306; Sigma-Aldrich), rabbit anti-STIL
(ab89314; Abcam), rabbit anti-SPDL1 (53), goat
anti-TACC3 (AF5720-SP; R&D Systems), mouse
anti-TACC3 (H00010460-M02;Abnoa), rabbit anti-
TACC3 (ab134154; Abcam), rabbit anti-TGN46
(ABT95; Merck Millipore), mouse anti-TOP2A
(MAB4197;MerckMillipore), and rabbit anti-TPX2
(NB500-179; Novus Biological). Secondary anti-
bodies usedwere Alexa Fluor 405-, 488-, 568-, or
647-conjugated anti-human IgG, goat IgG, mouse
IgG, mouse IgM, rabbit IgG, rat IgG, or sheep
IgG (Molecular Probes). DNA was stained with
Hoechst 33342 (Molecular Probes).
Optical clearing of bovine, ovine, and
porcine oocytes
Oocytes were fixed, extracted, and blocked as for
routine immunofluorescence. Before incubation
with primary antibodies, lipid droplets in oocytes
were clearedwith 4000U/ml lipase fromCandida
rugose (Sigma-Aldrich) in 400 mM NaCl, 50 mM
tris (pH 7.2), 5 mM CaCl2, and 0.2% sodium
taurocholate supplemented with complete,
EDTA-free Protease Inhibitor Cocktail (Roche)
at room temperature for 20 to 40 min.
Protein-retention expansion microscopy
Expansion microscopy was performed as previ-
ously described for cell and tissue samples (54)
using the Expansion Microscopy Kit (Expansion
Technologies).
Expression constructs, mRNA synthesis,
protein expression, and purification
To generate constructs for mRNA synthesis, we
fused previously published coding sequenceswith
meGFP (Clonetech), mClover3 or 3×mClover3
(55), mPA-GFP (56), 3×CyOFP (57), mCherry (58),
mScarlet (59), or miRFP (60) and subcloned
them into pGEMHE (61) to obtain meGFP-
AKAP450 (62), AURA-meGFP (63), Bbs4-meGFP
(64), meGFP-BBS14 (65), TurboGFP-BUGZ (66),
mCherry-CDK5RAP2 (67), CEP72-meGFP (68),
mScarlet-CEP192 (69), CETN2-meGFP (70),meGFP-
centrobin (71), mClover3-CHC17 (21), chTOG-
mScarlet (72), mEmerald-CLIP170 (M. Davidson,
Florida State University, FL), meGFP-CPAP (73),
mClover3-GTSE1(72),H2B-miRFP(4),meGFP-HOOK3




P150 (81), meGFP-PAR6a (82), PCM1-mClover3
(Source BioScience), PCM1-mPA-GFP (Source
Bioscience), meGFP-Pericentrin (83), PRC1-
3×mClover3 (72), meGFP-rootletin (84), meGFP-
SAS6 (85), TACC3-mClover3 (72), TACC3-mPA-GFP
(72), mPA-GFP-TPX2 (86), (bovine) TRIM21
(ThermoFisher Scientific), (mouse) TRIM21 (87),
and g-tubulin-meGFP (88). EB3-3×mCherry was
subcloned frompEB3-mCherry (J.Ellenberg,EMBL,
Heidelberg, Germany) into pGEMHE. pGEMHE-
TACC3(DCID)-mClover3, pGEMHE-TACC3(DTACC)-
mClover3, and pGEMHE-TACC3(DNT) were
constructed from pGEMHE-TACC3-mClover3
usingQuikChange LightningMulti Site-Directed
MutagenesisKit (Agilent) or In-FusionHDCloning
Plus (Clonetech) or Q5 Site-DirectedMutagenesis
Kit (NEB). pGEMHE-mCherry-MAP4-MTBD (77),
pGEMHE-mPA-a-tubulin (77), pGEMHE-CEP250-
meGFP (89) and pGEMHE-mCherry-PLK1 (89)
were also use. All mRNAs were synthesized and
quantified as previously described (90).
To generate constructs for protein expression,
TACC3(DTACC) (Daa 594-838)-His6 and TACC
(aa594-838)-His were inserted into pGEX-6p-1
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Fig. 6. The N terminus of TACC3 is required for spindle assembly in mouse oocytes. (A) Still
images from time-lapse movies of control, TACC3-depleted, and TACC3(DNT)-TACC3–depleted
mouse oocytes. Green, microtubules (mClover3-MAP4-MTBD); magenta, aMTOCs (CEP192-
mScarlet); blue, chromosomes (H2B-miRFP). Time is given as hours:minutes after NEBD. Yellow
asterisks highlight the unfocused spindle intermediate. (B and C) Quantification of total fluorescence
intensity of microtubules and spindle volume in control, TACC3-depleted, and TACC3(DNT)-TACC3–
depleted mouse oocytes. The number of analyzed oocytes is specified in italics. Error bars
(shaded areas) represent SD. Scale bars, 5 mm.











(GE Healthcare), and His6-TACC3-His6 was in-
serted into pET-28c(+) (Novagen). GST-TACC3-
His6, GST-TACC3(DTACC)-His6, GST-TACC-His6
were expressed in and purified from BL21(DE3)
pLysS Competent Cells (Promega) as previously
described (26) with somemodifications. Briefly,
recombinant proteins were purified first using
Ni-NTAAgarose (Qiagen), followedbyQSepharose
Fast Flow (GE Healthcare). His6-TACC3-His was
expressed in NiCo21(DE3) (NEB) and purified
first using Ni-NTA Agarose, followed by Chitin
Resin (NEB).
Short-interfering RNAs
All short interfering RNAs (siRNAs) were pur-
chased from Qiagen. For knockdown of TACC3




TAGCTGAAGACAAA-3′. AllStars Negative Control
(Qiagen) was used as a control.
Microinjection of mouse oocytes,
follicles, and bovine oocytes
Mouse oocytes were microinjected with 3.5 pl of
mRNAs as previously described (4). mClover3-
MAP4-MTBD mRNA was microinjected at a
needle concentration of 83.5 ng/ml, PCM1-mPA-
GFP mRNA at 165.8 ng/ml, PRC1-3×mClover3
mRNA at 97 ng/ml, TACC3-mClover3 mRNA at
208.1 ng/ml, TACC3-mPA-GFP at 277.4 ng/ml,mPA-
GFP-a-tubulin mRNA at 250.5 ng/ ml, 3×CyOFP-
MAP4-MTBDmRNAat166.4ng/ml,CEP192-mScarlet
mRNA at 165.8 ng/ml, EB3-3×mCherry mRNA at
138.8 ng/ml, H2B-miRFPmRNAat 28.4 ng/ml, and
Trim21 mRNA at 421 ng/ml. For other mRNAs,
theywere individually titrated and carewas taken
that they did not induce phenotypes due to over-
expression. Oocytes were allowed to express
mRNAs for 3 to 4 hours before released into
dbcAMP-free medium for imaging.
Mouse follicles were microinjected with 6 pl
of siRNAs at a needle concentration of 2 mM as
previously described (47).
Bovine oocytes were microinjected with 7 pl
of TACC3-mClover3 mRNA and bovine TRIM21
mRNA at a needle concentration of 208.1 and
421 ng/ml, respectively. Oocytes were allowed to
express mRNAs for 3 to 9 hours before released
into dbcAMP-free, bicarbonate-buffered BO-IVM
(IVF Bioscience).
Peptide preincubation assay
Oocytes were fixed, extracted, and blocked as for
routine immunofluorescence. Rabbit polyclonal
anti-CHC17, polyclonal anti-GTSE1, and monoclo-
nal anti-TACC3 were preincubated with peptide
PQAPFGYGYTAPPYGQPQPGFGYSM(GenScript),
recombinant GTSE1 (OriGene), and recombinant
GST-TACC3-His6 (homemade), respectively, be-
fore applied to oocytes as previously described (90).
Trim-Away in mouse and bovine oocytes
Only affinity-purified antibodies were used in
this study for Trim-Away–mediated protein de-
pletion. Rabbit polyclonal anti-CHC17, polyclonal
anti-GTSE1, and monoclonal anti-TACC3 were
purified as previously described (90). The con-
trol IgG used was normal rabbit IgG (12-370;
Millipore).
For constitutive Trim-Away in mouse GV
oocytes, 3.5 pl ofmRNAs and 3.5 pl of antibodies
weremicroinjected as previously described (90).
All antibodies were microinjected at a needle
concentration of 1 mg/ml with 0.1% NP-40. Tar-
get proteins were allowed to be depleted for 3 to
4 hours before the oocytes were released into
dbcAMP-free medium for imaging. For acute
Trim-Away inmousemetaphase I oocytes, oocytes
were first microinjected with 3.5 pl of mRNAs
and then released into dbcAMP-free medium
after 3 hours. At ~6 hours upon release, oocytes
were further microinjected with 3.5 pl of anti-
bodies immediately before imaging.
For constitutive Trim-Away in bovine GV
oocytes, 7 pl of bovine TRIM21 mRNA and 7 pl of
anti-TACC3 at a needle concentration of 2mg/ml
with 0.1% NP-40 were microinjected. TACC3
was allowed to be depleted for 3 to 9 hours
before the oocytes were released into dbcAMP-
free, bicarbonate-buffered BO-IVM.
Immunoblotting
Thirty mouse metaphase I oocytes per lane were
washed inBSA-freeM2mediumand resuspended
in 4 ml of BSA-free M2 medium. 12 ml of 1.333×
NuPAGE LDS sample buffer (Thermo Fisher
Scientific) with 100 mMDTT was then added,
and the mixture was immediately snap-frozen in
liquid nitrogen for 5 min. Samples were thawed
and frozen twice more before heated at 100°C
for 5 min. Samples were resolved on a 15-well
NuPAGE 4 to 12% bis-tris protein gel of 1.0 mm
thickness (ThermoFisher Scientific)withNuPAGE
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Fig. 7. Loss of K-fibers and interpolar microtubules in TACC3-depleted oocytes. (A) Immuno-
fluorescence images of the metaphase I spindle in cold-treated control and TACC3-depleted mouse
oocytes. Gray, LISD (TACC3). Green, microtubules (a-tubulin); magenta, kinetochores (ACA); blue,
chromosomes (Hoechst). (B and C) Quantification of total fluorescence intensity of cold-stable
microtubules and spindle volume in cold-treated control and TACC3-depleted mouse metaphase I
oocytes. (D) Immunofluorescence images of the metaphase I spindle in calcium-treated control
and TACC3-depleted mouse oocytes. Green arrowheads highlight stable interpolar microtubules;
magenta arrowheads indicate K-fibers. (E and F) Quantification of total fluorescence intensity
of calcium-stable microtubules and spindle volume in calcium-treated control and TACC3-depleted
mouse metaphase I oocytes. (G) Immunofluorescence images of PRC1-3×mClover3 in control
and TACC3-depleted mouse metaphase I oocytes. Green, PRC1 (GFP); magenta, TPX2.
(H) Quantification of total fluorescence intensity of PRC1-marked microtubules in control and
TACC3-depleted mouse oocytes. The number of analyzed oocytes is specified in italics. Error
bars (shaded areas) represent SD. Scale bars, 5 mm.











MOPS SDS Running Buffer (Thermo Fisher
Scientific). Proteins were transferred onto a
0.45-mmPVDFmembrane with SDS-free Towbin
buffer at 200mA for 2 hours on ice. Blocking and
antibody incubations were performed in tris-
buffered saline (TBS) with 5% skim milk and
0.1% tween-20. Primary antibodies used were
mouse anti-AURA (610938; BD Biosciences),
rabbit anti-chTOG, mouse anti-CHC17 rabbit
anti-TACC3, and rat-a-tubulin. Secondary anti-
bodies used were HRP-conjugated anti-mouse
(P0447; Dako), anti-rabbit (31462; Invitrogen),
and anti-rat (sc-2032; Santa Cruz Biotechnology).
Blots were developed with SuperSignal West
Femto Maximum Sensitivity Substrate (Thermo
FisherScientific) anddocumentedwithAmersham
Imager 600 (GEHealthcare). Carewas taken that
the exposure time did not cause saturation.
Confocal and super-resolution microscopy
For confocal imaging, oocytes were imaged in
1 to 2 ml of M2 medium (for live mouse oocytes)
or PBS with 1% polyvinylpyrrolidone (PVP) and
0.5 mg/ml BSA (for fixed oocytes) under par-
affin oil in a 35-mm dish with a #1.0 coverslip.
Images were acquired with LSM 880 confocal
laser scanning microscopes (Zeiss) equipped
with an environmental incubator box and a 40×
C-Apochromat 1.2 NA water-immersion objec-
tive. A volume of 50 mm by 50 mm by 37.5 mm or
35 mmby 35 mmby 37.5 mm centered around the
chromosomes was typically recorded. Automatic
3D tracking was implemented for time-lapse
imagingwith a temporal resolution of 5 to 15min
usingAutofocuscreen (91) orMyPiC (92).mClover3
andmeGFPwere excited with a 488-nm laser line
and detected at 493 to 571 nm. CyOFPwas excited
with a 488-nm laser line and detected at 571 to
638 nm.mScarlet andmCherrywere excitedwith
a 561-nm laser line and detected at 571 to 638 nm.
miRFP was excited with a 633-nm laser line and
detected at 638 to 700 nm. Images of the control
and experimental groups were acquired under
identical imaging conditions on the same micro-
scope. For some images, shot noise was reduced
with a Gaussian filter. Airyscan images were ac-
quired using the Airyscan module on LSM800
and LSM880 confocal laser scanning micro-
scopes (Zeiss) and processed in ZEN (Zeiss) after
acquisition. Care was taken that the imaging
conditions (laser power, pixel-dwell time, and
detector gain) did not cause phototoxicity (for
live imaging), photobleaching, or saturation.
Drug addition and washout
All drugs except 1,6-hexanediol were prepared
in DMSO (Sigma-Aldrich) as 1000× stocks. To
depolymerize microtubules, metaphase I oocytes
were treated with 10 mM nocodazole (Sigma-
Aldrich). To regrow microtubules, metaphase I
oocytes were first washed into 10 mMnocodazole
for 45 to 60 min and then washed out into me-
dium without drug. To inhibit EG5, metaphase I
oocytes were treated with 100 mM monastrol
(Sigma-Aldrich) for 30 to 90 min. To inhibit
AURA, PLK1, and PLK4 in metaphase I oocytes,
MLN8237 (Selleckchem), BI2536 (Selleckchem)
and centrinone were used at 500 nM, 100 nM,
and 5 mM, respectively. Previous studies have
shown that these drugs do not exhibit non-
specific inhibition on other kinases at the indi-
cated concentrations (5, 89, 93). 1,6-hexanediol
(Sigma-Aldrich) was prepared as a 10× stock






For electron microscopy staining, mouse meta-
phase I oocytes were fixed as previously de-
scribed for mitotic cells (94) with some minor
modifications. Briefly, oocytes were fixed in
100 mM HEPES (pH 7.0, titrated with KOH),
50mMEGTA (pH 7.0, titratedwithKOH), 10mM
MgSO4, 3% sucrose, 3% EM-grade glutaralde-
hyde, 0.5% methanol-free formaldehyde, and
0.1% tannic acid at 37°C for 1 hour. Fixed oocytes
were first stained with 2% osmium tetroxide
(Electron Microscopy Sciences)–1.5% potassium
ferrocyanide (Electron Microscopy Sciences) in
0.1 M phosphate buffer (pH 7.4) for 1 hour.
Oocytes were then incubated with 0.1% tannic
acid (Sigma-Aldrich) for 30min and stainedwith
2% osmium tetroxide in water for 40 min. After
overnight staining with 1% uranyl acetate (SPI-
Chem) inwater at 4°C, oocyteswere further stained
with 0.02M lead nitrate (MerckMillipore)–0.03M
aspartic acid (Sigma-Aldrich) (pH 5.5) for 30min.
Oocytes were washed three times with water for
5 min between every staining step.
For immunoelectron microscopy of TACC3,
mousemetaphase I oocytes weremicroinjected
with 7pl of 0.3mg/mlUS Immunogold-conjugated
rabbit Fab anti-TACC3 (Aurion) with 0.1% NP-40.
After fixation as described above, silver enhance-
mentwas performedwithR-Gent SE-EM(Aurion).
All following processing steps were performed
in a microwave (Ted Pella) and oocytes were
washed three times with water for 40 s at 250W
between every staining step. Fixed oocytes were
first stained with 2% osmium tetroxide–1.5%
potassium ferrocyanide in 0.1 M phosphate
buffer (pH 7.4) for 8 min at 100 W (microwave
cycling between on and off every 2 min). Oocytes
were then incubatedwith 1% thiocarbohydrazide
(Sigma-Aldrich) for 12 min at 100 W (microwave
cycling between on and off every 2 min) and
stained with 2% osmium tetroxide in water for
12 min at 100W (microwave cycling between on
and off every 2 min). After overnight staining
with 1% uranyl acetate in water at 4°C, oocytes
were further stained with 0.02 M lead nitrate–
0.03M aspartic acid (pH 5.5) for 12 min at 100W
(microwave cycling between on and off every
2 min).
Oocytes were subsequently dehydrated in a
graded ethanol series (10, 30, 50, 75, 90, 100,
and 100%) for 40 s at 250 W and infiltrated in
a graded series (25, 50, 75, 90, 100, and 100%)
of Durcupan resin (Sigma-Aldrich) in ethanol
for 3 min at 250 W. Infiltrated oocytes were
embedded with minimal amount of resin on
top of an Aclar film as previously described (95).
Embedded oocytes were cut out and attached to
a SEM stub (Science Services) using silver-filled
EPO-TEK EE129-4 adhesive (Electron Micros-
copy Sciences), andwere cured overnight at 60°C.
Samples were coated with an 8-nm platinum
layer using the high-vacuum sputter coater EM
ACE600 (Leica) at 35-mA current. Afterwards,
samples were placed in the Crossbeam 540 FIB-
SEM (Zeiss). To ensure even milling and to pro-
tect the surface, a 400-nm platinum layer was
deposited on top of the region of interest at 3-nA
current. Atlas 3D (Fibics) was used to collect the
3D datasets. Samples were exposed with a 15-nA
current, and a 7-nA currentwas used to polish the
cross-section surface. Images were acquired at
1.5 kV with the ESB detector at a grid voltage of
1100 V (5-nm pixel size in xy) in a continuous
mill and acquire mode using 700 pA for the
milling aperture (5-nm z-step).
After acquisition, images were first aligned
using Linear Stack Alignment with SIFT in Fiji
(NIH) (96). Datasets were then cropped, inverted
and smoothed in Fiji. For better visualization of
microtubules, datasets were further subjected
to two rounds of Local contrast enhancement
(CLAHE) in Fiji. Specific parameters used for
the first round were: 127 for blocksize, 100 for
histogram bins, and 1.5 for maximum slope.
Specific parameters used for the second round
were 50 for blocksize, 256 for histogrambins, and
2.0 for maximum slope. To obtain a metaphase I
spindle parallel to the imaging plane, the result-
ing image stacks were rotated and resliced with
Interactive Stack Rotation in Fiji. 3D segmen-
tation and surface rendering were performed




For analyses of protein dynamics, oocytes co-
expressing fluorescent reporter(s) of interest
withH2B-miRFPwere rotatedwith an unbroken
microinjection needle on stage to obtain meiotic
spindles parallel to the imaging plane. Rectan-
gular or circular regions of interest (ROIs) were
marked and photobleached using the corre-
sponding excitation laser line (405, 488, 561,
and/or 633 nm) at the maximum power after the
third or fifth time point.
Photoactivation
For analyses of dissipation, oocytes coexpressing
mPA-a-tubulin, PCM1-mPA-GFP, TACC3-mPA-
GFP, ormPA-GFP-TPX2 with H2B-miRFPwere
rotated with an unbroken microinjection needle
on stage to obtainmeiotic spindles parallel to the
imaging plane. Rectangular ROIs were marked
and photoactivated using the 405-nm laser line
at the maximum power after the third or fifth
time point.
In vitro droplet assembly and dextran
exclusion assay
TACC3 droplets were assembled in an imaging
chamber as previously described for SPD-5 (32).
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Formost experiments, 20 mMpurifiedHis-tagged
proteins or recombinant GST (GenScript) in
50mM tris (pH 7.4), 500mMNaCl, 0.5 mMDTT,
1% glycerol, and 0.1% CHAPS (all from Sigma-
Aldrich) was added to 25 mM HEPES (pH 6.4),
150mMKCl, 0.5mMDTT, and 12%PEG-3350with
0.1mg/mlNTA-Atto647N (all fromSigma-Aldrich).
For dextran exclusion assay, 2.5 mg/ml Oregon
Green 488-conjugated dextran of 70,000 M.W.
(Molecular Probes) was included during the as-
sembly of the reaction.
Thioflavin T staining
Oocytes were fixed, extracted, and blocked as for
routine immunofluorescence. 10 mM thioflavin T
was applied to oocytes for 10 min as previously
described (98).
Cold-stable assay
Mouse metaphase I oocytes were incubated on
ice for 15 min and immediately fixed as for rou-
tine immunofluorescence.
Calcium-stable assay
Mouse metaphase I oocytes were incubated in
100 mM PIPES (pH 7.0, titrated with KOH),
1 mMMgCl2, 0.1 mMCaCl2, and 0.1% tritonX-100
at 37°C for 15 min and immediately fixed as for
routine immunofluorescence.
General quantification
Time-lapse movies of live mouse oocytes were
analyzed using Imaris (Bitplane). To determine
the stages of meiosis and to score for chromo-
some segregation defects, the timing of meiotic
progression was quantified relative to the time
of NEBD. NEBD was defined as the time point
when the sharp boundary between the nucleus
and cytoplasmdisappeared. Chromosome(s) that
failed to congress to the metaphase plate be-
fore anaphase onset or the end of the video were
scored as misaligned chromosomes. Anaphase
onset was defined as the last time point of meta-
phase (5 to 6 min) before chromosome separa-
tion was first observed. Chromosome(s) that
failed to clear the central spindle region within
10 to 12 and 20 to 24min of anaphase onset were
scored as mildly and severely lagging chromo-
somes, respectively. The presence of misaligned
or lagging chromosome(s) was further con-
firmed by 3D reconstruction of chromosomes
in Imaris as previously described (77).
Quantification of FRAP experiments
Mean intensities of photobleached areas over time
were exported fromZEN into Excel (Microsoft) for
further processing. The intensity of an unbleached
area in the cytoplasm of the same oocyte was
subtracted to correct for cytoplasmic background.
Background-corrected data were then normalized
to the mean intensity of prebleach time points
(F0). As the postbleach intensity could not be
normalized between individual plots due to var-
iable photobleaching efficiency, plots of intensity
(F) against time were fitted to single exponential
functions [F(t) = c – F∞e
−t/t where c is the offset,
F∞ is the amplitude of maximum intensity recov-
ered after equilibrium, and t is the time constant)
in OriginPro (OriginLab). Half-times ofmaximum
recovery (t1/2) and mobile fractions were deter-
mined by t × ln(2) andF∞/(F0− F′) (where F′ is the
minimum intensity measured immediately after
photobleaching), respectively.
Manual and automatic quantification of
plus-end growth velocity
To determine the growth rate of plus-ends of
astral microtubules, comet velocities were deter-
mined using the Kymograph function in Fiji.
Tracks were analyzed in Excel.
For plus-ends of microtubules within the spin-
dle, comets were automatically tracked using
u-track 2.2 (99) inMATLABR2017b (MathWorks).
For comet detection, low-pass and high-pass
Gaussian standard deviations were set to two
and six pixels, respectively. For comet tracking,
maximum gap to close was set to 0 frame to
eliminate discontinuous tracks. As astral micro-
tubules were protruding from the spindle in all
directions and their comets should be out of
focus before comets of spindle microtubules,
tracks longer than five frames were used for
further processing. This resulted in, on average,
>500 (for control group) and >300 (for experi-
mental group) tracks per oocyte within 2.5 min.
Quantification of
photoactivation experiments
To determine dissipation rates of a-tubulin,
mean intensities of photoactivated areas over
time were exported from ZEN into Excel for
further processing. Data were first corrected
for cytoplasmic background by subtracting the
intensity of the photoactivated areas before pho-
toactivation. Background-corrected data were
then normalized to the intensity of the first
postactivation time point (F0). Plots of intensity
(F) against time were fitted to one-component
exponential functions [y = Ae(c − x)/t, where c is
the offset,A is the fraction of the component, and
t is the time constant] in OriginPro. Half-times
of decay (t1/2) were calculated by t × ln(2). Single-
component exponential fitting was used because
double-component exponential fittingwas unable
to yield two distinct t, consistent with our pre-
vious studies on metaphase II spindles (77). This
was likely due to the fact that the fraction of
dynamic non-kinetochore-boundmicrotubules is
much more abundant than that of stable kineto-
chore microtubules in mouse meiotic spindles.
Manual quantification of fluorescence
intensities and volume by 3D
reconstruction of spindles and aMTOCs
Spindles and aMTOCs were labeled (withMAP4-
MTBD and CEP192, respectively) in live and (with
a-tubulin and pericentrin, respectively) fixed
oocytes. They were segmented by applying a
threshold in the corresponding channel using
the Surface function of Imaris. Cytoplasmic
aMTOCs that were not part of the spindle were
manually removed. Depending on the signal-to-
noise ratio in each oocyte, a suitable threshold
value was selected and maintained for the entire
time series. The volumes of spindles and aMTOCs
were exported into Excel. The mean and total in-
tensities for spindle proteins (a-tubulin, MAP4-
MTBD, PRC1, or TACC3) and aMTOCs proteins
(CEP192 or Pericentrin)were exported into Excel.
For live imaging, data from individual oocytes
were aligned to the time of NEBD or the onset of
microtubule nucleation. To normalize individual
dataset, all (mean or sum) intensities for a chan-
nel from both the control and experimental
groups were divided by the average (mean or
total) intensity for that channel from either the
control or experimental group at steady state.
For some experiments, normalized data from
different datasets were interpolated to identical
time intervals in OriginPro.
For immunofluorescence, all (mean or sum)
intensities for a channel from both the control
and experimental groups were normalized to the
average (mean or total) intensity for that channel
from the control group.
Automatic quantification of fluorescence
intensities and volume by 3D
reconstruction of spindles
To consistently reconstruct the spindles from dif-
ferent cold-stable assays, an in-house–developed
MATLAB script (https://github.com/Emoenni/
batch_surfaces) was used for automatic surface
creation in Imaris.
Individual sectionsof adatasetwerebackground-
subtracted by a Gaussian smoothed image with a
sigma equal to 80% of the background scale given
and smoothedwith amedian filter. The size of the
filter was determined by the nearest odd integer
to twice the object detail given.
To automatically determine a threshold for
the Surface function in Imaris, Otsu’s method
was implemented via the “multithresh.m” func-
tion in MATLAB. This function allows the com-
putation of multiple thresholds for multilevel
images. A single threshold was first computed
and the volume of the surface was approximated
by multiplying the number of voxels above the
threshold with the volume of a voxel. When the
volume was not within the range of possible
volumes, more thresholds were computed. This
was repeated until an appropriate threshold was
found or a number of five thresholdswas reached.
The unaltered values of object detail, background
scale, and a filter based on the intensity mean of
the second channel were then used for surface
creation in Imaris. For spindles, the common
center of homogeneous mass of all surfaces was
computed, and all surfaces with a center of mass
>10 mm from the common one were removed.
Specific parameters used for spindles were:
0.15 mm for object detail, 0.6 mm for background
scale, and 50 to 1000 mm3 for volume range.
Statistical analysis
Average (mean) and standard deviation (SD)were
calculated in Excel. Statistical significance based
on unpaired, two-tailed Student’s t test (for ab-
solute values) and two-tailed Fisher’s exact test (for
categorical values) were calculated in OriginPro
or Prism (GraphPad). All box plots showmedian
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(horizontal black line),mean (small black squares),
25th and 75th percentiles (boxes), 5th and 95th
percentiles (whiskers), and 1st and 99th percen-
tiles (crosses). All data are from at least two
independent experiments. P values are desig-
nated as *P < 0.05, **P < 0.01, ***P < 0.001, and
****P < 0.0001. Nonsignificant values are indi-
cated as NS.
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Fig. S1 Systematic analysis of the localization of centrosomal and spindle pole-related 
proteins on acentrosomal spindles in mouse oocytes. (A) Fluorescence images of AKAP450, 
CAMSAP3, CEP72, CEP170, CHC17, chTOG, GTSE1, HAUS6, HOOK3, KANSL3, KIZ, 
LRRC36, MCAK, MYO10, NDE1, NDEL1, PCM1, SPDL1, TACC3, AURA, pT288-AURA, 
CDK5RAP2, Centrobin, CEP120, CEP192, CNAP1, CP110, DISC1, γ-tubulin, KIF2B, MCRS1, 
NEDD1, NuMA, pS395-NuMA, pT2055-NuMA, Pericentrin, PLK1, pT210-PLK1, PLK4, 
TOP2A, DHC, Dynamitin, KIF2A, LIS1, P150glued, ASPM, GMAP210, MKLP2, CLIP170, 
TPX2, GM130, TGN46, BBS4, BBS14, BUGZ, CEP63, CEP135, CEP152, CEP164, CETN2, 
CPAP, LRRC45, NEK2A, Ninein, ODF2, PAR6A, Rootletin, SSX2IP, SAS6 and STIL in mouse 
metaphase I oocytes. Green, protein of interest; magenta, microtubules (α-tubulin or mCherry-
MAP4-MTBD) or aMTOCs (pericentrin). Inset is the magnification of region outlined by the 
dashed line box. Note that the prominent signal on spindle microtubules for PLK1 and GM130 
was due to the anti-mouse secondary antibody. All antibodies used for immunofluorescence of 
proteins with no detectable localization in mouse metaphase I oocytes had been tested to work in 
the surrounding cumulus cells. Yellow lines mark positions corresponding to fluorescence profiles 
in (B). (B) Fluorescence profiles of BBS4, BBS14, BUGZ, CEP63, CEP135, CEP152, CEP164, 
Centrin-2, CPAP, LRRC45, NEK2A, Ninein, ODF2, PAR6A, Rootletin, SSX2IP, SAS6 and STIL 











Fig. S2 The anti-TACC3 is specific in bovine oocytes. Immunofluorescence images of bovine 
metaphase I oocytes expressing TACC3-mClover3. Gray, microtubules (α-tubulin); green, 
exogenous TACC3 (GFP); magenta, total (exogenous and endogenous) TACC3; blue, 
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Fig. S3 The LISD is absent from mitotic spindles in centrosome-depleted mouse embryonic 
fibroblasts. (A) Schematic of centrosome depletion in NIH3T3 cells. (B) Immunofluorescence 
images of DMSO- and 300 nM centrinone-treated NIH3T3 cells. Green, TACC3; gray, 
microtubules (α-tubulin); magenta, chromosomes (Hoechst). Yellow lines mark positions 
corresponding to fluorescence profiles in (C). (C) Fluorescence profiles of TACC3 along lines 
passing through the spindles in DMSO- and 300 nM centrinone-treated NIH3T3 cells. (D) 
Quantification of TACC3 localization in DMSO- and 300 nM centrinone-treated NIH3T3 cells. 
The number of analyzed cells is specified in italics. Note that centrinone-treated cells with TACC3 
enrichment at spindle poles were positive for γ-tubulin, suggesting that these cells still possess 
their centrosomes. Scale bars, 5 µm. 
  












































































Fig. S4 AURA, but not PLK1 or PLK4 drives the assembly of the LISD. (A) Still images from 
time-lapse movies of DMSO-, 100 nM BI2536 (PLK1 inhibitor)- and 5 µM centrinone (PLK4 
inhibitor)-treated mouse metaphase I oocytes. Gray, aMTOCs (CEP192-mScarlet); green, LISD 
(TACC3-mClover3); magenta, microtubules (3×CyOFP-MAP4-MTBD); blue, chromosomes 
(H2B-miRFP). (B) Still images from time-lapse movies of DMSO- and 500 nM MLN8237 
(AURA inhibitor)-treated mouse metaphase I oocytes. Gray, aMTOCs (CEP192-mScarlet); green, 
LISD (TACC3-mClover3); magenta, microtubules (3×CyOFP-MAP4-MTBD); blue, 
chromosomes (H2B-miRFP). (C) Still images from time-lapse movies of acutely MLN8237-
treated mouse metaphase I oocytes. Green, LISD (TACC3-mClover3); magenta, microtubules 
(3×CyOFP-MAP4-MTBD) and aMTOCs (CEP192-mScarlet); blue, chromosomes (H2B-miRFP). 
Time is given as minutes after 500 nM MLN8237 addition. (D) Immunofluorescence images of 
acutely DMSO- and 500 nM MLN8237-treated mouse metaphase I oocytes. Green, LISD 
(TACC3); magenta, microtubules (α-tubulin); blue, chromosomes (Hoechst). (E) 
Immunofluorescence images of acutely DMSO- and 500 nM MLN8237-treated bovine metaphase 
I oocytes. Green, LISD (TACC3); magenta, microtubules (α-tubulin); blue, chromosomes 













































































Fig. S5 Specific depletion of endogenous TACC3 in mouse oocytes using Trim-Away. (A) 
Immunofluorescence images of non-preincubated, TACC3 peptide preincubated, control siRNA-
injected and TACC3 siRNA-injected mouse metaphase I oocytes. (B) Still images from time-lapse 
movies of control and TACC3-depleted mouse metaphase I oocytes expressing TACC3-
mClover3. Gray, TACC3. (C) Immunofluorescence images of the metaphase I spindle in control 
and TACC3-depleted mouse metaphase I oocytes. Gray, TACC3; green, aMTOCs (pericentrin); 
magenta, microtubules (α-tubulin); blue, chromosomes (Hoechst). (D) Immunoblots of control and 
TACC3-depleted mouse metaphase I oocytes for chTOG, CHC17, TACC3, α-tubulin and AURA. 
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Fig. S6 Depletion of TACC3 disrupts the assembly of the LISD. Immunofluorescence images 
of AKAP450, CAMSAP3, CHC17, chTOG, GTSE1, HAUS6, HOOK3, KANSL3, KIZ, MYO10, 
NDE(L)1 and PCM1 in control and TACC3-depleted mouse metaphase I oocytes. Yellow lines 

















































Fig. S7 GTSE1 is not essential for the assembly of the LISD. (A) Immunofluorescence images 
of non-preincubated and GTSE1 peptide preincubated mouse metaphase I oocytes. (B) 
Immunofluorescence images of control and GTSE1-depleted mouse metaphase I oocytes. Gray, 
GTSE1. Green, LISD (TACC3); magenta, microtubules (α-tubulin); blue, chromosomes 


















































































Fig. S8 CHC17 is required for the assembly of the LISD. (A) Immunofluorescence images of 
non-preincubated and CHC17 peptide preincubated mouse metaphase I oocytes. (B) 
Immunofluorescence images of control and CHC17-depleted mouse metaphase I oocytes. Gray, 
CHC17; green, LISD (TACC3); magenta, microtubules (α-tubulin); blue, chromosomes 
(Hoechst). (C) Still images from time-lapse movies of mouse metaphase I oocytes expressing 
TACC3-mClover3 and TACC3(ΔCID) (Δaa 522-577)-mClover3. The clathrin-interacting domain 
(CID) is required for TACC3’s interaction with CHC17 (20). Green, TACC3 constructs; magenta, 
microtubules (3×CyOFP-MAP4-MTBD); blue, chromosomes (H2B-miRFP). (D) Still images 
from time-lapse movies of mouse metaphase I oocytes expressing TACC3-mClover3 and 
TACC3(ΔTACC) (aa 1-593)-mClover3. The TACC domain is required for TACC3 to form the 
microtubule interaction surface with CHC17 (20). Green, TACC3 constructs; magenta, 
microtubules (3×CyOFP-MAP4-MTBD); blue, chromosomes (H2B-miRFP). Scale bars, 5 µm. 
 
  

























































Fig. S9 The LISD encapsulates K-fibers and a subset of spindle microtubules. 
Immunofluorescence images of mouse metaphase I spindles fixed early and late (before and after 
collapsing into monopolar spindles) after monastrol treatment. Mouse metaphase I oocytes were 
treated with monastrol to induce spindle shortening and broadening to better resolve the dense 
microtubules at the meiotic spindle poles. Green, LISD (TACC3); magenta, microtubules (α-
tubulin). Insets are magnifications of regions outlined by dashed line boxes. Yellow arrowhead 
indicates a K-fiber. Yellow bracket indicates non-kinetochore-bound microtubules encapsulated 





































































Fig. S10 The LISD extends towards the spindle midzone and is enriched on K-fibers. (A) 
Single confocal sections of the metaphase I spindles in bovine and porcine oocytes. Green, LISD 
(TACC3). Magenta, microtubules (α-tubulin). Yellow arrowheads indicate K-fibers. (B) A single 
confocal section of a cold-treated mouse metaphase I spindle. Green, LISD (TACC3); magenta, 
microtubules (α-tubulin). (C) A single section of FIB-SEM of mouse early metaphase I oocytes 
injected with Fab anti-TACC3 US ImmunoGold. (D) Single sections of the region outlined by 
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Fig. S11 CHC17 and PCM1 have a similar localization pattern as TACC3 throughout oocyte 
maturation. (A) Immunofluorescence images of CHC17 in mouse oocytes fixed at different times 
after NEBD. Gray, microtubules (α-tubulin). Green, CHC17; magenta, aMTOCs (pericentrin). (B) 
Immunofluorescence images of PCM1 in mouse oocytes fixed at different times after NEBD. 
Gray, microtubules (α-tubulin). Green, PCM1; magenta, aMTOCs (pericentrin). Note that two 
different PCM1 antibodies were used for staining oocytes before and after NEBD. (C) Single 
confocal sections of cold-treated mouse metaphase I spindle. Green, CHC17 or PCM1; magenta, 
microtubules (α-tubulin). Scale bars, 5 µm. 
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Fig. S12 Spherical condensates in acutely nocodazole-treated mouse metaphase I oocytes are 
dependent on AURA. Still images from time-lapse movies of spherical condensates in acutely 
MLN8237-treated mouse metaphase I oocytes pre-treated with 10 µM nocodazole. Green, 
TACC3; magenta, microtubules (3×CyOFP-MAP4-MTBD) and aMTOCs (CEP192-mScarlet); 
blue, chromosomes (Hoechst). Insets are magnifications of regions outlined by dashed line boxes. 





















































Fig. S13 The LISD is not enclosed by membranes. (A) A schematic representation showing the 
workflow for FIB-SEM of a spindle pole in mouse late metaphase I oocytes. (B) A single FIB-
SEM section showing the threshold-based segmentation. Yellow arrows indicate the running 
direction of microtubules. a.v., autophagic vacuole, mit., mitochondria, s.p., spindle pole and ves., 
vesicular structure. Note that the contrast within the spindle region only allowed for segmentation 
of microtubules. Insets are magnifications of regions outlined by dashed line boxes. Scale bar, 1 
µm. (C) 3D rendered model of a spindle pole in mouse late metaphase I oocytes. Green, 
microtubules; red, LISD; yellow, mitochondria; purple, membranes. Scale bar, 5 µm. 
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Fig. S14 Proteins in the LISD and spherical condensates are dynamic. (A) FRAP of TACC3-
mClover3 in spherical condensates in acutely 10 µM nocodazole-treated mouse metaphase I 
oocytes. The number of analyzed spherical condensates is specified in italics. (B) FRAP of 
TACC3-mClover3, mClover3-CHC17, PCM1-mClover3 and chTOG-mScarlet in mouse 
metaphase I oocytes. The number of analyzed spindle poles is specified in italics. (C) FRAP of 
mEGFP-Pericentrin, mCherry-CEP192, mCherry-CDK5RAP2, NEDD1-mCherry, AURA-
mEGFP and mCherry-PLK1 in mouse metaphase I oocytes. The number of analyzed aMTOCs is 
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Fig. S15 The LISD is liquid-like. (A) Still images from time-lapse movies of mouse metaphase I 
oocytes after nocodazole washout. Green, LISD (TACC3-mClover3); red, microtubules 
(3×CyOFP-MAP4-MTBD) and aMTOCs (CEP192-mScarlet); blue, chromosomes (H2B-miRFP). 
(B) Still images from time-lapse movies of acutely 1,6-hexanediol-treated mouse metaphase I 
oocytes. Green, LISD (TACC3-mClover3); magenta, aMTOCs (CEP192-mScarlet). Insets are 
magnifications of regions outlined by dashed line boxes. Time is given as minutes after 3.5% 1,6-
hexanediol addition. Yellow lines mark positions corresponding to fluorescence profiles in (C). 
(C) Quantification of fluorescence intensity of TACC3-mClover3 and CEP192-mScarlet in (A) at 
different times. (D) Fluorescence image of thioflavin T-stained mouse metaphase I oocytes. The 

























































Fig. S16 Spherical condensates in acutely nocodazole-treated mouse metaphase I oocytes are 
disassembled by TACC3 depletion, but mildly affected by CHC17 depletion. (A) Still images 
from time-lapse movies of control and TACC3-depleted mouse metaphase I oocytes pre-treated 
with 10 µM nocodazole. Green, CHC17; magenta, aMTOCs (CEP192-mScarlet); blue, 
chromosomes (H2B-miRFP). (B) Still images from time-lapse movies of control and CHC17-
depleted mouse metaphase I oocytes pre-treated with 10 µM nocodazole. Green, TACC3; 

































































































































Fig. S17 TACC3 phase-separates in vitro. (A) Fluorescence images of GST-TACC3 droplets at 
different pH values, ionic strengths, PEG concentrations and protein concentrations. Green, GST-
TACC3. (B) Fluorescence images of His-TACC3 droplets in pH 6.4 buffer with 150 mM KCl and 
12% PEG. Green, His-TACC3. (C) Fluorescence images of AURA, Centrin-2 and His-TACC3 in 
pH 6.4 buffer with 150 mM KCl and 12% PEG. (D) FRAP of His-TACC3 droplets in pH 6.4 
buffer with 150 mM KCl and 12% PEG. Gray, His-TACC3. The number of analyzed droplets is 









































































































Fig. S18 LISD protrusions and spherical condensates do not concentrate tubulin dimers. (A) 
Fluorescence images of non-injected and rhodamine (Rhod)-tubulin-injected mouse metaphase I 
oocytes pre-treated with 10 µM nocodazole. Green, TACC3; magenta, Rhod-tubulin. (B) 
Quantification of fold enrichment of Rhod-tubulin in the cytosol and in the spherical condensates. 
The number of analyzed oocytes is specified in italics. (C) Immunofluorescence images of 
spherical condensates in acutely 10 µM nocodazole-treated mouse metaphase I oocytes. Green, 
TACC3; magenta, α-tubulin. (D) Immunofluorescence images of LISD protrusions in mouse 
metaphase I oocytes. Green, LISD (TACC3); magenta, α-tubulin. (E) Quantification of fold 
enrichment of α-tubulin in the cytosol and in the LISD protrusions. The number of analyzed 
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Fig. S19 Destabilized microtubules in TACC3-depleted oocytes. (A and B) Quantification of 
EB3 comet velocity of astral-like and spindle microtubules in control and TACC3-depleted mouse 
metaphase I oocytes. (C) Dissipation of mPA-GFP-α-tubulin fluorescence signal in control and 
TACC3-depleted mouse metaphase I oocytes. (D) Distribution of half-life of mPA-GFP-α-tubulin 
fluorescence signal dissipation in control and TACC3-depleted mouse metaphase I oocytes. The 
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Fig. S20 RNAi and acute depletion of TACC3 also leads to spindle defects in mouse 
metaphase I oocytes. (A and B) Quantification of total fluorescence intensity of microtubules and 
spindle volume in control siRNA-injected, TACC3 siRNA-injected, control and TACC3-depleted 
mouse metaphase I oocytes. (C) Still images from time-lapse movies of control and acutely 
TACC3-depleted mouse metaphase I oocytes. Green, microtubules (3×CyOFP-MAP4-MTBD) 
and aMTOCs (CEP192-mScarlet). Magenta, chromosomes (H2B-miRFP). Time is given as 
minutes after antibody microinjection. (D and E) Quantification of total fluorescence intensity of 
microtubules and spindle volume in control and acutely TACC3-depleted mouse metaphase I 
oocytes. The number of analyzed oocytes is specified in italics. Error bars (shaded areas) represent 
S.D. Scale bars, 5 µm. 
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Fig. S21 Inhibition of AURA and depletion of CHC17 similarly leads to spindle defects in 
mouse metaphase I oocytes. (A) Immunofluorescence images of DMSO- and 500 nM MLN8237-
treated mouse metaphase I oocytes. Green, LISD (TACC3); magenta, aMTOCs (Pericentrin); red, 
microtubules (α-tubulin); blue, chromosomes (Hoechst). (B) Immunofluorescence images of 
DMSO- and 500 nM MLN8237-treated mouse metaphase I oocytes treated with cold. Green, LISD 
(TACC3); magenta, microtubules (α-tubulin); blue, chromosomes (Hoechst). (C) Quantification 
of mean fluorescence intensity of TACC3-mClover3 in DMSO- and 500 nM MLN8237-treated 
mouse oocytes. (D and E) Quantification of total fluorescence intensity of microtubules and 
spindle volume in DMSO- and 500 nM MLN8237-treated mouse oocytes. (F) Still images from 
time-lapse movies of control and CHC17-depleted mouse metaphase I oocytes. Gray, LISD 
(TACC3-mClover3); green, microtubules (3×CyOFP-MAP4-MTBD); magenta, aMTOCs 
(CEP192-mScarlet); blue, chromosomes (H2B-miRFP). (G) Quantification of mean fluorescence 
intensity of TACC3-mClover3 in control and CHC17-depleted mouse oocytes. (H and I) 
Quantification of total fluorescence intensity of microtubules and spindle volume in control and 
CHC17-depleted mouse oocytes. The number of analyzed oocytes is specified in italics. Error bars 


































































































































































































































































































































Fig. S22 Depletion of TACC3 leads to aMTOC defects in mouse metaphase I oocytes. (A) 
Still images from time-lapse movies of control and TACC3-depleted mouse metaphase I oocytes. 
Gray, aMTOCs (CEP192-mScarlet). Time is given as hours:minutes after NEBD. (B) 
Quantification of the number of aMTOCs at spindle poles in control and TACC3-depleted mouse 
oocytes. (C and D) Quantification of total fluorescence intensity and volume of all aMTOCs at 
spindle poles in control and TACC3-depleted mouse oocytes. (E and F) Quantification of the 
volume and surface area:volume (SA:V) ratio of individual aMTOCs at spindle poles in control 
and TACC3-depleted mouse metaphase I oocytes. (G) Quantification of the number of aMTOCs 
per pole in control and TACC3-depleted mouse metaphase I oocytes. (H and I) Quantification of 
total fluorescence intensity and volume of all aMTOCs at spindle poles in control and TACC3-
depleted mouse metaphase I oocytes. (J and K) Quantification of the volume and SA:V ratio of 
individual aMTOCs at spindle poles in control and TACC3-depleted mouse metaphase I oocytes. 
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Fig. S23 Inhibition of AURA and depletion of CHC17 similarly leads to aMTOC defects in 
mouse metaphase I oocytes. (A) Still images from representative time-lapse movies of 500 nM 
MLN8237-treated mouse oocytes. Gray, aMTOCs (CEP192-mScarlet). Time is given as 
hours:minutes after NEBD. (B) Quantification of the number of aMTOCs at spindle poles per 
oocyte in DMSO- and 500 nM MLN8237-treated mouse metaphase I oocytes. (C, D and E) 
Quantification of total fluorescence intensity, volume and SA:V ratio of individual aMTOCs at 
spindle poles in DMSO- and 500 nM MLN8237-treated mouse metaphase I oocytes. (F) 
Quantification of the number of aMTOC at spindle poles per oocyte in control and CHC17-
depleted mouse metaphase I oocytes. (G, H and I) Quantification of total fluorescence intensity, 
volume and SA:V ratio of individual aMTOCs at spindle poles in control and CHC17-depleted 
mouse metaphase I oocytes. The number of analyzed oocytes or aMTOCs is specified in italics. 
































Fig. S24 Inhibition of AURA leads to severe spindle assembly defects in bovine metaphase I 
oocytes. Immunofluorescence images of DMSO- and 500 nM MLN8237-treated bovine 
metaphase I oocytes. Green, LISD (TACC3); magenta, microtubules (α-tubulin); blue, 
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Fig. S25 TACC3(ΔNT) largely rescues chromosome segregation defects. (A) Quantification of 
the timing of spindle bipolarization in control, TACC3-depleted and TACC3(ΔNT)-TACC3-
depleted mouse oocytes. (B) Quantification of unfocused spindle intermediates before 
bipolarization in control, TACC3-depleted and TACC3(ΔNT)-TACC3-depleted mouse oocytes. 
(C) Quantification of spindle pole morphology in control, TACC3-depleted and TACC3(ΔNT)-
TACC3-depleted mouse oocytes. (D) Quantification of misaligned chromosomes in control, 
TACC3-depleted and TACC3(ΔNT)-TACC3-depleted mouse oocytes. (E) Quantification of 
anaphase progression in control, TACC3-depleted and TACC3(ΔNT)-TACC3-depleted mouse 
oocytes. (F) Quantification of the timing of anaphase onset in control, TACC3-depleted and 
TACC3(ΔNT)-TACC3-depleted mouse oocytes. (G) Quantification of lagging chromosomes in 
control, TACC3-depleted mouse and TACC3(ΔNT)-TACC3-depleted oocytes. The number of 




































































































































Fig. S26 The formation of the central spindle is affected in TACC3-depleted oocytes. (A) Still 
images from time-lapse movies of different stages of anaphase in control and TACC3-depleted 
mouse oocytes. Gray, microtubules (mClover3-MAP4-MTBD). Scale bar, 5 µm. (B and C) 
Quantification of total fluorescence intensity of microtubules and volume of the central spindle in 







No. Group Protein Localization in mouse 
metaphase I oocytes 
Confirmed by Previously mapped 
in mouse metaphase 
I oocytes 
Antibodies and/or 




CENPJ/ CPAP No spindle localization (lost 
from aMTOCs after NEBD) 
Live imaging / ✓ (73) 
2  CEP63 No spindle localization IF / ✓ (e.g. PMID 
27974163) 
3  CEP135 No spindle localization IF / ✓ (e.g. PMID 
26609813) 
4  CEP152 No spindle localization (lost 
from aMTOCs after NEBD) 
IF 102 ✓ (e.g. PMID 
28607478) 
5  CEP164 No spindle localization IF / ✓ (e.g. PMID 
29440264) 
6  CEP170 LISD IF / ✗ 
7  CEP250/ CNAP1 aMTOCs (initially lost from 
aMTOCs after NEBD) 
IF, live imaging 103 ✓ (e.g. PMID 
27486244)/ ✓ (89) 
8  CETN2 No spindle localization IF, Live imaging / ✓ (e.g. PMID 
9004043)/ ✓ (70) 
9  Centrobin/ CNTROB aMTOCs Live imaging 103 ✓ (71) 
10  CP110 aMTOCs IF / ✓ (e.g. PMID 
23486064) 
11  CROCC/ rootletin No spindle localization (lost 
from aMTOCs after NEBD) 
Live imaging / ✓ (84) 
12  LRRC45 No spindle localization (lost 
from aMTOCs after NEBD) 
Live imaging / ✓ (76) 
13  NEK2A No spindle localization (lost 
from aMTOCs after NEBD) 
Live imaging / ✓ (79) 
14  Ninein No spindle localization IF / ✓ (e.g. PMID 
28290481) 






16  SAS6 No spindle localization (lost 
from aMTOCs after NEBD) 
Live imaging / ✓ (85) 




AKAP9/ AKAP450 LISD IF, live imaging / ✓ (e.g. PMID 
28687497) / ✓ 
(62) 
19 proteins  CEP120 aMTOCs, spindle 
microtubules 
IF / ✗ 
20  CEP192 aMTOCs IF, live imaging 102 ✗ / ✓ (69) 
21  CEP215/ CDK5RAP2 aMTOCs IF, live imaging 104 ✓ (e.g. PMID 
26297806) / ✓ 
(67) 
22  NEDD1 aMTOCs, spindle 
microtubules 
IF, live imaging 105 ✓ (e.g. 29547120) 
/ ✓ (78) 
23  PCNT/ pericentrin aMTOCs IF, live imaging 106 ✓ (e.g. PMID 
22851319)/ ✓ (83) 
24  TUBG1/ γ-tubulin aMTOCs, spindle 
microtubules 
IF, live imaging 107, 108 ✓ (e.g. PMID 




AURKA/ AURA aMTOCs, spindle 
microtubules 
IF, live imaging 109 ✗ / ✓ (63) 
26 their 
substrates 
pT288-AURA aMTOCs IF 110 
 
✓ (e.g. PMID 
29276128) 
27  PLK1 aMTOCs, kinetochores IF, live imaging 111 ✓ (e.g. PMID 
25533956) / ✓ 
(89) 
28  pT210-PLK1 aMTOCs, kinetochores IF 112, 113 ✓ (e.g. PMID 
26293378) 






30  pS395-NuMA aMTOCs IF / ✓ (e.g. PMID 
28302921) 
31  pT2055-NuMA aMTOCs IF / ✗ 
32 Other 
centrosomal  
DISC1 aMTOCs IF / ✓ (e.g. PMID 
24560582) 
33 proteins KIZ LISD IF / ✗ 
34  TOP2A aMTOCs, kinetochores IF / ✓ (e.g. PMID 
25762097) 
35 Centriolar  BBS4 No spindle localization Live imaging / ✓ (64) 
36 satellite  CEP72 LISD Live imaging / ✓ (68) 
37 proteins CEP290/ BBS14 No spindle localization (lost 
from aMTOCs after NEBD) 
Live imaging / ✓ (65) 
38  LRRC36 LISD Live imaging / ✓ (68) 
39  PARD6A/ PAR6A No spindle localization Live imaging / ✓ (82) 
40  PCM1 LISD IF, live imaging / ✓ (52) / ✗ 
41  SSX2IP No spindle localization IF / ✓ (e.g. PMID 
23435261) 
42 Minus-end  CAMSAP3 LISD IF / ✓ (48) 
43 binding 
proteins 
KANSL3 Spindle microtubules, LISD IF / ✓ (e.g. PMID 
26243146) 




CLIP170 Spindle microtubules Live imaging / ✗ 
46 proteins DCTN1/ P150glued Kinetochores, spindle 
microtubules 
IF, live imaging / ✓ (e.g. PMID 
28572454)/ ✓ (81) 
47  DCTN2/ dynamitin Kinetochores, spindle 
microtubules 
IF, live imaging 114 ✓ (e.g. PMID 
15043813)/ ✓(82) 
48  DHC Kinetochores, spindle 
microtubules 






49  HOOK3 LISD IF, live imaging / ✗ / ✓ (74) 
50  LIS1 Kinetochores IF / ✗ 
51  NDE1 LISD IF / ✓ (e.g. PMID 
21394081) 
52  NDEL1 LISD IF / ✗ 
53  NUMA1/ NuMA aMTOCs IF 115 ✓ (e.g. PMID 
26656453) 
54  SPDL1/ spindly Kinetochores, LISD IF / ✓ (53) 
55 Microtubule-
related  
ASPM Spindle microtubules IF 116 ✓ (e.g. PMID 
28436967) 
56 proteins BUGZ No spindle localization Live imaging / ✓ (66) 
57  CLTC/ CHC17 LISD IF, live imaging / ✓ (e.g. PMID 
12960147) / ✓ 
(21) 
58  CKAP5/ chTOG LISD IF, live imaging / ✗ / ✓ (72) 
59  GTSE1 LISD IF, live imaging / ✓ (20) / ✓ (72) 
60  FAM29A/ HAUS6 Spindle microtubules, LISD IF / ✓ (49) 
61  KIF2A Kinetochores, spindle 
microtubules 
IF 117 ✓ (e.g. PMID 
18411309) 
62  KIF2B aMTOCs Live imaging / ✓ (75) 
63  KIF2C/ MCAK Kinetochores, LISD IF 117 ✓ (50) 
64  KIF20A/ MKLP2 Spindle microtubules IF / ✓ (51) 
65  MYO10 Cortical cap, LISD IF / ✓ (e.g. PMID 
24443004) 
66  TACC3 LISD IF, live imaging / ✓ (e.g. PMID 
29089377)/ ✓ (72) 
67  TPX2 Spindle microtubules IF, live imaging 118 ✓ (e.g. PMID 
24813613)/ ✓ (86) 
68 Microtubule- 
related   
GOLGA2/ GM130 Foci around aMTOCs and in 
the cytosol 








TGOLN2/TGN46 Foci around aMTOCs and in 
the cytosol 
IF / ✓ (e.g. PMID 
27861594) 
70  TRIP11/ GMAP210 Spindle microtubules IF / ✓ (e.g. PMID 
27458799 
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Movie S1 Confocal sections of a mouse metaphase I spindle stained for the LISD (green, TACC3), 
aMTOCs (magenta, pericentrin) and microtubules (gray, α-tubulin). 
 
Movie S2 Time-lapse movie of an acutely nocodazole-treated mouse metaphase I oocyte 
expressing TACC3-mClover3 (green, to label the LISD) and EB3-3×mCherry (magenta, to label 
microtubules). 
 
Movie S3 Time-lapse movie of fusing spherical condensates in an acutely nocodazole-treated 
mouse metaphase I oocyte expressing TACC3-mClover3 (gray, to label the spherical condensates). 
 
Movie S4 Time-lapse movie of meiotic maturation of a control mouse oocyte microinjected with 
mClover3-MAP4-MTBD (green, to label microtubules), CEP192-mScarlet (magenta, to label 
aMTOCs), H2B-miRFP (blue, to label chromosomes), Trim21 and control IgG. 
 
Movie S5 Time-lapse movie of meiotic maturation of a TACC3-depleted mouse oocyte 
microinjected with mClover3-MAP4-MTBD (green, to label microtubules), CEP192-mScarlet 
(magenta, to label aMTOCs), H2B-miRFP (blue, to label chromosomes), Trim21 and anti-TACC3. 
 
Movie S6 Time-lapse movie of meiotic maturation of a TACC3(ΔNT)-TACC3-depleted mouse 





mScarlet (magenta, to label aMTOCs), H2B-miRFP (blue, to label chromosomes), Trim21, anti-
TACC3 and TACC3(ΔNT). 
 
Movie S7 Confocal sections of a calcium-treated metaphase I spindle in a control mouse oocyte 
microinjected with Trim21 and control IgG stained for microtubules (gray, α-tubulin) and 
chromosomes (magenta, Hoechst). 
 
Movie S8 Confocal sections of a calcium-treated metaphase I spindle in a TACC3-depleted mouse 
oocyte microinjected with Trim21 and anti-TACC3 stained for microtubules (gray, α-tubulin) and 
chromosomes (magenta, Hoechst). 
 
Movie S9 Confocal sections of a metaphase I spindle in a control mouse oocyte microinjected with 
PRC1-3×mClover3, Trim21 and control IgG stained for interpolar microtubules (gray and green, 
GFP) and K-fibers (magenta, TPX2). 
 
Movie S10 Confocal sections of a metaphase I spindle in a TACC3-depleted mouse oocyte 
microinjected with PRC1-3×mClover3, Trim21 and anti-TACC3 stained for interpolar 




4. Author contributions 
 
For publication 1 (Acute and rapid degradation of endogenous proteins by Trim-Away), I wrote 
the manuscript with Dean Clift and Melina Schuh, simplified and optimized the methods for 
conducting Trim-Away in mouse oocytes and early embryos, and optimized the peptide pre-
incubation assay and mRNA preparation. 
 
For publication 2 (A liquid-like spindle domain promotes acentrosomal spindle assembly in 
mammalian oocytes), I wrote the manuscript with Bianka Seres and Melina Schuh, performed all 
experiments and analyzed the data with the help of Bianka Seres with the following exceptions: 
Anna Steyer prepared electron samples with me and performed FIB-SEM; Eike Mönnich wrote 
all in-house-developed scripts and plugins and analyzed comet velocities with Bianka Seres; Dean 
Clift initiated the systematic analysis of protein localization and characterization of the LISD; 






5. Summary of the results 
 
Identification of the LISD: A liquid-like meiotic spindle domain 
As immunoprecipitation followed by mass spectrometry is not feasible without at least thousands 
of mouse oocytes, I decided to dissect the molecular composition of the LISD by performing a 
protein localization screen in live and fixed mouse oocytes. I reasoned that the LISD is in close 
proximity of the spindle, so I selected 70 centrosomal and spindle-related proteins (publication 2 
Fig. 1A). Other than TACC3, 18 other proteins also localized to the LISD: centrosomal proteins 
(AKAP450, CEP170 and KIZ), centriolar satellite proteins (CEP72, PCM1 and LRRC36), minus-
end binding proteins (CAMSAP3 and KANSL3), dynein-related proteins (HOOK3, NDE1, 
NDEL1 and SPDL1), and proteins that control microtubule nucleation and stability (CHC17, 
chTOG, GTSE1, HAUS6, MCAK and MYO10). Moreover, the LISD was present in the spindle 
of cow, pig and sheep oocytes, but not in wildtype or centrosome-depleted somatic cells 
(publication 2 Fig. 1C, and fig. S3, A to D). 
 
The LISD was a liquid-like condensate 
To characterize the LISD, I initially imaged the LISD at high temporal resolution. Interestingly, I 
observed fusions between the droplet-like protrusions around the spindle poles (publication 2 Fig. 
3A). As these protrusions existed in a spindle region that is largely devoid of microtubules, I asked 
whether the LISD can be maintained independently of microtubules. Upon the acute addition of 
nocodazole, a microtubule-depolymerizing drug, the LISD was transiently maintained, but then 
eventually disappeared and reassembled into new spherical condensates (publication 2 Fig. 3B). 
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These nocodazole-induced condensates also underwent fusions (publication 2 Fig. 3D). In 
addition, the LISD displayed other properties reminiscent of liquids: focused ion beam-scanning 
electron microscopy (FIB-SEM) revealed the absence of a surrounding membrane (publication 2 
fig. S13); half fluorescence recovery after photobleaching (FRAP) and photoactivation revealed 
the rearrangement of its components within the structure (publication 2 Fig. 3, E and F); and 
FRAP revealed the rapid exchange of its components with the cytosol (publication 2 fig. S14, A 
and B). In further support of its liquid-like status, the LISD could be reversibly disassembled and 
reassembled upon nocodazole addition and washout (publication 2 Fig. 3B, and fig. S15A), was 
perturbed by 1,6-hexanediol that disrupts weak hydrophobic interactions63 (publication 2 Fig. 3G, 
and fig. S15, B and C), and was not stained by thioflavin T that detects amyloid-like interactions64 
(publication 2 Fig. S15D). 
 
AURA kinase drove LISD assembly 
As the LISD was timely assembled with the spindle during meiosis (publication 2 Fig. 2, A and 
B), I asked whether the regulatory kinases that control spindle assembly in multiple systems also 
drives LISD assembly65. To this end, I utilized well-characterized, small molecule inhibitors 
against these regulatory kinases. Whereas pharmacological inhibition of PLK1 and PLK4 did not 
interfere LISD assembly, inhibition of AURA disrupted LISD assembly (publication 2 fig. S4, A 
to E). 
 
Optimization of Trim-Away in mammalian oocytes 
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Of the LISD proteins that I identified, there are two known mitotic substrates of AURA: TACC3 
and GTSE166-69. To examine their role in LISD assembly, it was possible to deplete them early at 
follicle stage using RNAi70 or at any desired stage using Trim-Away. Trim-Away was chosen 
instead of RNAi because the proteins may have additional role during follicle development, and 
depleting them early at follicle stage may complicate the interpretation of phenotypes at later stages. 
However, one issue with the original Trim-Away protocol was that it requires separate 
microinjections of TRIM21 mRNA and antibody (publication 1 Fig. 3B), compromising the 
survival and developmental rates of oocytes. To circumvent this, I established an alternative 
protocol that allows separate delivery of mRNA and antibody in one single microinjection 
(publication 1 Fig. 3, A and C). 
 
TACC3 and CHC17 were also essential for LISD assembly 
Both TACC3 and GTSE1 were successfully depleted using Trim-Away (publication 2 figs. S5, 
A to D, and S7A). Whereas GTSE1 depletion only had a minor effect on LISD assembly 
(publication 2 fig. S7B), TACC3 depletion fully disassembled the LISD and led to the dispersion 
of multiple LISD proteins from the spindle (publication 2 fig. S6). As TACC3 binds to 
microtubules together with CHC1771,72, I asked whether CHC17 is also critical to LISD assembly. 
Similar to TACC3 depletion, CHC17 depletion completely disassembled the LISD (publication 
2 fig. S8, A and B). And consistent with the codependence of LISD assembly on TACC3 and 
CHC17, TACC3 mutants72 that are unable to interact with CHC17 (publication 2 fig. S8C) or 
form the microtubule-binding interface with CHC17 (publication 2 fig. S8D) were not 
incorporated into the LISD. 
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TACC3 phase-separated via its N terminus 
Although TACC3 binding to microtubules seemed to be required for LISD assembly (publication 
2 fig. S8D), the nocodazole-induced condensates could persist in the absence of microtubules 
(publication 2 Fig. 3B). Therefore I asked whether both TACC3 and CHC17 are essential for 
maintaining the nocodazole-induced condensates. Surprisingly, TACC3 depletion, but not CHC17 
depletion, disassembled the nocodazole-induced condensates (publication 2 fig. S16, A and B). I 
thus tested whether TACC3 alone can phase-separate in vitro. Strikingly, recombinant TACC3 
could self-organize into spherical droplets in the presence of the molecular crowding agent 
polyethylene glycol (PEG) publication 2 fig. S17, A to C). These droplets could wet glass surfaces, 
undergo fusion, exclude 70 kDa dextran and rapidly recover after photobleaching (publication 2 
Fig. 4, A to D, and fig. S17D). In silico analysis predicted that both human and mouse TACC3 
contain a disordered N terminus and a structured, coiled-coil-containing C terminus (publication 
2 Fig. 4E). As both disordered and coiled-coil domains have been implicated in driving phase 
separation in recent studies73, I purified different recombinant TACC3 fragments to test which 
region(s) is/are sufficient for phase separation in vitro. Whereas the N terminus fragment of 
TACC3 self-organized into spherical droplets as the full length TACC3, the C terminus fragment 
self-organized into network-like, filamentous structures (publication 2 Fig. 4F). Consistent with 
the in vitro data, expression of the C terminus fragment of TACC3 failed to restore LISD assembly 
in TACC3-depleted oocytes, but assembled network-like, filamentous structures at the spindle 
poles and along K-fibres (publication 2 Fig. 4, G and H). 
 




Whereas BuGZ, PLK4 and SPD5 are proposed to promote microtubule nucleation in centrosomal 
spindles by locally enriching tubulin dimers56-58, the LISD did not appear to concentrate tubulin 
dimers (publication 2 fig. S18, A to E). Instead, TACC3 depletion altered microtubule dynamics: 
microtubule growth rates were significantly reduced, and their overall turnover was significantly 
increased (publication 2 fig. S19, A to D). I then hypothesized that the LISD locally sequesters 
microtubule regulatory factors to promote acentrosomal spindle assembly. To investigate this 
hypothesis, I disrupted the LISD by three different means: AURA inhibition, TACC3 depletion 
and CHC17 depletion. All these treatments caused a severe reduction in total microtubule intensity 
and spindle volume to around half of the values in control oocytes (publication 2 Fig. 5, A to C; 
figs. S20, A to E, and S21, A to I). Furthermore, AURA inhibition and TACC3 depletion in cow 
oocytes similarly led to a severe reduction in microtubules (publication 2 Fig. 5, D to F, and fig. 
S24). 
 
To uncover LISD-specific functions in oocytes, I utilized TACC3(ΔNT), the C terminus fragment 
that lacks the N terminus required for phase separation and LISD assembly (publication 2 Fig. 4, 
F to H) but has been shown to rescue phenotypes of TACC3 depletion in Xenopus mitotic extracts 
and in mitotic cells69,72. Remarkably, TACC3(ΔNT) did not rescue the reduction in total 
microtubule intensity in TACC3-depleted oocytes (publication 2 Fig. 6, A to C). Although not as 
strongly as in TACC3-depleted oocytes, the spindle volume in TACC3(ΔNT)-TACC3-depleted 
oocytes was still significantly reduced when compared with that in wildtype oocytes (publication 
2 Fig. 6, A to C). By contrast, phenotypes related to K-fibers, such as reduced progression into 
anaphase and presence of lagging chromosomes in TACC3-depleted oocytes, were largely rescued 
by TACC(ΔNT) (publication 2 fig. S25, D to G). 
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K-fibers and interpolar microtubules were depleted 
To investigate further the substantial loss of spindle microtubules, I examined K-fibers and 
interpolar microtubules, which are the two major populations of spindle microtubules74.  
 
To assess K-fibers, oocytes were briefly placed on ice to depolymerize dynamic, non-kinetochore-
bound microtubules, leaving behind the more stable, kinetochore-bound microtubules that are 
bundled to form K-fibers75. TACC3-depleted oocytes had significantly less K-fibers (publication 
2 Fig. 7, A to C). 
 
As there are no standard assays for evaluating interpolar microtubules, I assessed interpolar 
microtubules by three different approaches. First, I treated oocytes with calcium ions, which 
destabilize microtubules76 but preserve K-fibers and stable interpolar microtubules in mouse 
oocytes77. A more severe microtubule loss was observed when compared with the cold-stable assay 
(publication 2 Fig. 7, E and F). Second, I established a fluorescent reporter for the microtubule 
cross-linker PRC1, which associates with interpolar microtubules in mitotic cells78. In line with 
the calcium-stable assay, PRC1-labeled microtubules were severely reduced in TACC3-depleted 
oocytes (publication 2 Fig. 7, G and H). Third, I examined the central spindle. During anaphase, 
K-fibers were depolymerized, leaving behind largely the interpolar microtubules in the central 
spindle79. The total intensity and volume of the central spindle were significantly reduced in 






An optimized protocol for Trim-Away in mammalian oocytes 
In the original Trim-Away protocol, GV-arrested oocytes are first microinjected with TRIM21 
mRNA and then allowed to rest for three to four hours for protein expression and recovery from 
microinjection27. Before released from GV arrest, oocytes are microinjected with antibody to 
induce target degradation27. The two rounds of microinjection markedly reduce the survival and 
developmental rates of oocytes and are often challenging even for experienced microinjectionist. 
In the new protocol, oocytes are co-microinjected with TRIM21 mRNA and antibody. This is 
achieved with the use of a less viscous silicone oil, which prevents prior mixing of the TRIM21 
mRNA solution and antibody solution in the loading capillary and in the microinjection needle. 
This eliminates the need of the second microinjection, making Trim-Away experiments as simple 
as other routine experiments that require only a single microinjection. Besides, target degradation 
begins as TRIM21 mRNA is translated, allowing more time for the oocytes to thoroughly degrade 
the target before released from GV arrest. 
 
A novel principle of spindle assembly 
My work uncover an unprecedented principle of acentrosomal spindle assembly in mammalian 
oocytes: Microtubule regulatory factors are organized into a liquid-like domain to promote meiotic 
spindle assembly in the absence of centrosomes. Enriching these factors in local proximity of the 
spindle may be particularly crucial for large cells such as oocytes, where these factors would 
otherwise be dispersed throughout the large ooplasm. Liquid-liquid phase separation represents an 
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idea principle for such a purpose: It sequesters factors within proximity of spindle microtubules, 
but still allows them to diffuse dynamically along the spindle. This could help to promote the even 
distribution of these factors throughout the spindle, and to titrate their local concentration in order 
to promote efficient spindle assembly within the large cytoplasmic volume. 
 
Does the LISD play a role beyond spindle assembly in mammalian oocytes? 
Although many of the LISD proteins have been studied extensively in mitotic cells, structures that 
resemble the LISD have not been reported in other cell types so far and were not observed in mouse 
embryonic fibroblasts on my hands. As suggested by one of the reviewers for publication 2, I even 
attempted to deplete the centrosomes in somatic cells using centrinone, an inhibitor of PLK4 kinase 
and centriole duplication, and examine TACC3 in these centrosome-depleted cells. Nevertheless, 
I did not observe any liquid-like structures in these acentrosomal spindles. Hence, the LISD is 
likely an oocyte-specific feature. Notably though, when TACC3 is highly overexpressed in 
somatic cells, it forms large spherical structures that can associate with the mitotic spindle and 
persist in the presence of nocodazole80. However, in line with my observations, such structures 
were absent when TACC3 is expressed at endogenous level80,81. Whether these structures are 
physiologically relevant and whether they form by phase separation remain unclear. Therefore, 
mammalian oocytes appear to utilize the same set of microtubule regulatory factors as mitotic cells, 
but organize them into a prominent liquid-like domain. 
 
The first study of ‘fatty’ mammalian oocytes using high-resolution light microscopy 
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Cow, pig and sheep oocytes have a lot of lipid droplets of different sizes in their cytoplasm, which 
heavily scatters light and only allows visualization of less than twenty microns below the cortex. 
To image these ‘fatty’ mammalian oocytes in the past, they were pre-permeabilized with a 
detergent-containing solution that stabilizes microtubules before fixation82. However, variations 
between staining of individual oocytes were huge and whether the spindles remain native is unclear. 
Inspired by a recent optimization for CLARITY83, a tissue clearing technique, I established an 
optical clearing protocol based on the use of lipase from Candida rugose that has less protease 
contamination when compared with lipase from porcine pancreas. With one step of lipase 
treatment added to the routine immunostaining protocol, this allowed visualization of the full 
spindle and even the whole cytoplasmic actin network (unpublished) in these ‘fatty’ mammalian 
oocytes. I believe this technique will be a game changer for studies that involve ‘fatty’ mammalian 
oocytes. 
 
The first volume electron microscopy of mammalian oocytes 
To demonstrate the absence of a membrane surrounding the LISD, I decided to use FIB-SEM 
rather than performing immunostaining for markers of different membranes, which could be 
compromised due to the extraction with detergent. However, FIB-SEM, or electron microscopy in 
general, of the LISD or even the spindle was not trivial because they are largely composed of 
proteins and thus contrasted poorly by most heavy metal stains, which are lipophilic. In the past 
transmission electron microscopy studies of mammalian oocytes, sufficient contrast was only 
obtained after extensive extraction of the cytoplasm37,84. Fortunately, after a series of optimizations 
for the fixation, staining and imaging protocols, sufficient contrast was obtained with reduced 
osmium-thiocarbohydrazide-osmium staining in oocytes fixed with a mix of formaldehyde and 
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glutaraldehyde, which allowed semi-automatic, threshold-based segmentation. In addition, I 
combined the use of ultrasmall gold-conjugated Fab85 and microinjection to implement 
immunogold labelling for TACC3 in intact oocytes. Hopefully, these development will lead to 
more ultrastructural studies of mammalian oocytes in the field. 
 
Which is more centrosome-like: aMTOCs or the LISD? 
During mitotic PCM assembly, long coiled coil proteins such as centrosomin (Drosophila) and 
SPD-5 (C. elegans) multimerize to form the PCM “scaffold”, which in turn recruits PCM “clients” 
such as tubulin, kinases, etc86-87. Similar hierarchy has recently been demonstrated by elegant in 
vitro reconstitutions using SPD-5, PLK-1, SPD-2, TPXL-1 and ZYG-956. Although centrosomal 
proteins could be found in both aMTOCs and the LISD, aMTOCs appear to be more centrosome-
like because (i) microtubule nucleator γ-tubulin was present in aMTOCs but not the LISD and (ii) 
I observed similar ‘scaffold’-‘client’ relationships in aMTOCs but not the LISD using FRAP. 
Intriguingly, aMTOCs undergo fragmentation and clustering to remodel into different sizes during 
meiosis, and persist in the presence of nocodazole42. Whether aMTOCs are also a type of 
condensates like the mitotic PCM in Drosophila and C. elegans remains to be investigated56, 88. 
 
Conditions for phase separation of TACC3 in vitro 
To test if TACC3 could phase-separate in vitro, I added the molecular crowding agent PEG to 
recombinant TACC3 as described for SPD-556. A concern raised by one of the reviewers was that 
whether such in vitro conditions are physiologically relevant. This concern is totally valid as the 
presence or absence of molecular crowding agent could have a big impact on the assemblies 
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obtained. Taking SPD-5 as an example of how versatile proteins are, SPD-5 was reported to 
assemble network-like structures in the absence of PEG in 201587. But in 2017, when the authors 
took into account the crowded environment in the cytoplasm and incubated SPD-5 in the presence 
of PEG, they obtained droplet-like structures56. Back to the case of TACC3, although I used a 
relatively high concentration of PEG (12%), I believe our in vitro conditions are justifiable based 
on two observations. First, I observed droplet-like TACC3 structures in vivo and full-length 
TACC3 self-organized into droplets in vitro. Second, the C terminus of TACC3 self-organized 
into network-like structures in vitro, and I observed similar structures in TACC3(ΔNT)-TACC3-
depleted oocytes. In line with their expected material properties, the network-like structures for 
TACC3(ΔNT) were resistant to cold treatment, but not the droplet-like structures for full-length 
TACC3. Such consistency between our in vitro and in vivo data suggests that our in vitro 
conditions are likely physiologically relevant. 
 
The LISD versus nocodazole-induced condensates 
Although the LISD and nocodazole-induced condensates were similar in many perspectives, such 
as their morphology, liquid-like properties, AURA dependence and TACC3 dependence, they are 
different in their sensitivity to 3.5% 1,6-hexanediol and CHC17 dependence. Whereas the 
nocodazole-induced condensates were fully disassembled by the addition of 3.5% 1,6-hexanediol, 
the LISD was not. Whereas the LISD was disassembled upon CHC17 depletion, the nocodazole-
induced condensates were not. Together with the fact that the N terminus of TACC3 was sufficient 
for phase separation in vitro but not incorporation into the LISD in vivo, one likely explanation is 
that the C terminus of TACC3, which is required for interactions with CHC17 and the formation 
of microtubule-binding interface72, also plays a role in LISD assembly. Binding of TACC3-
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CHC17 complex to microtubules may help to stabilize the condensates in vivo, thus conferring the 
LISD a higher resistance to 1,6-hexanediol than the nocodazole-induced condensates. 
 
Phase separation in mitotic spindle assembly versus meiotic spindle assembly 
During mitotic spindle assembly, phase separation has been proposed as a mechanism for 
enriching tubulin dimers around the centrosomes or existing microtubules to facilitate microtubule 
nucleation56-58,61. However, the LISD did not concentrate tubulin dimers but enrich different 
microtubule regulatory factors during meiotic spindle assembly. Why mammalian oocytes do not 
concentrate tubulin dimers as in somatic cells? Recent computational modeling suggests that 
tubulin dimers are not limiting in large cytoplasmic volume89,90, so enriching tubulin dimers may 
be less an important issue in large oocytes. Intriguingly, a recent study suggest that when tubulin 
dimers are not limiting, microtubule dynamics becomes a key factor in determining spindle size91. 
If this also applies to mammalian oocytes, this may indeed explain why phase separation of 
microtubule regulatory factors is used to modulate microtubule dynamics. 
 
PRC1: a novel reporter for interpolar microtubules 
To visualize interpolar microtubules in intact oocytes, I established a fluorescent reporter for the 
microtubule crosslinker PRC1. In mouse oocytes, whereas TPX2 labeled K-fibers and some 
interpolar microtubules, PRC1 predominantly labeled interpolar microtubules. Notably, at the 
spindle midzone, PRC1 was enriched and labeled bundles of overlapping interpolar microtubules 
that lie below each pair of K-fibers. In mitotic cells, these microtubules were termed the bridging 
fibers92, and it was found that sliding of microtubules within drives spindle pole separation and 
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pushes K-fibers poleward93. Indeed, a previous study on mouse oocytes also revealed a similar 
localization for the microtubule-stabilizing protein HURP46. The functions of these bridging fiber-
like microtubules in mouse oocytes remain to be determined. 
 
Outlook 
Although this thesis addresses most aspects of the LISD, there are several open questions. First, 
why TACC3 phase-separate in oocytes during meiosis, but not in GV oocytes or mitotic cells. This 
could be due to differences in TACC3 concentration in the cytoplasm, or differences in AURA 
activity. Second, how AURA regulates LISD assembly. Preliminary experiments with S558 
phosphomutants of TACC3 suggested that AURA does not regulate LISD assembly through the 
canonical S558 phosphorylation (unpublished). Once the critical phosphorylation site(s) is/are 
identified, we could construct phosphomutants that fail to phase-separate and repeat the rescue 
experiments as for TACC3(ΔNT) to further delineate LISD-specific functions. Third, how the 
LISD could be integrated into the current picture of meiotic spindle assembly. After the initial 
microtubule nucleation from aMTOCs and the RanGTP pathway41,44,45, the LISD may help 
stabilizing microtubules nucleated from either or both pathways. Fourth, whether the LISD is 
present on the meiotic spindle in human oocytes. Unlike other mammalian oocytes, the spindle in 
human oocytes is particularly unstable49. It will be interesting if the LISD is absent in human 
oocytes. And finally, whether disturbance in the LISD occurs naturally, for instance, with aging. 
Disturbance in the LISD likely has a negative impact on the meiotic spindle, which could be a 
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